{"id": "243_487_1_314", "text": "Flightless-I, a gelsolin family member and transcriptional regulator, preferentially binds directly to activated cytosolic CaMK-II.", "text_with_entity_marker": "[E1]Flightless-I[/E1], a gelsolin family member and transcriptional regulator, preferentially binds directly to activated cytosolic [E2]CaMK-II[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Flightless-I", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "CaMK-II", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "243_488_3_315", "text": "Fli-I is not a CaMK-II substrate, but binds directly and preferentially to constitutively active (T287D) CaMK-II over inactive CaMK-II", "text_with_entity_marker": "[E1]Fli-I[/E1] is not a [E2]CaMK-II[/E2] substrate, but binds directly and preferentially to constitutively active (T287D) CaMK-II over inactive CaMK-II", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Fli-I", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "CaMK-II", "entity_2_idx": [[15, 22]], "entity_2_idx_in_text_with_entity_marker": [28, 35], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "339_680_7_449", "text": "Btb3p degradation requires its binding to a conserved N-terminal region of Pcu3p that precisely maps to the equivalent SKP1/F box adaptor binding domain of CUL1", "text_with_entity_marker": "Btb3p degradation requires its binding to a conserved N-terminal region of [E1]Pcu3p[/E1][E2]Btb3p[/E2] degradation requires its binding to a conserved N-terminal region of Pcu3p that precisely maps to the equivalent SKP1/F box adaptor binding domain of CUL1", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Pcu3p", "entity_1_idx": [[75, 80]], "entity_1_idx_in_text_with_entity_marker": [79, 84], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Btb3p", "entity_2_idx": [[0, 5]], "entity_2_idx_in_text_with_entity_marker": [93, 98], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "200_402_1_265", "text": "FtsL and FtsB are two inner-membrane proteins that are essential constituents of the cell division apparatus of Escherichia coli", "text_with_entity_marker": "[E1]FtsL[/E1] and [E2]FtsB[/E2] are two inner-membrane proteins that are essential constituents of the cell division apparatus of Escherichia coli", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "FtsL", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "FtsB", "entity_2_idx": [[9, 13]], "entity_2_idx_in_text_with_entity_marker": [22, 26], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "22_45_1_42", "text": "The Kr  ppel-like zinc finger protein Glis2 functions as a negative modulator of the Wnt/beta-catenin signaling pathway.", "text_with_entity_marker": "The Kr  ppel-like zinc finger protein [E1]Glis2[/E1] functions as a negative modulator of the Wnt/[E2]beta-catenin[/E2] signaling pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Glis2", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[89, 101]], "entity_2_idx_in_text_with_entity_marker": [102, 114], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "22_46_7_43", "text": "Our results indicate that Glis2 interacts with beta-catenin and suggest that Glis2 functions as a negative modulator of beta-catenin/TCF-mediated transcription.", "text_with_entity_marker": "Our results indicate that [E1]Glis2[/E1] interacts with [E2]beta-catenin[/E2] and suggest that Glis2 functions as a negative modulator of beta-catenin/TCF-mediated transcription.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Glis2", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[47, 59]], "entity_2_idx_in_text_with_entity_marker": [60, 72], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "220_442_11_290", "text": "Thus, we demonstrated in vivo hetero- and homointeractions of ClpQ and ClpY molecules, as well as a direct association between ClpY and substrate SulA, thereby supporting previous in vitro biochemical findings.", "text_with_entity_marker": "Thus, we demonstrated in vivo hetero- and homointeractions of [E1]ClpQ[/E1] and [E2]ClpY[/E2] molecules, as well as a direct association between ClpY and substrate SulA, thereby supporting previous in vitro biochemical findings.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ClpQ", "entity_1_idx": [[62, 66]], "entity_1_idx_in_text_with_entity_marker": [66, 70], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "ClpY", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "220_442_11_291", "text": "Thus, we demonstrated in vivo hetero- and homointeractions of ClpQ and ClpY molecules, as well as a direct association between ClpY and substrate SulA, thereby supporting previous in vitro biochemical findings.", "text_with_entity_marker": "Thus, we demonstrated in vivo hetero- and homointeractions of ClpQ and [E1]ClpY[/E1] molecules, as well as a direct association between ClpY and substrate [E2]SulA[/E2], thereby supporting previous in vitro biochemical findings.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ClpY", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "SulA", "entity_2_idx": [[146, 150]], "entity_2_idx_in_text_with_entity_marker": [159, 163], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "257_515_1_342", "text": "A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability.", "text_with_entity_marker": "A functional [E1]SUMO[/E1]-interacting motif in the transactivation domain of [E2]c-Myb[/E2] regulates its myeloid transforming ability.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "SUMO", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "c-Myb", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "257_516_11_343", "text": "This establishes SUMO binding as a mechanism involved in modulating the transactivation activity of c-Myb, and responsible for keeping the transforming potential of the oncoprotein in check.", "text_with_entity_marker": "This establishes [E1]SUMO[/E1] binding as a mechanism involved in modulating the transactivation activity of [E2]c-Myb[/E2], and responsible for keeping the transforming potential of the oncoprotein in check.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "SUMO", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "c-Myb", "entity_2_idx": [[100, 105]], "entity_2_idx_in_text_with_entity_marker": [113, 118], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "132_265_1_180", "text": "Mapping eIF5A binding sites for Dys1 and Lia1: in vivo evidence for regulation of eIF5A hypusination.", "text_with_entity_marker": "Mapping [E1]eIF5A[/E1] binding sites for [E2]Dys1[/E2] and Lia1: in vivo evidence for regulation of eIF5A hypusination.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "eIF5A", "entity_1_idx": [[8, 13]], "entity_1_idx_in_text_with_entity_marker": [12, 17], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Dys1", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "132_265_1_181", "text": "Mapping eIF5A binding sites for Dys1 and Lia1: in vivo evidence for regulation of eIF5A hypusination.", "text_with_entity_marker": "Mapping [E1]eIF5A[/E1] binding sites for Dys1 and [E2]Lia1[/E2]: in vivo evidence for regulation of eIF5A hypusination.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "eIF5A", "entity_1_idx": [[8, 13]], "entity_1_idx_in_text_with_entity_marker": [12, 17], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Lia1", "entity_2_idx": [[41, 45]], "entity_2_idx_in_text_with_entity_marker": [54, 58], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "183_367_1_238", "text": "Adenosine-triphosphate-sensitive K+ channel (Kir6.1): a novel phosphospecific interaction partner of connexin 43 (Cx43).", "text_with_entity_marker": "[E1]Adenosine-triphosphate-sensitive K+ channel (Kir6.1)[/E1]: a novel phosphospecific interaction partner of [E2]connexin 43 (Cx43).[/E2]", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Adenosine-triphosphate-sensitive K+ channel (Kir6.1)", "entity_1_idx": [[0, 52]], "entity_1_idx_in_text_with_entity_marker": [4, 56], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "connexin 43 (Cx43).", "entity_2_idx": [[101, 120]], "entity_2_idx_in_text_with_entity_marker": [114, 133], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "183_368_7_239", "text": "Our data provide an interesting lead about a possible partnership between Cx43 and Kir6.1, which will help in better understanding their role in ischemia/hypoxia preconditioning.", "text_with_entity_marker": "Our data provide an interesting lead about a possible partnership between [E1]Cx43[/E1] and [E2]Kir6.1[/E2], which will help in better understanding their role in ischemia/hypoxia preconditioning.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Cx43", "entity_1_idx": [[74, 78]], "entity_1_idx_in_text_with_entity_marker": [78, 82], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Kir6.1", "entity_2_idx": [[83, 89]], "entity_2_idx_in_text_with_entity_marker": [96, 102], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "275_551_1_373", "text": "A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3.", "text_with_entity_marker": "A Crohn's disease variant in Atg16l1 enhances its degradation by [E1]caspase 3[/E1][E2]Atg16l1[/E2] enhances its degradation by caspase 3.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "caspase 3", "entity_1_idx": [[65, 74]], "entity_1_idx_in_text_with_entity_marker": [69, 78], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Atg16l1", "entity_2_idx": [[29, 36]], "entity_2_idx_in_text_with_entity_marker": [87, 94], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "275_552_8_374", "text": "These findings demonstrate that caspase 3 activation in the presence of a common risk allele leads to accelerated degradation of ATG16L1, placing cellular stress, apoptotic stimuli and impaired autophagy in a unified pathway that predisposes to Crohn's disease.", "text_with_entity_marker": "These findings demonstrate that [E1]caspase 3[/E1] activation in the presence of a common risk allele leads to accelerated degradation of [E2]ATG16L1[/E2], placing cellular stress, apoptotic stimuli and impaired autophagy in a unified pathway that predisposes to Crohn's disease.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "caspase 3", "entity_1_idx": [[32, 41]], "entity_1_idx_in_text_with_entity_marker": [36, 45], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "ATG16L1", "entity_2_idx": [[129, 136]], "entity_2_idx_in_text_with_entity_marker": [142, 149], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "326_654_11_441", "text": "These results provide the first evidence suggesting that 14-3-3 regulates LRRK2 and that disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.", "text_with_entity_marker": "These results provide the first evidence suggesting that [E1]14-3-3[/E1] regulates [E2]LRRK2[/E2] and that disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "14-3-3", "entity_1_idx": [[57, 63]], "entity_1_idx_in_text_with_entity_marker": [61, 67], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "LRRK2", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "184_370_2_240", "text": "Earlier work has shown that PC1 and PC2 assemble into a polycystin complex implicated in kidney morphogenesis", "text_with_entity_marker": "Earlier work has shown that [E1]PC1[/E1] and [E2]PC2[/E2] assemble into a polycystin complex implicated in kidney morphogenesis", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "PC1", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "PC2", "entity_2_idx": [[36, 39]], "entity_2_idx_in_text_with_entity_marker": [49, 52], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "10_22_12_21", "text": "This indicates that AtGRIP and AtARL1 interact directly", "text_with_entity_marker": "This indicates that [E1]AtGRIP[/E1] and [E2]AtARL1[/E2] interact directly", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AtGRIP", "entity_1_idx": [[20, 26]], "entity_1_idx_in_text_with_entity_marker": [24, 30], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "AtARL1", "entity_2_idx": [[31, 37]], "entity_2_idx_in_text_with_entity_marker": [44, 50], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "211_423_1_277", "text": "Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.", "text_with_entity_marker": "[E1]Dok-R[/E1] mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of [E2]c-Src[/E2] and Csk.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Dok-R", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "c-Src", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "211_423_1_278", "text": "Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.", "text_with_entity_marker": "[E1]Dok-R[/E1] mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and [E2]Csk[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Dok-R", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Csk", "entity_2_idx": [[160, 163]], "entity_2_idx_in_text_with_entity_marker": [173, 176], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "211_424_2_279", "text": "The recruitment of Dok-R to the EGFR, which is mediated through its phosphotyrosine binding (PTB) domain, results in attenuation of mitogen-activated protein kinase (MAPK) activation", "text_with_entity_marker": "The recruitment of [E1]Dok-R[/E1] to the [E2]EGFR[/E2], which is mediated through its phosphotyrosine binding (PTB) domain, results in attenuation of mitogen-activated protein kinase (MAPK) activation", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Dok-R", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "128_257_1_175", "text": "Pathogenic NPHP5 mutations impair protein interaction with Cep290, a prerequisite for ciliogenesis.", "text_with_entity_marker": "Pathogenic [E1]NPHP5[/E1] mutations impair protein interaction with [E2]Cep290[/E2], a prerequisite for ciliogenesis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "NPHP5", "entity_1_idx": [[11, 16]], "entity_1_idx_in_text_with_entity_marker": [15, 20], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Cep290", "entity_2_idx": [[59, 65]], "entity_2_idx_in_text_with_entity_marker": [72, 78], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "240_482_2_311", "text": "The Sld2 and Dpb11 proteins of budding yeast form a phosphorylation-dependent complex that is essential for chromosomal DNA replication", "text_with_entity_marker": "The [E1]Sld2[/E1] and [E2]Dpb11[/E2] proteins of budding yeast form a phosphorylation-dependent complex that is essential for chromosomal DNA replication", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Sld2", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Dpb11", "entity_2_idx": [[13, 18]], "entity_2_idx_in_text_with_entity_marker": [26, 31], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "238_478_9_307", "text": "At the molecular level, introduction of the E50K mutation disrupts the interaction between Optn and Rab8 GTPase, a protein involved in the regulation of vesicle transport from Golgi to plasma membrane", "text_with_entity_marker": "At the molecular level, introduction of the [E1]E50K[/E1] mutation disrupts the interaction between [E2]Optn[/E2] and Rab8 GTPase, a protein involved in the regulation of vesicle transport from Golgi to plasma membrane", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "E50K", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Optn", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "238_478_9_308", "text": "At the molecular level, introduction of the E50K mutation disrupts the interaction between Optn and Rab8 GTPase, a protein involved in the regulation of vesicle transport from Golgi to plasma membrane", "text_with_entity_marker": "At the molecular level, introduction of the [E1]E50K[/E1] mutation disrupts the interaction between Optn and [E2]Rab8[/E2] GTPase, a protein involved in the regulation of vesicle transport from Golgi to plasma membrane", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "E50K", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Rab8", "entity_2_idx": [[100, 104]], "entity_2_idx_in_text_with_entity_marker": [113, 117], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "205_412_6_268", "text": "CD2BP1 and its murine ortholog, proline-serine-threonine phosphatase interacting protein (PSTPIP1), are adaptor proteins known to interact with PEST-type protein tyrosine phosphatases (PTP)", "text_with_entity_marker": "[E1]CD2BP1[/E1] and its murine ortholog, proline-serine-threonine phosphatase interacting protein (PSTPIP1), are adaptor proteins known to interact with PEST-type [E2]protein tyrosine phosphatases (PTP)[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD2BP1", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "protein tyrosine phosphatases (PTP)", "entity_2_idx": [[154, 189]], "entity_2_idx_in_text_with_entity_marker": [167, 202], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "205_412_6_269", "text": "CD2BP1 and its murine ortholog, proline-serine-threonine phosphatase interacting protein (PSTPIP1), are adaptor proteins known to interact with PEST-type protein tyrosine phosphatases (PTP)", "text_with_entity_marker": "CD2BP1 and its murine ortholog, [E1]proline-serine-threonine phosphatase interacting protein (PSTPIP1)[/E1], are adaptor proteins known to interact with PEST-type [E2]protein tyrosine phosphatases (PTP)[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "proline-serine-threonine phosphatase interacting protein (PSTPIP1)", "entity_1_idx": [[32, 98]], "entity_1_idx_in_text_with_entity_marker": [36, 102], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "protein tyrosine phosphatases (PTP)", "entity_2_idx": [[154, 189]], "entity_2_idx_in_text_with_entity_marker": [167, 202], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "54_110_2_80", "text": "Here we demonstrate that the transcription factor CBP, which is also implicated in cell proliferation and differentiation, acts as a p53 coactivator and potentiates its transcriptional activity", "text_with_entity_marker": "Here we demonstrate that the transcription factor [E1]CBP[/E1], which is also implicated in cell proliferation and differentiation, acts as a [E2]p53[/E2] coactivator and potentiates its transcriptional activity", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "110_222_9_146", "text": "The redox dependence of events leading to supramolecular complexes is consistent with a role of CP12 in coordinating the reversible inactivation of chloroplast enzymes A(4)-GAPDH and PRK during darkness in photosynthetic tissues.", "text_with_entity_marker": "The redox dependence of events leading to supramolecular complexes is consistent with a role of [E1]CP12[/E1] in coordinating the reversible inactivation of chloroplast enzymes [E2]A(4)-GAPDH[/E2] and PRK during darkness in photosynthetic tissues.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CP12", "entity_1_idx": [[96, 100]], "entity_1_idx_in_text_with_entity_marker": [100, 104], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "A(4)-GAPDH", "entity_2_idx": [[168, 178]], "entity_2_idx_in_text_with_entity_marker": [181, 191], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "110_222_9_147", "text": "The redox dependence of events leading to supramolecular complexes is consistent with a role of CP12 in coordinating the reversible inactivation of chloroplast enzymes A(4)-GAPDH and PRK during darkness in photosynthetic tissues.", "text_with_entity_marker": "The redox dependence of events leading to supramolecular complexes is consistent with a role of [E1]CP12[/E1] in coordinating the reversible inactivation of chloroplast enzymes A(4)-GAPDH and [E2]PRK[/E2] during darkness in photosynthetic tissues.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CP12", "entity_1_idx": [[96, 100]], "entity_1_idx_in_text_with_entity_marker": [100, 104], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "PRK", "entity_2_idx": [[183, 186]], "entity_2_idx_in_text_with_entity_marker": [196, 199], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "288_577_1_395", "text": "Structural determinants for the binding of anthrax lethal factor to oligomeric protective antigen.", "text_with_entity_marker": "Structural determinants for the binding of [E1]anthrax lethal factor[/E1] to oligomeric [E2]protective antigen[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "anthrax lethal factor", "entity_1_idx": [[43, 64]], "entity_1_idx_in_text_with_entity_marker": [47, 68], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "protective antigen", "entity_2_idx": [[79, 97]], "entity_2_idx_in_text_with_entity_marker": [92, 110], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "288_578_1_396", "text": "Anthrax lethal toxin assembles at the surface of mammalian cells when the lethal factor (LF) binds via its amino-terminal domain, LF(N), to oligomeric forms of activated protective antigen (PA)", "text_with_entity_marker": "Anthrax lethal toxin assembles at the surface of mammalian cells when the [E1]lethal factor (LF)[/E1] binds via its amino-terminal domain, LF(N), to oligomeric forms of activated [E2]protective antigen (PA)[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "lethal factor (LF)", "entity_1_idx": [[74, 92]], "entity_1_idx_in_text_with_entity_marker": [78, 96], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "protective antigen (PA)", "entity_2_idx": [[170, 193]], "entity_2_idx_in_text_with_entity_marker": [183, 206], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "168_337_1_217", "text": "BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity.", "text_with_entity_marker": "[E1]BTG2[/E1] is an LXXLL-dependent co-repressor for [E2]androgen receptor[/E2] transcriptional activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "BTG2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "androgen receptor", "entity_2_idx": [[44, 61]], "entity_2_idx_in_text_with_entity_marker": [57, 74], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "168_338_9_218", "text": "These findings, for the first time, demonstrate that BTG2 complexes with AR via an LxxLL-dependent mechanism and may play a role in prostate cancer via modulating the AR signaling pathway.", "text_with_entity_marker": "These findings, for the first time, demonstrate that [E1]BTG2[/E1] complexes with [E2]AR[/E2] via an LxxLL-dependent mechanism and may play a role in prostate cancer via modulating the AR signaling pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "BTG2", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "AR", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "47_96_3_72", "text": "Hox proteins, such as Drosophila Ultrabithorax, have low DNA-binding specificity by themselves but gain affinity and specificity when they bind together with the homeoprotein Extradenticle (or Pbxl in mammals)", "text_with_entity_marker": "Hox proteins, such as Drosophila [E1]Ultrabithorax[/E1], have low DNA-binding specificity by themselves but gain affinity and specificity when they bind together with the homeoprotein [E2]Extradenticle[/E2] (or Pbxl in mammals)", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ultrabithorax", "entity_1_idx": [[33, 46]], "entity_1_idx_in_text_with_entity_marker": [37, 50], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Extradenticle", "entity_2_idx": [[175, 188]], "entity_2_idx_in_text_with_entity_marker": [188, 201], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "73_148_9_102", "text": "Collectively, the current results suggest a model wherein 14-3-3   binds to Ser12-phosphorylated Fbx4 to mediate dimerization and function.", "text_with_entity_marker": "Collectively, the current results suggest a model wherein [E1]14-3-3[/E1]   binds to Ser12-phosphorylated [E2]Fbx4[/E2] to mediate dimerization and function.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "14-3-3", "entity_1_idx": [[58, 64]], "entity_1_idx_in_text_with_entity_marker": [62, 68], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Fbx4", "entity_2_idx": [[97, 101]], "entity_2_idx_in_text_with_entity_marker": [110, 114], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "321_644_3_437", "text": "Through this interaction, VCP modulates the fibrillogenesis of pathogenic forms of Atx-3 in a concentration-dependent manner, with low concentrations of VCP stimulating fibrillogenesis and excess concentrations suppressing it", "text_with_entity_marker": "Through this interaction, [E1]VCP[/E1] modulates the fibrillogenesis of pathogenic forms of [E2]Atx-3[/E2] in a concentration-dependent manner, with low concentrations of VCP stimulating fibrillogenesis and excess concentrations suppressing it", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "VCP", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Atx-3", "entity_2_idx": [[83, 88]], "entity_2_idx_in_text_with_entity_marker": [96, 101], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "193_388_1_253", "text": "Enthoprotin, a newly identified component of clathrin-coated vesicles, interacts with the trans-Golgi network (TGN) clathrin adapters AP-1 and GGA2", "text_with_entity_marker": "[E1]Enthoprotin[/E1], a newly identified component of clathrin-coated vesicles, interacts with the trans-Golgi network (TGN) clathrin adapters [E2]AP-1[/E2] and GGA2", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Enthoprotin", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "193_388_1_254", "text": "Enthoprotin, a newly identified component of clathrin-coated vesicles, interacts with the trans-Golgi network (TGN) clathrin adapters AP-1 and GGA2", "text_with_entity_marker": "[E1]Enthoprotin[/E1], a newly identified component of clathrin-coated vesicles, interacts with the trans-Golgi network (TGN) clathrin adapters AP-1 and [E2]GGA2[/E2]", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Enthoprotin", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "GGA2", "entity_2_idx": [[143, 147]], "entity_2_idx_in_text_with_entity_marker": [156, 160], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d219.s1899_AIMed.d219.s1899.p0", "text": "14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain.", "text_with_entity_marker": "[E1]14-3-3 zeta[/E1] negatively regulates [E2]raf-1[/E2] activity by interactions with the Raf-1 cysteine-rich domain.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "14-3-3 zeta", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "raf-1", "entity_2_idx": [[33, 38]], "entity_2_idx_in_text_with_entity_marker": [46, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d219.s1899_AIMed.d219.s1899.p1", "text": "14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain.", "text_with_entity_marker": "[E1]14-3-3 zeta[/E1] negatively regulates raf-1 activity by interactions with the [E2]Raf-1[/E2] cysteine-rich domain.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "14-3-3 zeta", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d219.s1901_AIMed.d219.s1901.p1", "text": "We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.", "text_with_entity_marker": "We recently reported that [E1]Ras[/E1] interaction with the [E2]Raf-1 cysteine-rich domain[/E2] (Raf-CRD, residues 139-184) may be required for Raf-1 activation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1 cysteine-rich domain", "entity_2_idx": [[51, 77]], "entity_2_idx_in_text_with_entity_marker": [64, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d219.s1901_AIMed.d219.s1901.p2", "text": "We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.", "text_with_entity_marker": "We recently reported that [E1]Ras[/E1] interaction with the Raf-1 cysteine-rich domain ([E2]Raf-CRD[/E2], residues 139-184) may be required for Raf-1 activation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-CRD", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d219.s1906_AIMed.d219.s1906.p0", "text": "Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not Ras, to the Raf-CRD.", "text_with_entity_marker": "Moreover, mutation of [E1]Raf-1[/E1] residues 143-145 impairs binding of 14-3-3, but not [E2]Ras[/E2], to the Raf-CRD.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[80, 83]], "entity_2_idx_in_text_with_entity_marker": [93, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1132_AIMed.d133.s1132.p1", "text": "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.", "text_with_entity_marker": "[E1]JNK1[/E1]: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the [E2]c-Jun[/E2] activation domain.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "JNK1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[91, 96]], "entity_2_idx_in_text_with_entity_marker": [104, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1136_AIMed.d133.s1136.p0", "text": "Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV.", "text_with_entity_marker": "Significantly, [E1]Ha-Ras[/E1] partially activates [E2]JNK1[/E2] and potentiates the activation caused by UV.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ha-Ras", "entity_1_idx": [[15, 21]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JNK1", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1137_AIMed.d133.s1137.p0", "text": "JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73.", "text_with_entity_marker": "[E1]JNK1[/E1] binds to the [E2]c-Jun[/E2] transactivation domain and phosphorylates it on Ser-63 and Ser-73.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "JNK1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[18, 23]], "entity_2_idx_in_text_with_entity_marker": [31, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p0", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in [E1]TrkA[/E1] involved in binding to [E2]nerve growth factor[/E2] (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TrkA", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nerve growth factor", "entity_2_idx": [[67, 86]], "entity_2_idx_in_text_with_entity_marker": [80, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s375_AIMed.d43.s375.p9", "text": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "text_with_entity_marker": "Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in [E1]TrkC[/E1] involved in binding to [E2]neurotrophin-3[/E2] have been mapped in this domain, the Trk amino acids that provide specificity remained unclear.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "TrkC", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "neurotrophin-3", "entity_2_idx": [[134, 148]], "entity_2_idx_in_text_with_entity_marker": [147, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p9", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained [E1]neurotrophin-3[/E1] binding equivalent to [E2]TrkC[/E2], and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "neurotrophin-3", "entity_1_idx": [[82, 96]], "entity_1_idx_in_text_with_entity_marker": [86, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkC", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d43.s377_AIMed.d43.s377.p14", "text": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB.", "text_with_entity_marker": "The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-3 binding equivalent to TrkC, and also bound [E1]brain-derived neurotrophin[/E1], although with lower affinity compared with [E2]TrkB[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "brain-derived neurotrophin", "entity_1_idx": [[140, 166]], "entity_1_idx_in_text_with_entity_marker": [144, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TrkB", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1467_AIMed.d174.s1467.p10", "text": "The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130.", "text_with_entity_marker": "The high affinity interleukin-6 (IL-6) signaling complex consists of [E1]IL-6[/E1] and two membrane-associated receptor components: a low affinity but specific [E2]IL-6 receptor[/E2] and the affinity converter/signal transducing protein gp130.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[151, 164]], "entity_2_idx_in_text_with_entity_marker": [164, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1468_AIMed.d174.s1468.p19", "text": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "text_with_entity_marker": "Monomeric (IL-6M) and dimeric (IL-6D) forms of Escherichia coli-derived human IL-6 and the extracellular (\"soluble\") portions of the [E1]IL-6[/E1] receptor ([E2]sIL-6R[/E2]) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[133, 137]], "entity_1_idx_in_text_with_entity_marker": [137, 141], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1469_AIMed.d174.s1469.p0", "text": "Although IL-6D has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "text_with_entity_marker": "Although [E1]IL-6D[/E1] has a higher binding affinity for immobilized [E2]sIL-6R[/E2], as determined by biosensor analysis employing surface plasmon resonance detection, IL-6M is more potent than IL-6D in a STAT3 phosphorylation assay.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6D", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[61, 67]], "entity_2_idx_in_text_with_entity_marker": [74, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1471_AIMed.d174.s1471.p0", "text": "The increased binding affinity of IL-6D appears to be due to its ability to cross-link two sIL-6R molecules on the biosensor surface.", "text_with_entity_marker": "The increased binding affinity of [E1]IL-6D[/E1] appears to be due to its ability to cross-link two [E2]sIL-6R[/E2] molecules on the biosensor surface.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6D", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sIL-6R", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1473_AIMed.d174.s1473.p7", "text": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 IL-6R gp130)2 complex.", "text_with_entity_marker": "These data imply that IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric ([E1]IL-6[/E1] [E2]IL-6R[/E2] gp130)2 complex.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[124, 128]], "entity_1_idx_in_text_with_entity_marker": [128, 132], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1474_AIMed.d174.s1474.p0", "text": "A model is presented whereby the trimeric complex of IL-6R, gp130, and IL-6M forms before the functional hexamer.", "text_with_entity_marker": "A model is presented whereby the trimeric complex of [E1]IL-6R[/E1], [E2]gp130[/E2], and IL-6M forms before the functional hexamer.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6R", "entity_1_idx": [[53, 58]], "entity_1_idx_in_text_with_entity_marker": [57, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p1", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the [E1]IL-6R[/E1] but its decreased ability to couple with gp130, we suggest that a stable [E2]IL-6[/E2] dimer may be an efficient IL-6 antagonist.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6R", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[117, 121]], "entity_2_idx_in_text_with_entity_marker": [130, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d174.s1475_AIMed.d174.s1475.p3", "text": "Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.", "text_with_entity_marker": "Due to its increased affinity for the IL-6R but its decreased ability to couple with [E1]gp130[/E1], we suggest that a stable [E2]IL-6[/E2] dimer may be an efficient IL-6 antagonist.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "gp130", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[117, 121]], "entity_2_idx_in_text_with_entity_marker": [130, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1660_AIMed.d195.s1660.p1", "text": "Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.", "text_with_entity_marker": "Competitive binding of [E1]alpha-actinin[/E1] and calmodulin to the [E2]NMDA receptor[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-actinin", "entity_1_idx": [[23, 36]], "entity_1_idx_in_text_with_entity_marker": [27, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[59, 72]], "entity_2_idx_in_text_with_entity_marker": [72, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1660_AIMed.d195.s1660.p2", "text": "Competitive binding of alpha-actinin and calmodulin to the NMDA receptor.", "text_with_entity_marker": "Competitive binding of alpha-actinin and [E1]calmodulin[/E1] to the [E2]NMDA receptor[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "calmodulin", "entity_1_idx": [[41, 51]], "entity_1_idx_in_text_with_entity_marker": [45, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[59, 72]], "entity_2_idx_in_text_with_entity_marker": [72, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p37", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E1]alpha-Actinin-2[/E1] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the [E2]NMDA receptor[/E2], and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[483, 498]], "entity_1_idx_in_text_with_entity_marker": [487, 502], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NMDA receptor", "entity_2_idx": [[592, 605]], "entity_2_idx_in_text_with_entity_marker": [605, 618], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d195.s1662_AIMed.d195.s1662.p38", "text": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain.", "text_with_entity_marker": "The activity of NMDA (N-methyl-D-aspartate) receptors is mechanosensitive and dependent on the integrity of actin, suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton. alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95. [E1]alpha-Actinin-2[/E1] binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and [E2]PSD-95[/E2] from rat brain.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-Actinin-2", "entity_1_idx": [[483, 498]], "entity_1_idx_in_text_with_entity_marker": [487, 502], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PSD-95", "entity_2_idx": [[661, 667]], "entity_2_idx_in_text_with_entity_marker": [674, 680], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p3", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] (neuromodulin, B-50, F1), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p4", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "[E1]GAP-43[/E1] (neuromodulin, B-50, F1), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p7", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 ([E1]neuromodulin[/E1], B-50, F1), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "neuromodulin", "entity_1_idx": [[8, 20]], "entity_1_idx_in_text_with_entity_marker": [12, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p8", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 ([E1]neuromodulin[/E1], B-50, F1), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "neuromodulin", "entity_1_idx": [[8, 20]], "entity_1_idx_in_text_with_entity_marker": [12, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p10", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, [E1]B-50[/E1], F1), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "B-50", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p11", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, [E1]B-50[/E1], F1), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "B-50", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p12", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, B-50, [E1]F1[/E1]), a [E2]protein kinase C[/E2] (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "F1", "entity_1_idx": [[28, 30]], "entity_1_idx_in_text_with_entity_marker": [32, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[35, 51]], "entity_2_idx_in_text_with_entity_marker": [48, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1532_AIMed.d180.s1532.p13", "text": "GAP-43 (neuromodulin, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "text_with_entity_marker": "GAP-43 (neuromodulin, B-50, [E1]F1[/E1]), a protein kinase C ([E2]PKC[/E2]) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "F1", "entity_1_idx": [[28, 30]], "entity_1_idx_in_text_with_entity_marker": [32, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p1", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between [E1]GAP-43[/E1] and the calcium effector protein, [E2]calmodulin[/E2] (CaM).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[130, 140]], "entity_2_idx_in_text_with_entity_marker": [143, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1533_AIMed.d180.s1533.p2", "text": "In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, calmodulin (CaM).", "text_with_entity_marker": "In the yeast-based cloning system, the only strong interaction that was detected between [E1]GAP-43[/E1] and the calcium effector protein, calmodulin ([E2]CaM[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[89, 95]], "entity_1_idx_in_text_with_entity_marker": [93, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1534_AIMed.d180.s1534.p0", "text": "PKC phosphorylates GAP-43 on serine 41.", "text_with_entity_marker": "[E1]PKC[/E1] phosphorylates [E2]GAP-43[/E2] on serine 41.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PKC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GAP-43", "entity_2_idx": [[19, 25]], "entity_2_idx_in_text_with_entity_marker": [32, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p0", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of [E1]GAP-43[/E1] alone bound [E2]CaM[/E2] more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[57, 60]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1536_AIMed.d180.s1536.p3", "text": "Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "text_with_entity_marker": "Surprisingly, the N-terminal third of GAP-43 alone bound [E1]CaM[/E1] more strongly than did intact [E2]GAP-43[/E2], suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CaM", "entity_1_idx": [[57, 60]], "entity_1_idx_in_text_with_entity_marker": [61, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GAP-43", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d180.s1537_AIMed.d180.s1537.p0", "text": "These results, along with other recent findings, suggest a novel role for the interaction between GAP-43 and CaM.", "text_with_entity_marker": "These results, along with other recent findings, suggest a novel role for the interaction between [E1]GAP-43[/E1] and [E2]CaM[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GAP-43", "entity_1_idx": [[98, 104]], "entity_1_idx_in_text_with_entity_marker": [102, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CaM", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1180_AIMed.d140.s1180.p0", "text": "Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.", "text_with_entity_marker": "[E1]Cdi1[/E1], a human G1 and S phase protein phosphatase that associates with [E2]Cdk2[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p0", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human [E2]Cdc2[/E2], Cdk2, and Cdk3, but not with Cdk4.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdc2", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p1", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human Cdc2, [E2]Cdk2[/E2], and Cdk3, but not with Cdk4.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d140.s1182_AIMed.d140.s1182.p2", "text": "In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.", "text_with_entity_marker": "In yeast, [E1]Cdi1[/E1] interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and [E2]Cdk3[/E2], but not with Cdk4.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdi1", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk3", "entity_2_idx": [[88, 92]], "entity_2_idx_in_text_with_entity_marker": [101, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1806_AIMed.d209.s1806.p0", "text": "Human RIN1 was first characterized as a RAS binding protein based on the properties of its carboxyl-terminal domain.", "text_with_entity_marker": "Human [E1]RIN1[/E1] was first characterized as a [E2]RAS[/E2] binding protein based on the properties of its carboxyl-terminal domain.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1807_AIMed.d209.s1807.p0", "text": "We now show that full-length RIN1 interacts with activated RAS in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.", "text_with_entity_marker": "We now show that full-length [E1]RIN1[/E1] interacts with activated [E2]RAS[/E2] in mammalian cells and defines a minimum region of 434 aa required for efficient RAS binding.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p0", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "[E1]RIN1[/E1] interacts with the \"effector domain\" of [E2]RAS[/E2] and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[45, 48]], "entity_2_idx_in_text_with_entity_marker": [58, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1808_AIMed.d209.s1808.p9", "text": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of RAF1, a known RAS effector.", "text_with_entity_marker": "RIN1 interacts with the \"effector domain\" of RAS and employs some RAS determinants that are common to, and others that are distinct from, those required for the binding of [E1]RAF1[/E1], a known [E2]RAS[/E2] effector.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RAF1", "entity_1_idx": [[172, 176]], "entity_1_idx_in_text_with_entity_marker": [176, 180], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1809_AIMed.d209.s1809.p0", "text": "The same domain of RIN1 that binds RAS also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "text_with_entity_marker": "The same domain of [E1]RIN1[/E1] that binds [E2]RAS[/E2] also interacts with 14-3-3 proteins, extending the similarity between RIN1 and other RAS effectors.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[35, 38]], "entity_2_idx_in_text_with_entity_marker": [48, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1810_AIMed.d209.s1810.p0", "text": "When expressed in mammalian cells, the RAS binding domain of RIN1 can act as a dominant negative signal transduction blocker.", "text_with_entity_marker": "When expressed in mammalian cells, the [E1]RAS[/E1] binding domain of [E2]RIN1[/E2] can act as a dominant negative signal transduction blocker.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RAS", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RIN1", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1812_AIMed.d209.s1812.p0", "text": "This RIN1 sequence shows preferential binding to the ABL-SH3 domain in vitro.", "text_with_entity_marker": "This [E1]RIN1[/E1] sequence shows preferential binding to the [E2]ABL-SH3[/E2] domain in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[5, 9]], "entity_1_idx_in_text_with_entity_marker": [9, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ABL-SH3", "entity_2_idx": [[53, 60]], "entity_2_idx_in_text_with_entity_marker": [66, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d209.s1813_AIMed.d209.s1813.p0", "text": "Moreover, the amino-terminal domain of RIN1 directly associates with, and is tyrosine phosphorylated by, c-ABL.", "text_with_entity_marker": "Moreover, the amino-terminal domain of [E1]RIN1[/E1] directly associates with, and is tyrosine phosphorylated by, [E2]c-ABL[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RIN1", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-ABL", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s637_AIMed.d76.s637.p0", "text": "The T-cell antigen CD5 acts as a receptor and substrate for the protein-tyrosine kinase p56lck.", "text_with_entity_marker": "The T-cell antigen [E1]CD5[/E1] acts as a receptor and substrate for the protein-tyrosine kinase [E2]p56lck[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[88, 94]], "entity_2_idx_in_text_with_entity_marker": [101, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p3", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "[E1]CD5[/E1] associates with the [E2]T-cell receptor zeta chain (TcR zeta)/CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "T-cell receptor zeta chain (TcR zeta)/CD3", "entity_2_idx": [[24, 65]], "entity_2_idx_in_text_with_entity_marker": [37, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p7", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the [E1]T-cell receptor zeta chain[/E1] (TcR zeta)/[E2]CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "T-cell receptor zeta chain", "entity_1_idx": [[24, 50]], "entity_1_idx_in_text_with_entity_marker": [28, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s639_AIMed.d76.s639.p11", "text": "CD5 associates with the T-cell receptor zeta chain (TcR zeta)/CD3 complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "text_with_entity_marker": "CD5 associates with the T-cell receptor zeta chain ([E1]TcR zeta[/E1])/[E2]CD3[/E2] complex and is rapidly phosphosphorylated on tyrosine residues as a result of TcR zeta/CD3 ligation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TcR zeta", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD3", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s641_AIMed.d76.s641.p0", "text": "In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.", "text_with_entity_marker": "In this study, we demonstrate that [E1]CD5[/E1] is coupled to the protein-tyrosine kinase [E2]p56lck[/E2] and can act as a substrate for p56lck.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[81, 87]], "entity_2_idx_in_text_with_entity_marker": [94, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s641_AIMed.d76.s641.p1", "text": "In this study, we demonstrate that CD5 is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for p56lck.", "text_with_entity_marker": "In this study, we demonstrate that [E1]CD5[/E1] is coupled to the protein-tyrosine kinase p56lck and can act as a substrate for [E2]p56lck[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[119, 125]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s646_AIMed.d76.s646.p0", "text": "The binding of p56lck to CD5 induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.", "text_with_entity_marker": "The binding of [E1]p56lck[/E1] to [E2]CD5[/E2] induced a 10- to 15-fold increase in p56lck catalytic activity, as measured by in vitro kinase analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p56lck", "entity_1_idx": [[15, 21]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[25, 28]], "entity_2_idx_in_text_with_entity_marker": [38, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s647_AIMed.d76.s647.p0", "text": "In vivo labelling with 32P(i) also showed a four- to fivefold increase in Y-394 occupancy in p56lck when associated with CD5.", "text_with_entity_marker": "In vivo labelling with 32P(i) also showed a four- to fivefold increase in Y-394 occupancy in [E1]p56lck[/E1] when associated with [E2]CD5[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p56lck", "entity_1_idx": [[93, 99]], "entity_1_idx_in_text_with_entity_marker": [97, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s648_AIMed.d76.s648.p0", "text": "The use of glutathione S-transferase-Lck fusion proteins in precipitation analysis showed that the SH2 domain of p56lck could recognize CD5 as expressed in the baculovirus expression system.", "text_with_entity_marker": "The use of glutathione S-transferase-Lck fusion proteins in precipitation analysis showed that the SH2 domain of [E1]p56lck[/E1] could recognize [E2]CD5[/E2] as expressed in the baculovirus expression system.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p56lck", "entity_1_idx": [[113, 119]], "entity_1_idx_in_text_with_entity_marker": [117, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD5", "entity_2_idx": [[136, 139]], "entity_2_idx_in_text_with_entity_marker": [149, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d76.s649_AIMed.d76.s649.p1", "text": "CD5 interaction with p56lck represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "text_with_entity_marker": "[E1]CD5[/E1] interaction with [E2]p56lck[/E2] represents a novel variant of a receptor-kinase complex in which receptor can also serve as substrate. ( ABSTRACT TRUNCATED AT 250 WORDS )", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD5", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p56lck", "entity_2_idx": [[21, 27]], "entity_2_idx_in_text_with_entity_marker": [34, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d41.s358_AIMed.d41.s358.p0", "text": "The HFE-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "text_with_entity_marker": "The [E1]HFE[/E1]-[E2]TfR[/E2] complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HFE", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TfR", "entity_2_idx": [[8, 11]], "entity_2_idx_in_text_with_entity_marker": [21, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1441_AIMed.d171.s1441.p0", "text": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.", "text_with_entity_marker": "Crystal structure of the [E1]p27Kip1[/E1] cyclin-dependent-kinase inhibitor bound to the [E2]cyclin A[/E2]-Cdk2 complex.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[25, 32]], "entity_1_idx_in_text_with_entity_marker": [29, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[80, 88]], "entity_2_idx_in_text_with_entity_marker": [93, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1441_AIMed.d171.s1441.p1", "text": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.", "text_with_entity_marker": "Crystal structure of the [E1]p27Kip1[/E1] cyclin-dependent-kinase inhibitor bound to the cyclin A-[E2]Cdk2[/E2] complex.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[25, 32]], "entity_1_idx_in_text_with_entity_marker": [29, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1441_AIMed.d171.s1441.p2", "text": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.", "text_with_entity_marker": "Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the [E1]cyclin A[/E1]-[E2]Cdk2[/E2] complex.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[80, 88]], "entity_1_idx_in_text_with_entity_marker": [84, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p0", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human [E1]p27Kip1 kinase[/E1] inhibitory domain bound to the phosphorylated [E2]cyclin A[/E2]-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27Kip1 kinase", "entity_1_idx": [[35, 49]], "entity_1_idx_in_text_with_entity_marker": [39, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[96, 104]], "entity_2_idx_in_text_with_entity_marker": [109, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p2", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human [E1]p27Kip1 kinase[/E1] inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 ([E2]Cdk2[/E2]) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27Kip1 kinase", "entity_1_idx": [[35, 49]], "entity_1_idx_in_text_with_entity_marker": [39, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1442_AIMed.d171.s1442.p4", "text": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom.", "text_with_entity_marker": "The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated [E1]cyclin A[/E1]-cyclin-dependent kinase 2 ([E2]Cdk2[/E2]) complex has been determined at 2.3 angstrom.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin A", "entity_1_idx": [[96, 104]], "entity_1_idx_in_text_with_entity_marker": [100, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1443_AIMed.d171.s1443.p0", "text": "p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.", "text_with_entity_marker": "[E1]p27Kip1[/E1] binds the complex as an extended structure interacting with both [E2]cyclin A[/E2] and Cdk2.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin A", "entity_2_idx": [[73, 81]], "entity_2_idx_in_text_with_entity_marker": [86, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d171.s1443_AIMed.d171.s1443.p1", "text": "p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2.", "text_with_entity_marker": "[E1]p27Kip1[/E1] binds the complex as an extended structure interacting with both cyclin A and [E2]Cdk2[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27Kip1", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Cdk2", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d36.s301_AIMed.d36.s301.p0", "text": "Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices.", "text_with_entity_marker": "Molecular determinants of the interaction between the C-terminal domain of Alzheimer's [E1]beta-amyloid peptide[/E1] and [E2]apolipoprotein E[/E2] alpha-helices.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "beta-amyloid peptide", "entity_1_idx": [[87, 107]], "entity_1_idx_in_text_with_entity_marker": [91, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "apolipoprotein E", "entity_2_idx": [[112, 128]], "entity_2_idx_in_text_with_entity_marker": [125, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d36.s303_AIMed.d36.s303.p1", "text": "We further demonstrated that apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic activity of Abeta(29-42) via a direct interaction.", "text_with_entity_marker": "We further demonstrated that [E1]apolipoprotein E2[/E1] and E3 but not apolipoprotein E4 can decrease the fusogenic activity of [E2]Abeta[/E2](29-42) via a direct interaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "apolipoprotein E2", "entity_1_idx": [[29, 46]], "entity_1_idx_in_text_with_entity_marker": [33, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[119, 124]], "entity_2_idx_in_text_with_entity_marker": [132, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p3", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and [E2]Fas ligand[/E2] (FasL/CD95L).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[120, 130]], "entity_2_idx_in_text_with_entity_marker": [133, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s262_AIMed.d31.s262.p4", "text": "Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).", "text_with_entity_marker": "Here, we demonstrate that [E1]TR6[/E1] specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand ([E2]FasL[/E2]/CD95L).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TR6", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[132, 136]], "entity_2_idx_in_text_with_entity_marker": [145, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s265_AIMed.d31.s265.p6", "text": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.", "text_with_entity_marker": "It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both [E1]lymphotoxin beta[/E1] receptor ([E2]LTbetaR[/E2]) and HVEM/TR2 receptors.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "lymphotoxin beta", "entity_1_idx": [[110, 126]], "entity_1_idx_in_text_with_entity_marker": [114, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[137, 144]], "entity_2_idx_in_text_with_entity_marker": [150, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p5", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with [E2]HVEM[/E2]/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HVEM", "entity_2_idx": [[66, 70]], "entity_2_idx_in_text_with_entity_marker": [79, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p6", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM/[E2]TR2[/E2] and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TR2", "entity_2_idx": [[71, 74]], "entity_2_idx_in_text_with_entity_marker": [84, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d31.s266_AIMed.d31.s266.p7", "text": "Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.", "text_with_entity_marker": "Our data suggest that TR6 inhibits the interactions of [E1]LIGHT[/E1] with HVEM/TR2 and [E2]LTbetaR[/E2], thereby suppressing LIGHT- mediated HT29 cell death.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIGHT", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LTbetaR", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1043_AIMed.d123.s1043.p0", "text": "Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system.", "text_with_entity_marker": "Characterization of an interaction between [E1]insulin receptor substrate 1[/E1] and the [E2]insulin receptor[/E2] by using the two-hybrid system.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "insulin receptor substrate 1", "entity_1_idx": [[43, 71]], "entity_1_idx_in_text_with_entity_marker": [47, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[80, 96]], "entity_2_idx_in_text_with_entity_marker": [93, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p1", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "[E1]Insulin receptor substrate 1[/E1] (IRS-1) is a major substrate of the [E2]insulin receptor[/E2] and has been implicated in insulin signaling.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Insulin receptor substrate 1", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[65, 81]], "entity_2_idx_in_text_with_entity_marker": [78, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1044_AIMed.d123.s1044.p3", "text": "Insulin receptor substrate 1 (IRS-1) is a major substrate of the insulin receptor and has been implicated in insulin signaling.", "text_with_entity_marker": "Insulin receptor substrate 1 ([E1]IRS-1[/E1]) is a major substrate of the [E2]insulin receptor[/E2] and has been implicated in insulin signaling.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[65, 81]], "entity_2_idx_in_text_with_entity_marker": [78, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1045_AIMed.d123.s1045.p1", "text": "Although IRS-1 is thought to interact with the insulin receptor, the nature of the interaction has not been defined.", "text_with_entity_marker": "Although [E1]IRS-1[/E1] is thought to interact with the [E2]insulin receptor[/E2], the nature of the interaction has not been defined.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[47, 63]], "entity_2_idx_in_text_with_entity_marker": [60, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1046_AIMed.d123.s1046.p1", "text": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the insulin receptor.", "text_with_entity_marker": "In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human [E1]IRS-1[/E1] and the [E2]insulin receptor[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[166, 182]], "entity_2_idx_in_text_with_entity_marker": [179, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d123.s1047_AIMed.d123.s1047.p0", "text": "We demonstrate that IRS-1 forms a specific complex with the cytoplasmic domain of the insulin receptor when both are expressed as hybrid proteins in yeast cells.", "text_with_entity_marker": "We demonstrate that [E1]IRS-1[/E1] forms a specific complex with the cytoplasmic domain of the [E2]insulin receptor[/E2] when both are expressed as hybrid proteins in yeast cells.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[20, 25]], "entity_1_idx_in_text_with_entity_marker": [24, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[86, 102]], "entity_2_idx_in_text_with_entity_marker": [99, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1561_AIMed.d184.s1561.p0", "text": "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.", "text_with_entity_marker": "[E1]CD4[/E1]-induced interaction of primary HIV-1 [E2]gp120[/E2] glycoproteins with the chemokine receptor CCR-5.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[41, 46]], "entity_2_idx_in_text_with_entity_marker": [54, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p0", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E2]CD4[/E2] interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p1", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with [E2]CCR-5[/E2] and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[153, 158]], "entity_2_idx_in_text_with_entity_marker": [166, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p5", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E1]CD4[/E1] interacts specifically with [E2]CCR-5[/E2] and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[153, 158]], "entity_2_idx_in_text_with_entity_marker": [166, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1564_AIMed.d184.s1564.p0", "text": "The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.", "text_with_entity_marker": "The apparent affinity of the interaction between [E1]gp120[/E1] and [E2]CCR-5[/E2] was dramatically lower in the absence of soluble CD4.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1565_AIMed.d184.s1565.p2", "text": "Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.", "text_with_entity_marker": "Additionally, in the absence of gp120, an interaction between a two-domain [E1]CD4[/E1] fragment and [E2]CCR-5[/E2] was observed.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[75, 78]], "entity_1_idx_in_text_with_entity_marker": [79, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1566_AIMed.d184.s1566.p0", "text": "A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "text_with_entity_marker": "A [E1]gp120[/E1] fragment retaining the [E2]CD4[/E2]-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[31, 34]], "entity_2_idx_in_text_with_entity_marker": [44, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1566_AIMed.d184.s1566.p1", "text": "A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "text_with_entity_marker": "A [E1]gp120[/E1] fragment retaining the CD4-binding site and overlapping epitopes was able to interact with [E2]CCR-5[/E2] only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p7", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of [E1]gp12O[/E1]-[E2]CD4[/E2] complexes with CCR-5.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp12O", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p8", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of [E1]gp12O[/E1]-CD4 complexes with [E2]CCR-5[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gp12O", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p9", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-[E1]CD4[/E1] complexes with [E2]CCR-5[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s361_AIMed.d42.s361.p0", "text": "The BMP receptors belong to the family of serine/threonine kinase receptors, whose activation has been investigated intensively for the transforming growth factor-beta (TGF-beta) receptor subfamily.", "text_with_entity_marker": "The BMP receptors belong to the family of serine/threonine kinase receptors, whose activation has been investigated intensively for the [E1]transforming growth factor-beta[/E1] ([E2]TGF-beta[/E2]) receptor subfamily.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transforming growth factor-beta", "entity_1_idx": [[136, 167]], "entity_1_idx_in_text_with_entity_marker": [140, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TGF-beta", "entity_2_idx": [[169, 177]], "entity_2_idx_in_text_with_entity_marker": [182, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d216.s1878_AIMed.d216.s1878.p0", "text": "Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Ras, and even its mutation to alanine would disturb the arrangements of residues in the transition state.", "text_with_entity_marker": "Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of [E1]GAP-334[/E1] and glutamine-61 of [E2]Ras[/E2], and even its mutation to alanine would disturb the arrangements of residues in the transition state.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GAP-334", "entity_1_idx": [[98, 105]], "entity_1_idx_in_text_with_entity_marker": [102, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ras", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d34.s285_AIMed.d34.s285.p0", "text": "Presenilin 1 (PS1) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.", "text_with_entity_marker": "[E1]Presenilin 1[/E1] ([E2]PS1[/E2]) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Presenilin 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[14, 17]], "entity_2_idx_in_text_with_entity_marker": [27, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1579_AIMed.d186.s1579.p0", "text": "cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.", "text_with_entity_marker": "cDNA cloning and characterization of the human [E1-E2]interleukin 13[/E1] receptor[/E2] alpha chain.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13", "entity_1_idx": [[47, 61]], "entity_1_idx_in_text_with_entity_marker": [54, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor", "entity_2_idx": [[47, 70]], "entity_2_idx_in_text_with_entity_marker": [54, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1579_AIMed.d186.s1579.p1", "text": "cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.", "text_with_entity_marker": "cDNA cloning and characterization of the human [E1-E2]interleukin 13[/E1] receptor alpha chain[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13", "entity_1_idx": [[47, 61]], "entity_1_idx_in_text_with_entity_marker": [54, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor alpha chain", "entity_2_idx": [[47, 82]], "entity_2_idx_in_text_with_entity_marker": [54, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1579_AIMed.d186.s1579.p2", "text": "cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.", "text_with_entity_marker": "cDNA cloning and characterization of the human [E1-E2]interleukin 13 receptor[/E1] alpha chain[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13 receptor", "entity_1_idx": [[47, 70]], "entity_1_idx_in_text_with_entity_marker": [54, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13 receptor[/E1] alpha chain", "entity_2_idx": [[47, 82]], "entity_2_idx_in_text_with_entity_marker": [54, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p0", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1-E2]interleukin 13[/E1] receptor[/E2] alpha chain (IL-13Ralpha).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13", "entity_1_idx": [[48, 62]], "entity_1_idx_in_text_with_entity_marker": [55, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor", "entity_2_idx": [[48, 71]], "entity_2_idx_in_text_with_entity_marker": [55, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p1", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1-E2]interleukin 13[/E1] receptor alpha chain[/E2] (IL-13Ralpha).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13", "entity_1_idx": [[48, 62]], "entity_1_idx_in_text_with_entity_marker": [55, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13[/E1] receptor alpha chain", "entity_2_idx": [[48, 83]], "entity_2_idx_in_text_with_entity_marker": [55, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p2", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1]interleukin 13[/E1] receptor alpha chain ([E2]IL-13Ralpha[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13", "entity_1_idx": [[48, 62]], "entity_1_idx_in_text_with_entity_marker": [52, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[85, 96]], "entity_2_idx_in_text_with_entity_marker": [98, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p3", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1-E2]interleukin 13 receptor[/E1] alpha chain[/E2] (IL-13Ralpha).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13 receptor", "entity_1_idx": [[48, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin 13 receptor[/E1] alpha chain", "entity_2_idx": [[48, 83]], "entity_2_idx_in_text_with_entity_marker": [55, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p4", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1]interleukin 13 receptor[/E1] alpha chain ([E2]IL-13Ralpha[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13 receptor", "entity_1_idx": [[48, 71]], "entity_1_idx_in_text_with_entity_marker": [52, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[85, 96]], "entity_2_idx_in_text_with_entity_marker": [98, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1580_AIMed.d186.s1580.p5", "text": "We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).", "text_with_entity_marker": "We have cloned cDNAs corresponding to the human [E1]interleukin 13 receptor alpha chain[/E1] ([E2]IL-13Ralpha[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin 13 receptor alpha chain", "entity_1_idx": [[48, 83]], "entity_1_idx_in_text_with_entity_marker": [52, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[85, 96]], "entity_2_idx_in_text_with_entity_marker": [98, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p0", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of [E1]IL-13Ralpha[/E1] and [E2]gammac[/E2] are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-13Ralpha", "entity_1_idx": [[71, 82]], "entity_1_idx_in_text_with_entity_marker": [75, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[87, 93]], "entity_2_idx_in_text_with_entity_marker": [100, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p1", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of [E1]IL-13Ralpha[/E1] and gammac are similar, and like [E2]gammac[/E2], IL-13Ralpha is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-13Ralpha", "entity_1_idx": [[71, 82]], "entity_1_idx_in_text_with_entity_marker": [75, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p2", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of [E1]IL-13Ralpha[/E1] and gammac are similar, and like gammac, [E2]IL-13Ralpha[/E2] is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-13Ralpha", "entity_1_idx": [[71, 82]], "entity_1_idx_in_text_with_entity_marker": [75, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[124, 135]], "entity_2_idx_in_text_with_entity_marker": [137, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p3", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and [E1]gammac[/E1] are similar, and like [E2]gammac[/E2], IL-13Ralpha is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "gammac", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gammac", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p4", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and [E1]gammac[/E1] are similar, and like gammac, [E2]IL-13Ralpha[/E2] is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "gammac", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[124, 135]], "entity_2_idx_in_text_with_entity_marker": [137, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d186.s1584_AIMed.d186.s1584.p5", "text": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.", "text_with_entity_marker": "Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like [E1]gammac[/E1], [E2]IL-13Ralpha[/E2] is located on chromosome X.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "gammac", "entity_1_idx": [[116, 122]], "entity_1_idx_in_text_with_entity_marker": [120, 126], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13Ralpha", "entity_2_idx": [[124, 135]], "entity_2_idx_in_text_with_entity_marker": [137, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1388_AIMed.d165.s1388.p0", "text": "At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "text_with_entity_marker": "At least two of the subunits of [E1]TFIIH[/E1] ([E2]XPB[/E2] and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIH", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPB", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1388_AIMed.d165.s1388.p1", "text": "At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "text_with_entity_marker": "At least two of the subunits of [E1]TFIIH[/E1] (XPB and [E2]XPD[/E2] proteins) are implicated in the disease xeroderma pigmentosum (XP).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIH", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1388_AIMed.d165.s1388.p2", "text": "At least two of the subunits of TFIIH (XPB and XPD proteins) are implicated in the disease xeroderma pigmentosum (XP).", "text_with_entity_marker": "At least two of the subunits of TFIIH ([E1]XPB[/E1] and [E2]XPD[/E2] proteins) are implicated in the disease xeroderma pigmentosum (XP).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPB", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p0", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], [E2]XPD[/E2], p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPD", "entity_2_idx": [[54, 57]], "entity_2_idx_in_text_with_entity_marker": [67, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p1", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, [E2]p62[/E2], p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p2", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, p62, [E2]p44[/E2], and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p3", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, p62, p44, and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p4", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned [E1]XPB[/E1], XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPB", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p5", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], [E2]p62[/E2], p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p62", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p6", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], p62, [E2]p44[/E2], and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p7", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], p62, p44, and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p8", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, [E1]XPD[/E1], p62, p44, and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPD", "entity_1_idx": [[54, 57]], "entity_1_idx_in_text_with_entity_marker": [58, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p9", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, [E1]p62[/E1], [E2]p44[/E2], and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p62", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p44", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p10", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, [E1]p62[/E1], p44, and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p62", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p11", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, [E1]p62[/E1], p44, and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p62", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p12", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, p62, [E1]p44[/E1], and [E2]p34[/E2] genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p44", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p34", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p13", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, p62, [E1]p44[/E1], and p34 genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p44", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1389_AIMed.d165.s1389.p14", "text": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and p34 genes (all of which encode polypeptide subunits of TFIIH) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "text_with_entity_marker": "We have exploited the availability of the cloned XPB, XPD, p62, p44, and [E1]p34[/E1] genes (all of which encode polypeptide subunits of [E2]TFIIH[/E2]) to examine interactions between in vitro-translated polypeptides by co-immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p34", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIH", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1390_AIMed.d165.s1390.p0", "text": "Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).", "text_with_entity_marker": "Additionally we have examined interactions between [E1]TFIIH[/E1] components, the human NER protein [E2]XPG[/E2], and the CSB protein which is implicated in Cockayne syndrome (CS).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIH", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "XPG", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1390_AIMed.d165.s1390.p1", "text": "Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).", "text_with_entity_marker": "Additionally we have examined interactions between [E1]TFIIH[/E1] components, the human NER protein XPG, and the [E2]CSB[/E2] protein which is implicated in Cockayne syndrome (CS).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIH", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d165.s1390_AIMed.d165.s1390.p2", "text": "Additionally we have examined interactions between TFIIH components, the human NER protein XPG, and the CSB protein which is implicated in Cockayne syndrome (CS).", "text_with_entity_marker": "Additionally we have examined interactions between TFIIH components, the human NER protein [E1]XPG[/E1], and the [E2]CSB[/E2] protein which is implicated in Cockayne syndrome (CS).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "XPG", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CSB", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1252_AIMed.d148.s1252.p0", "text": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.", "text_with_entity_marker": ".Originally identified as a 'mitotic cyclin', [E1]cyclin A[/E1] exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an [E2]S-phase-promoting factor[/E2] (SPF) as well as a candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cyclin A", "entity_1_idx": [[46, 54]], "entity_1_idx_in_text_with_entity_marker": [50, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "S-phase-promoting factor", "entity_2_idx": [[227, 251]], "entity_2_idx_in_text_with_entity_marker": [240, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1252_AIMed.d148.s1252.p1", "text": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.", "text_with_entity_marker": ".Originally identified as a 'mitotic cyclin', [E1]cyclin A[/E1] exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor ([E2]SPF[/E2]) as well as a candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cyclin A", "entity_1_idx": [[46, 54]], "entity_1_idx_in_text_with_entity_marker": [50, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SPF", "entity_2_idx": [[253, 256]], "entity_2_idx_in_text_with_entity_marker": [266, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1252_AIMed.d148.s1252.p2", "text": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene.", "text_with_entity_marker": ".Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an [E1]S-phase-promoting factor[/E1] ([E2]SPF[/E2]) as well as a candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "S-phase-promoting factor", "entity_1_idx": [[227, 251]], "entity_1_idx_in_text_with_entity_marker": [231, 255], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SPF", "entity_2_idx": [[253, 256]], "entity_2_idx_in_text_with_entity_marker": [266, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d148.s1253_AIMed.d148.s1253.p0", "text": "Other recent studies have identified human cyclin D1 (PRAD1) as a putative G1 cyclin and candidate proto-oncogene.", "text_with_entity_marker": "Other recent studies have identified human [E1]cyclin D1[/E1] ([E2]PRAD1[/E2]) as a putative G1 cyclin and candidate proto-oncogene.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cyclin D1", "entity_1_idx": [[43, 52]], "entity_1_idx_in_text_with_entity_marker": [47, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PRAD1", "entity_2_idx": [[54, 59]], "entity_2_idx_in_text_with_entity_marker": [67, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s203_AIMed.d25.s203.p0", "text": "Assaying of tumor necrosis factor alpha, complement factors, and alpha-1-antitrypsin in the diagnosis of malignant serous effusions.", "text_with_entity_marker": "Assaying of [E1]tumor necrosis factor alpha[/E1], complement factors, and [E2]alpha-1-antitrypsin[/E2] in the diagnosis of malignant serous effusions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor alpha", "entity_1_idx": [[12, 39]], "entity_1_idx_in_text_with_entity_marker": [16, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[65, 84]], "entity_2_idx_in_text_with_entity_marker": [78, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p0", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] ([E2]TNFalpha[/E2]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p1", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E2]TNFalpha[/E2], alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[182, 190]], "entity_2_idx_in_text_with_entity_marker": [195, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p2", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E2]alpha-1-antitrypsin[/E2] (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[192, 211]], "entity_2_idx_in_text_with_entity_marker": [205, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p3", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p4", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p5", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of [E1]tumor necrosis factor-alpha[/E1] (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumor necrosis factor-alpha", "entity_1_idx": [[65, 92]], "entity_1_idx_in_text_with_entity_marker": [69, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p6", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether [E2]TNFalpha[/E2], alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[182, 190]], "entity_2_idx_in_text_with_entity_marker": [195, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p7", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E2]alpha-1-antitrypsin[/E2] (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[192, 211]], "entity_2_idx_in_text_with_entity_marker": [205, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p8", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p9", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p10", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ([E1]TNFalpha[/E1]) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p11", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], [E2]alpha-1-antitrypsin[/E2] (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha-1-antitrypsin", "entity_2_idx": [[192, 211]], "entity_2_idx_in_text_with_entity_marker": [205, 224], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p12", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], alpha-1-antitrypsin ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p13", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], alpha-1-antitrypsin (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p14", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether [E1]TNFalpha[/E1], alpha-1-antitrypsin (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[182, 190]], "entity_1_idx_in_text_with_entity_marker": [186, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p15", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E1]alpha-1-antitrypsin[/E1] ([E2]alpha1AT[/E2]), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-1-antitrypsin", "entity_1_idx": [[192, 211]], "entity_1_idx_in_text_with_entity_marker": [196, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[213, 221]], "entity_2_idx_in_text_with_entity_marker": [226, 234], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p16", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E1]alpha-1-antitrypsin[/E1] (alpha1AT), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-1-antitrypsin", "entity_1_idx": [[192, 211]], "entity_1_idx_in_text_with_entity_marker": [196, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p17", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, [E1]alpha-1-antitrypsin[/E1] (alpha1AT), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-1-antitrypsin", "entity_1_idx": [[192, 211]], "entity_1_idx_in_text_with_entity_marker": [196, 215], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p18", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E1]alpha1AT[/E1]), and complement factors [E2]C3[/E2] and C4 can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[213, 221]], "entity_1_idx_in_text_with_entity_marker": [217, 225], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[247, 249]], "entity_2_idx_in_text_with_entity_marker": [260, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p19", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin ([E1]alpha1AT[/E1]), and complement factors C3 and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[213, 221]], "entity_1_idx_in_text_with_entity_marker": [217, 225], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s204_AIMed.d25.s204.p20", "text": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.", "text_with_entity_marker": "The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors [E1]C3[/E1] and [E2]C4[/E2] can be used in the differential diagnosis of serous effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C3", "entity_1_idx": [[247, 249]], "entity_1_idx_in_text_with_entity_marker": [251, 253], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[254, 256]], "entity_2_idx_in_text_with_entity_marker": [267, 269], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p0", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "[E1]TNFalpha[/E1], [E2]alpha1AT[/E2], and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[10, 18]], "entity_2_idx_in_text_with_entity_marker": [23, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p1", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "[E1]TNFalpha[/E1], alpha1AT, and complement factors [E2]C3[/E2] and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[43, 45]], "entity_2_idx_in_text_with_entity_marker": [56, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p2", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "[E1]TNFalpha[/E1], alpha1AT, and complement factors C3 and [E2]C4[/E2] concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[50, 52]], "entity_2_idx_in_text_with_entity_marker": [63, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p3", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "TNFalpha, [E1]alpha1AT[/E1], and complement factors [E2]C3[/E2] and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[10, 18]], "entity_1_idx_in_text_with_entity_marker": [14, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[43, 45]], "entity_2_idx_in_text_with_entity_marker": [56, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p4", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "TNFalpha, [E1]alpha1AT[/E1], and complement factors C3 and [E2]C4[/E2] concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[10, 18]], "entity_1_idx_in_text_with_entity_marker": [14, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[50, 52]], "entity_2_idx_in_text_with_entity_marker": [63, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s206_AIMed.d25.s206.p5", "text": "TNFalpha, alpha1AT, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "text_with_entity_marker": "TNFalpha, alpha1AT, and complement factors [E1]C3[/E1] and [E2]C4[/E2] concentrations were measured simultaneously in blood and serous effusion using commercially available methods.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C3", "entity_1_idx": [[43, 45]], "entity_1_idx_in_text_with_entity_marker": [47, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[50, 52]], "entity_2_idx_in_text_with_entity_marker": [63, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p0", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was [E1]alpha1AT[/E1] effusion, [E2]C4[/E2] serum, TNFalpha-effusion, and C3 effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[29, 37]], "entity_1_idx_in_text_with_entity_marker": [33, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[48, 50]], "entity_2_idx_in_text_with_entity_marker": [61, 63], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p1", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was [E1]alpha1AT[/E1] effusion, C4 serum, [E2]TNFalpha[/E2]-effusion, and C3 effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[29, 37]], "entity_1_idx_in_text_with_entity_marker": [33, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[58, 66]], "entity_2_idx_in_text_with_entity_marker": [71, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p2", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was [E1]alpha1AT[/E1] effusion, C4 serum, TNFalpha-effusion, and [E2]C3[/E2] effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha1AT", "entity_1_idx": [[29, 37]], "entity_1_idx_in_text_with_entity_marker": [33, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[81, 83]], "entity_2_idx_in_text_with_entity_marker": [94, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p3", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was alpha1AT effusion, [E1]C4[/E1] serum, [E2]TNFalpha[/E2]-effusion, and C3 effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C4", "entity_1_idx": [[48, 50]], "entity_1_idx_in_text_with_entity_marker": [52, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFalpha", "entity_2_idx": [[58, 66]], "entity_2_idx_in_text_with_entity_marker": [71, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p4", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was alpha1AT effusion, [E1]C4[/E1] serum, TNFalpha-effusion, and [E2]C3[/E2] effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C4", "entity_1_idx": [[48, 50]], "entity_1_idx_in_text_with_entity_marker": [52, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[81, 83]], "entity_2_idx_in_text_with_entity_marker": [94, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s210_AIMed.d25.s210.p5", "text": "Their order of selection was alpha1AT effusion, C4 serum, TNFalpha-effusion, and C3 effusion.", "text_with_entity_marker": "Their order of selection was alpha1AT effusion, C4 serum, [E1]TNFalpha[/E1]-effusion, and [E2]C3[/E2] effusion.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[58, 66]], "entity_1_idx_in_text_with_entity_marker": [62, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[81, 83]], "entity_2_idx_in_text_with_entity_marker": [94, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p0", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of [E1]TNFalpha[/E1], complement factors [E2]C3[/E2] and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C3", "entity_2_idx": [[46, 48]], "entity_2_idx_in_text_with_entity_marker": [59, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p1", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of [E1]TNFalpha[/E1], complement factors C3 and [E2]C4[/E2], and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[53, 55]], "entity_2_idx_in_text_with_entity_marker": [66, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p2", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of [E1]TNFalpha[/E1], complement factors C3 and C4, and [E2]alpha1AT[/E2] may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFalpha", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p3", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of TNFalpha, complement factors [E1]C3[/E1] and [E2]C4[/E2], and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C3", "entity_1_idx": [[46, 48]], "entity_1_idx_in_text_with_entity_marker": [50, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "C4", "entity_2_idx": [[53, 55]], "entity_2_idx_in_text_with_entity_marker": [66, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p4", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of TNFalpha, complement factors [E1]C3[/E1] and C4, and [E2]alpha1AT[/E2] may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C3", "entity_1_idx": [[46, 48]], "entity_1_idx_in_text_with_entity_marker": [50, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d25.s212_AIMed.d25.s212.p5", "text": "Determination of TNFalpha, complement factors C3 and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "text_with_entity_marker": "Determination of TNFalpha, complement factors C3 and [E1]C4[/E1], and [E2]alpha1AT[/E2] may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "C4", "entity_1_idx": [[53, 55]], "entity_1_idx_in_text_with_entity_marker": [57, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1AT", "entity_2_idx": [[61, 69]], "entity_2_idx_in_text_with_entity_marker": [74, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s181_AIMed.d22.s181.p0", "text": "Present data concerning the renin-angiotensin system of extrarenal origin.", "text_with_entity_marker": "Present data concerning the [E1]renin[/E1]-[E2]angiotensin[/E2] system of extrarenal origin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "renin", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "angiotensin", "entity_2_idx": [[34, 45]], "entity_2_idx_in_text_with_entity_marker": [47, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p0", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal [E2]angiotensin[/E2]-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "angiotensin", "entity_2_idx": [[97, 108]], "entity_2_idx_in_text_with_entity_marker": [110, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p1", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E2]isorenin[/E2], tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "isorenin", "entity_2_idx": [[140, 148]], "entity_2_idx_in_text_with_entity_marker": [153, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p2", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, [E2]tonin[/E2], D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tonin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p3", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p4", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding [E1]RAS[/E1] of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAS", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p5", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with [E2]isorenin[/E2], tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "isorenin", "entity_2_idx": [[140, 148]], "entity_2_idx_in_text_with_entity_marker": [153, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p6", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with isorenin, [E2]tonin[/E2], D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tonin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p7", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with isorenin, tonin, D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p8", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal [E1]angiotensin[/E1]-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "angiotensin", "entity_1_idx": [[97, 108]], "entity_1_idx_in_text_with_entity_marker": [101, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p9", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E1]isorenin[/E1], [E2]tonin[/E2], D and G cathepsin and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "isorenin", "entity_1_idx": [[140, 148]], "entity_1_idx_in_text_with_entity_marker": [144, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tonin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p10", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E1]isorenin[/E1], tonin, D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "isorenin", "entity_1_idx": [[140, 148]], "entity_1_idx_in_text_with_entity_marker": [144, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p11", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with [E1]isorenin[/E1], tonin, D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "isorenin", "entity_1_idx": [[140, 148]], "entity_1_idx_in_text_with_entity_marker": [144, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p12", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, [E1]tonin[/E1], D and [E2]G cathepsin[/E2] and ending with the conversion enzyme and chymase.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tonin", "entity_1_idx": [[150, 155]], "entity_1_idx_in_text_with_entity_marker": [154, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "G cathepsin", "entity_2_idx": [[163, 174]], "entity_2_idx_in_text_with_entity_marker": [176, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p13", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, [E1]tonin[/E1], D and G cathepsin and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tonin", "entity_1_idx": [[150, 155]], "entity_1_idx_in_text_with_entity_marker": [154, 159], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s182_AIMed.d22.s182.p14", "text": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.", "text_with_entity_marker": "After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and [E1]G cathepsin[/E1] and ending with the conversion enzyme and [E2]chymase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "G cathepsin", "entity_1_idx": [[163, 174]], "entity_1_idx_in_text_with_entity_marker": [167, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "chymase", "entity_2_idx": [[217, 224]], "entity_2_idx_in_text_with_entity_marker": [230, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d22.s185_AIMed.d22.s185.p0", "text": "While the circulating RAS of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue RAS, in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.", "text_with_entity_marker": "While the circulating [E1]RAS[/E1] of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue [E2]RAS[/E2], in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAS", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAS", "entity_2_idx": [[143, 146]], "entity_2_idx_in_text_with_entity_marker": [156, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1758_AIMed.d204.s1758.p0", "text": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "text_with_entity_marker": "Wild-type [E1]MMP-1[/E1], as well as the [E2]MMP-1[/E2] mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP-1", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1758_AIMed.d204.s1758.p1", "text": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "text_with_entity_marker": "Wild-type [E1]MMP-1[/E1], as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-[E2]MMP-1[/E2]], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP-1", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1758_AIMed.d204.s1758.p2", "text": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "text_with_entity_marker": "Wild-type [E1]MMP-1[/E1], as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with [E2]trypsin[/E2] or 4-aminophenylmercuric acetate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[10, 15]], "entity_1_idx_in_text_with_entity_marker": [14, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trypsin", "entity_2_idx": [[189, 196]], "entity_2_idx_in_text_with_entity_marker": [202, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1758_AIMed.d204.s1758.p3", "text": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "text_with_entity_marker": "Wild-type MMP-1, as well as the [E1]MMP-1[/E1] mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-[E2]MMP-1[/E2]], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP-1", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1758_AIMed.d204.s1758.p4", "text": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "text_with_entity_marker": "Wild-type MMP-1, as well as the [E1]MMP-1[/E1] mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with [E2]trypsin[/E2] or 4-aminophenylmercuric acetate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trypsin", "entity_2_idx": [[189, 196]], "entity_2_idx_in_text_with_entity_marker": [202, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1758_AIMed.d204.s1758.p5", "text": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-MMP-1], exhibit enzymatic activity upon cleavage of the prodomain by treatment with trypsin or 4-aminophenylmercuric acetate.", "text_with_entity_marker": "Wild-type MMP-1, as well as the MMP-1 mutant lacking the C-terminal hemopexin-like domain [des-(248-450)-[E1]MMP-1[/E1]], exhibit enzymatic activity upon cleavage of the prodomain by treatment with [E2]trypsin[/E2] or 4-aminophenylmercuric acetate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trypsin", "entity_2_idx": [[189, 196]], "entity_2_idx_in_text_with_entity_marker": [202, 209], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1760_AIMed.d204.s1760.p0", "text": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.", "text_with_entity_marker": "Deletion of the complete active-site [des-(161-228)-[E1]MMP-1[/E1]] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of [E2]MMP-1[/E2] proteins which are unable to digest collagen type I or beta-casein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP-1", "entity_2_idx": [[187, 192]], "entity_2_idx_in_text_with_entity_marker": [200, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1760_AIMed.d204.s1760.p1", "text": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.", "text_with_entity_marker": "Deletion of the complete active-site [des-(161-228)-[E1]MMP-1[/E1]] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest [E2]collagen type I[/E2] or beta-casein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "collagen type I", "entity_2_idx": [[229, 244]], "entity_2_idx_in_text_with_entity_marker": [242, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1760_AIMed.d204.s1760.p2", "text": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.", "text_with_entity_marker": "Deletion of the complete active-site [des-(161-228)-[E1]MMP-1[/E1]] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or [E2]beta-casein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-casein", "entity_2_idx": [[248, 259]], "entity_2_idx_in_text_with_entity_marker": [261, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1760_AIMed.d204.s1760.p3", "text": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.", "text_with_entity_marker": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of [E1]MMP-1[/E1] proteins which are unable to digest [E2]collagen type I[/E2] or beta-casein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[187, 192]], "entity_1_idx_in_text_with_entity_marker": [191, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "collagen type I", "entity_2_idx": [[229, 244]], "entity_2_idx_in_text_with_entity_marker": [242, 257], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1760_AIMed.d204.s1760.p4", "text": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.", "text_with_entity_marker": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of [E1]MMP-1[/E1] proteins which are unable to digest collagen type I or [E2]beta-casein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[187, 192]], "entity_1_idx_in_text_with_entity_marker": [191, 196], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-casein", "entity_2_idx": [[248, 259]], "entity_2_idx_in_text_with_entity_marker": [261, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1760_AIMed.d204.s1760.p5", "text": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest collagen type I or beta-casein.", "text_with_entity_marker": "Deletion of the complete active-site [des-(161-228)-MMP-1] within the catalytic domain, or mutation of a single His residue of the Zn2+ binding domain (His199), generates stable forms of MMP-1 proteins which are unable to digest [E1]collagen type I[/E1] or [E2]beta-casein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "collagen type I", "entity_1_idx": [[229, 244]], "entity_1_idx_in_text_with_entity_marker": [233, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-casein", "entity_2_idx": [[248, 259]], "entity_2_idx_in_text_with_entity_marker": [261, 272], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1761_AIMed.d204.s1761.p0", "text": "In addition to co-immunoprecipitation analysis, we have established a rapid and sensitive ELISA assay using immobilized rTIMP to determine the structural requirements of MMP-1 to form complexes with its inhibitor.", "text_with_entity_marker": "In addition to co-immunoprecipitation analysis, we have established a rapid and sensitive ELISA assay using immobilized [E1]rTIMP[/E1] to determine the structural requirements of [E2]MMP-1[/E2] to form complexes with its inhibitor.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rTIMP", "entity_1_idx": [[120, 125]], "entity_1_idx_in_text_with_entity_marker": [124, 129], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP-1", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1763_AIMed.d204.s1763.p0", "text": "Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-MMP-1, interact with TIMP.", "text_with_entity_marker": "Neither mutation of His199, nor deletion mutants des-(161-228)-[E1]MMP-1[/E1] and des-(161-228/248-450)-[E2]MMP-1[/E2], interact with TIMP.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[63, 68]], "entity_1_idx_in_text_with_entity_marker": [67, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MMP-1", "entity_2_idx": [[95, 100]], "entity_2_idx_in_text_with_entity_marker": [108, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1763_AIMed.d204.s1763.p1", "text": "Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-MMP-1, interact with TIMP.", "text_with_entity_marker": "Neither mutation of His199, nor deletion mutants des-(161-228)-[E1]MMP-1[/E1] and des-(161-228/248-450)-MMP-1, interact with [E2]TIMP[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[63, 68]], "entity_1_idx_in_text_with_entity_marker": [67, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TIMP", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d204.s1763_AIMed.d204.s1763.p2", "text": "Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-MMP-1, interact with TIMP.", "text_with_entity_marker": "Neither mutation of His199, nor deletion mutants des-(161-228)-MMP-1 and des-(161-228/248-450)-[E1]MMP-1[/E1], interact with [E2]TIMP[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MMP-1", "entity_1_idx": [[95, 100]], "entity_1_idx_in_text_with_entity_marker": [99, 104], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TIMP", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p0", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, [E2]transforming growth factors (TGF) beta1[/E2] and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transforming growth factors (TGF) beta1", "entity_2_idx": [[201, 240]], "entity_2_idx_in_text_with_entity_marker": [214, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p1", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, [E2]interleukin (IL) 1[/E2] and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin (IL) 1", "entity_2_idx": [[248, 266]], "entity_2_idx_in_text_with_entity_marker": [261, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p2", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist ([E2]IL 1ra[/E2]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL 1ra", "entity_2_idx": [[296, 302]], "entity_2_idx_in_text_with_entity_marker": [309, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p3", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p4", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules [E1]tumour necrosis factors (TNF) alpha[/E1] and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tumour necrosis factors (TNF) alpha", "entity_1_idx": [[155, 190]], "entity_1_idx_in_text_with_entity_marker": [159, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p5", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, [E2]interleukin (IL) 1[/E2] and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin (IL) 1", "entity_2_idx": [[248, 266]], "entity_2_idx_in_text_with_entity_marker": [261, 279], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p6", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, interleukin (IL) 1 and its receptor antagonist ([E2]IL 1ra[/E2]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL 1ra", "entity_2_idx": [[296, 302]], "entity_2_idx_in_text_with_entity_marker": [309, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p7", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p8", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, [E1]transforming growth factors (TGF) beta1[/E1] and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transforming growth factors (TGF) beta1", "entity_1_idx": [[201, 240]], "entity_1_idx_in_text_with_entity_marker": [205, 244], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p9", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, [E1]interleukin (IL) 1[/E1] and its receptor antagonist ([E2]IL 1ra[/E2]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin (IL) 1", "entity_1_idx": [[248, 266]], "entity_1_idx_in_text_with_entity_marker": [252, 270], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL 1ra", "entity_2_idx": [[296, 302]], "entity_2_idx_in_text_with_entity_marker": [309, 315], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p10", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, [E1]interleukin (IL) 1[/E1] and its receptor antagonist (IL 1ra), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin (IL) 1", "entity_1_idx": [[248, 266]], "entity_1_idx_in_text_with_entity_marker": [252, 270], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p11", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, [E1]interleukin (IL) 1[/E1] and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "interleukin (IL) 1", "entity_1_idx": [[248, 266]], "entity_1_idx_in_text_with_entity_marker": [252, 270], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p12", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist ([E1]IL 1ra[/E1]), [E2]CD14[/E2] (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL 1ra", "entity_1_idx": [[296, 302]], "entity_1_idx_in_text_with_entity_marker": [300, 306], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD14", "entity_2_idx": [[305, 309]], "entity_2_idx_in_text_with_entity_marker": [318, 322], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p13", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist ([E1]IL 1ra[/E1]), CD14 (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL 1ra", "entity_1_idx": [[296, 302]], "entity_1_idx_in_text_with_entity_marker": [300, 306], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d20.s168_AIMed.d20.s168.p14", "text": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), CD14 (the receptor for lipopolysaccharide), P and E selectins, and platelet endothelial cell adhesion molecule (PECAM) 1.", "text_with_entity_marker": "Accordingly, a number of population studies have explored the association of ischaemic heart disease with gene polymorphisms of the inflammatory molecules tumour necrosis factors (TNF) alpha and beta, transforming growth factors (TGF) beta1 and 2, interleukin (IL) 1 and its receptor antagonist (IL 1ra), [E1]CD14[/E1] (the receptor for lipopolysaccharide), P and E selectins, and [E2]platelet endothelial cell adhesion molecule (PECAM) 1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CD14", "entity_1_idx": [[305, 309]], "entity_1_idx_in_text_with_entity_marker": [309, 313], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "platelet endothelial cell adhesion molecule (PECAM) 1", "entity_2_idx": [[372, 425]], "entity_2_idx_in_text_with_entity_marker": [385, 438], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1727_AIMed.d201.s1727.p0", "text": "Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.", "text_with_entity_marker": "[E1]Hepatitis B virus X protein[/E1] is a transcriptional modulator that communicates with [E2]transcription factor IIB[/E2] and the RNA polymerase II subunit 5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Hepatitis B virus X protein", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transcription factor IIB", "entity_2_idx": [[82, 106]], "entity_2_idx_in_text_with_entity_marker": [95, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1727_AIMed.d201.s1727.p1", "text": "Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.", "text_with_entity_marker": "[E1]Hepatitis B virus X protein[/E1] is a transcriptional modulator that communicates with transcription factor IIB and the [E2]RNA polymerase II subunit 5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Hepatitis B virus X protein", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RNA polymerase II subunit 5", "entity_2_idx": [[115, 142]], "entity_2_idx_in_text_with_entity_marker": [128, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1727_AIMed.d201.s1727.p2", "text": "Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.", "text_with_entity_marker": "Hepatitis B virus X protein is a transcriptional modulator that communicates with [E1]transcription factor IIB[/E1] and the [E2]RNA polymerase II subunit 5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transcription factor IIB", "entity_1_idx": [[82, 106]], "entity_1_idx_in_text_with_entity_marker": [86, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RNA polymerase II subunit 5", "entity_2_idx": [[115, 142]], "entity_2_idx_in_text_with_entity_marker": [128, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1728_AIMed.d201.s1728.p0", "text": "Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements.", "text_with_entity_marker": "[E1]Hepatitis B virus X protein[/E1] ([E2]HBx[/E2]) transactivates viral and cellular genes through a wide variety of cis-elements.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Hepatitis B virus X protein", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[29, 32]], "entity_2_idx_in_text_with_entity_marker": [42, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1731_AIMed.d201.s1731.p0", "text": "In this context, we examined the possibility that HBx and RPB5 interact with other general transcription factors.", "text_with_entity_marker": "In this context, we examined the possibility that [E1]HBx[/E1] and [E2]RPB5[/E2] interact with other general transcription factors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HBx", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1859_AIMed.d214.s1859.p0", "text": "This suggests that c-Cbl may link TCR activation to molecules that regulate GTP binding proteins.", "text_with_entity_marker": "This suggests that [E1]c-Cbl[/E1] may link [E2]TCR[/E2] activation to molecules that regulate GTP binding proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "c-Cbl", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[34, 37]], "entity_2_idx_in_text_with_entity_marker": [47, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1860_AIMed.d214.s1860.p0", "text": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "text_with_entity_marker": "The SH2/SH3-containing protein [E1]Vav[/E1] also contains a guanine nucleotide exchange factor domain, and [E2]Vav[/E2] has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Vav", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Vav", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1860_AIMed.d214.s1860.p1", "text": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "text_with_entity_marker": "The SH2/SH3-containing protein [E1]Vav[/E1] also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the [E2]TCR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Vav", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[217, 220]], "entity_2_idx_in_text_with_entity_marker": [230, 233], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d214.s1860_AIMed.d214.s1860.p2", "text": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and Vav has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the TCR.", "text_with_entity_marker": "The SH2/SH3-containing protein Vav also contains a guanine nucleotide exchange factor domain, and [E1]Vav[/E1] has a crucial role in thymocyte development and activation of peripheral T cells following stimulation through the [E2]TCR[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Vav", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TCR", "entity_2_idx": [[217, 220]], "entity_2_idx_in_text_with_entity_marker": [230, 233], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s511_AIMed.d58.s511.p0", "text": "A cDNA clone encoding a novel, widely expressed protein (called growth factor receptor-bound protein 2 or GRB2) containing one src homology 2 (SH2) domain and two SH3 domains was isolated.", "text_with_entity_marker": "A cDNA clone encoding a novel, widely expressed protein (called [E1]growth factor receptor-bound protein 2[/E1] or [E2]GRB2[/E2]) containing one src homology 2 (SH2) domain and two SH3 domains was isolated.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "growth factor receptor-bound protein 2", "entity_1_idx": [[64, 102]], "entity_1_idx_in_text_with_entity_marker": [68, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p0", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of [E1]GRB2[/E1] or [E2]H-ras[/E2] proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GRB2", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[27, 32]], "entity_2_idx_in_text_with_entity_marker": [40, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p1", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of [E1]GRB2[/E1] or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of [E2]GRB2[/E2] together with H-ras protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GRB2", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p2", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of [E1]GRB2[/E1] or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with [E2]H-ras[/E2] protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GRB2", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p3", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of GRB2 or [E1]H-ras[/E1] proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of [E2]GRB2[/E2] together with H-ras protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "H-ras", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p4", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of GRB2 or [E1]H-ras[/E1] proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with [E2]H-ras[/E2] protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "H-ras", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s516_AIMed.d58.s516.p5", "text": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of GRB2 together with H-ras protein stimulated DNA synthesis.", "text_with_entity_marker": "While injection of GRB2 or H-ras proteins alone into quiescent rat fibroblasts did not have mitogenic effect, microinjection of [E1]GRB2[/E1] together with [E2]H-ras[/E2] protein stimulated DNA synthesis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GRB2", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "H-ras", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d58.s517_AIMed.d58.s517.p0", "text": "These results suggest that GRB2/sem-5 plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.", "text_with_entity_marker": "These results suggest that [E1]GRB2[/E1]/[E2]sem-5[/E2] plays a crucial role in a highly conserved mechanism for growth factor control of ras signaling.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GRB2", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sem-5", "entity_2_idx": [[32, 37]], "entity_2_idx_in_text_with_entity_marker": [45, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1230_AIMed.d146.s1230.p0", "text": "Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.", "text_with_entity_marker": "Characterization of a novel high affinity human [E1-E2]IL-7[/E1] receptor[/E2]. Expression on T cells and association with IL-7 driven proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [55, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7[/E1] receptor", "entity_2_idx": [[48, 61]], "entity_2_idx_in_text_with_entity_marker": [55, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1230_AIMed.d146.s1230.p1", "text": "Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.", "text_with_entity_marker": "Characterization of a novel high affinity human [E1]IL-7[/E1] receptor. Expression on T cells and association with [E2]IL-7[/E2] driven proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [52, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1230_AIMed.d146.s1230.p2", "text": "Characterization of a novel high affinity human IL-7 receptor. Expression on T cells and association with IL-7 driven proliferation.", "text_with_entity_marker": "Characterization of a novel high affinity human [E1]IL-7 receptor[/E1]. Expression on T cells and association with [E2]IL-7[/E2] driven proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7 receptor", "entity_1_idx": [[48, 61]], "entity_1_idx_in_text_with_entity_marker": [52, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[106, 110]], "entity_2_idx_in_text_with_entity_marker": [119, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1234_AIMed.d146.s1234.p0", "text": "In this study the origin and function of the p90 and p76 molecules have been investigated.", "text_with_entity_marker": "In this study the origin and function of the [E1]p90[/E1] and [E2]p76[/E2] molecules have been investigated.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1235_AIMed.d146.s1235.p0", "text": "To determine the role of each of these receptors in IL-7 driven proliferation, IL-7R expression and proliferative capacity were monitored during mitogenic stimulation.", "text_with_entity_marker": "To determine the role of each of these receptors in [E1]IL-7[/E1] driven proliferation, [E2]IL-7R[/E2] expression and proliferative capacity were monitored during mitogenic stimulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[79, 84]], "entity_2_idx_in_text_with_entity_marker": [92, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p0", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the [E2]p76[/E2] IL-7R, and not with expression of the p90 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p1", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the p76 [E2]IL-7R[/E2], and not with expression of the p90 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p2", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the p76 IL-7R, and not with expression of the [E2]p90[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p3", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to [E1]IL-7[/E1] correlated with expression of the p76 IL-7R, and not with expression of the p90 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p4", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the [E1]p76[/E1] [E2]IL-7R[/E2], and not with expression of the p90 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p5", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the [E1]p76[/E1] IL-7R, and not with expression of the [E2]p90[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p6", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the [E1]p76[/E1] IL-7R, and not with expression of the p90 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p7", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 [E1]IL-7R[/E1], and not with expression of the [E2]p90[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p8", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 [E1]IL-7R[/E1], and not with expression of the p90 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[108, 113]], "entity_1_idx_in_text_with_entity_marker": [112, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1236_AIMed.d146.s1236.p9", "text": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the p90 IL-7R.", "text_with_entity_marker": "These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the [E1]p90[/E1] [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1238_AIMed.d146.s1238.p0", "text": "Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.", "text_with_entity_marker": "Deglycosylation studies showed that the [E1]p90[/E1] and [E2]p76[/E2] IL-7R are not simply differently glycosylated isoforms of a single receptor.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[48, 51]], "entity_2_idx_in_text_with_entity_marker": [61, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1238_AIMed.d146.s1238.p1", "text": "Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.", "text_with_entity_marker": "Deglycosylation studies showed that the [E1]p90[/E1] and p76 [E2]IL-7R[/E2] are not simply differently glycosylated isoforms of a single receptor.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[52, 57]], "entity_2_idx_in_text_with_entity_marker": [65, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1238_AIMed.d146.s1238.p2", "text": "Deglycosylation studies showed that the p90 and p76 IL-7R are not simply differently glycosylated isoforms of a single receptor.", "text_with_entity_marker": "Deglycosylation studies showed that the p90 and [E1]p76[/E1] [E2]IL-7R[/E2] are not simply differently glycosylated isoforms of a single receptor.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[52, 57]], "entity_2_idx_in_text_with_entity_marker": [65, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p0", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the [E2]p90[/E2] IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p1", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the p90 [E2]IL-7R[/E2] but not T-cell clones that express predominantly the p76 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p2", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the [E2]p76[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[175, 178]], "entity_2_idx_in_text_with_entity_marker": [188, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p3", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned [E1]IL-7R[/E1] were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p4", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the [E1]p90[/E1] [E2]IL-7R[/E2] but not T-cell clones that express predominantly the p76 IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p5", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the [E1]p90[/E1] IL-7R but not T-cell clones that express predominantly the [E2]p76[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[175, 178]], "entity_2_idx_in_text_with_entity_marker": [188, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p6", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the [E1]p90[/E1] IL-7R but not T-cell clones that express predominantly the p76 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p7", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 [E1]IL-7R[/E1] but not T-cell clones that express predominantly the [E2]p76[/E2] IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[175, 178]], "entity_2_idx_in_text_with_entity_marker": [188, 191], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p8", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 [E1]IL-7R[/E1] but not T-cell clones that express predominantly the p76 [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1239_AIMed.d146.s1239.p9", "text": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the p76 IL-7R.", "text_with_entity_marker": "In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the [E1]p76[/E1] [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[175, 178]], "entity_1_idx_in_text_with_entity_marker": [179, 182], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1240_AIMed.d146.s1240.p0", "text": "These antibodies also immunoprecipitated the cloned IL-7R as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa IL-7R.", "text_with_entity_marker": "These antibodies also immunoprecipitated the cloned [E1]IL-7R[/E1] as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[183, 188]], "entity_2_idx_in_text_with_entity_marker": [196, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p0", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned [E2]IL-7R[/E2], thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p1", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the [E2]p76[/E2] IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[168, 171]], "entity_2_idx_in_text_with_entity_marker": [181, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p2", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 [E2]IL-7R[/E2] is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p3", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of [E1]p76[/E1]-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p4", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned [E1]IL-7R[/E1], thereby excluding the possibility that the [E2]p76[/E2] IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[118, 123]], "entity_1_idx_in_text_with_entity_marker": [122, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[168, 171]], "entity_2_idx_in_text_with_entity_marker": [181, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p5", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned [E1]IL-7R[/E1], thereby excluding the possibility that the p76 [E2]IL-7R[/E2] is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[118, 123]], "entity_1_idx_in_text_with_entity_marker": [122, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p6", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned [E1]IL-7R[/E1], thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[118, 123]], "entity_1_idx_in_text_with_entity_marker": [122, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p7", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the [E1]p76[/E1] [E2]IL-7R[/E2] is a previously undescribed splice variant of the cloned IL-7R.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[168, 171]], "entity_1_idx_in_text_with_entity_marker": [172, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p8", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the [E1]p76[/E1] IL-7R is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[168, 171]], "entity_1_idx_in_text_with_entity_marker": [172, 175], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1241_AIMed.d146.s1241.p9", "text": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.", "text_with_entity_marker": "In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the p76 [E1]IL-7R[/E1] is a previously undescribed splice variant of the cloned [E2]IL-7R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[172, 177]], "entity_1_idx_in_text_with_entity_marker": [176, 181], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[235, 240]], "entity_2_idx_in_text_with_entity_marker": [248, 253], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p0", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] [E2]IL-7R[/E2] is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p1", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned [E2]IL-7R[/E2], and imply that the p90 and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[80, 85]], "entity_2_idx_in_text_with_entity_marker": [93, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p2", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the [E2]p90[/E2] and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p3", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p4", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the [E1]p90[/E1] IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p5", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned [E2]IL-7R[/E2], and imply that the p90 and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[80, 85]], "entity_2_idx_in_text_with_entity_marker": [93, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p6", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned IL-7R, and imply that the [E2]p90[/E2] and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p7", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned IL-7R, and imply that the p90 and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p8", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 [E1]IL-7R[/E1] is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[36, 41]], "entity_1_idx_in_text_with_entity_marker": [40, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p9", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned [E1]IL-7R[/E1], and imply that the [E2]p90[/E2] and p76 IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p90", "entity_2_idx": [[106, 109]], "entity_2_idx_in_text_with_entity_marker": [119, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p10", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned [E1]IL-7R[/E1], and imply that the p90 and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p11", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned [E1]IL-7R[/E1], and imply that the p90 and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p12", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the [E1]p90[/E1] and [E2]p76[/E2] IL-7R have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p76", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p13", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the [E1]p90[/E1] and p76 [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p90", "entity_1_idx": [[106, 109]], "entity_1_idx_in_text_with_entity_marker": [110, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1242_AIMed.d146.s1242.p14", "text": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and p76 IL-7R have different extracellular domains.", "text_with_entity_marker": "These data demonstrate that the p90 IL-7R is the T-cell homologue of the cloned IL-7R, and imply that the p90 and [E1]p76[/E1] [E2]IL-7R[/E2] have different extracellular domains.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p76", "entity_1_idx": [[114, 117]], "entity_1_idx_in_text_with_entity_marker": [118, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7R", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d146.s1243_AIMed.d146.s1243.p0", "text": "Taken together these data suggest that the 76-kDa receptor is a novel high affinity IL-7R that may be necessary for IL-7 driven proliferation in human T cells.", "text_with_entity_marker": "Taken together these data suggest that the 76-kDa receptor is a novel high affinity [E1]IL-7R[/E1] that may be necessary for [E2]IL-7[/E2] driven proliferation in human T cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-7R", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-7", "entity_2_idx": [[116, 120]], "entity_2_idx_in_text_with_entity_marker": [129, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p0", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] ([E2]TH[/E2]), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p1", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), [E2]aromatic L-amino acid decarboxylase[/E2] (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aromatic L-amino acid decarboxylase", "entity_2_idx": [[78, 113]], "entity_2_idx_in_text_with_entity_marker": [91, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p2", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), aromatic L-amino acid decarboxylase ([E2]AADC[/E2]), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p3", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), aromatic L-amino acid decarboxylase (AADC), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p4", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, [E1]tyrosine hydroxylase[/E1] (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "tyrosine hydroxylase", "entity_1_idx": [[51, 71]], "entity_1_idx_in_text_with_entity_marker": [55, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p5", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), [E2]aromatic L-amino acid decarboxylase[/E2] (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "aromatic L-amino acid decarboxylase", "entity_2_idx": [[78, 113]], "entity_2_idx_in_text_with_entity_marker": [91, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p6", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), aromatic L-amino acid decarboxylase ([E2]AADC[/E2]), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p7", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), aromatic L-amino acid decarboxylase (AADC), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p8", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase ([E1]TH[/E1]), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p9", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), [E1]aromatic L-amino acid decarboxylase[/E1] ([E2]AADC[/E2]), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "aromatic L-amino acid decarboxylase", "entity_1_idx": [[78, 113]], "entity_1_idx_in_text_with_entity_marker": [82, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p10", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), [E1]aromatic L-amino acid decarboxylase[/E1] (AADC), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "aromatic L-amino acid decarboxylase", "entity_1_idx": [[78, 113]], "entity_1_idx_in_text_with_entity_marker": [82, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p11", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), [E1]aromatic L-amino acid decarboxylase[/E1] (AADC), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "aromatic L-amino acid decarboxylase", "entity_1_idx": [[78, 113]], "entity_1_idx_in_text_with_entity_marker": [82, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p12", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase ([E1]AADC[/E1]), and [E2]GTP cyclohydrolase I[/E2] (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GTP cyclohydrolase I", "entity_2_idx": [[126, 146]], "entity_2_idx_in_text_with_entity_marker": [139, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p13", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase ([E1]AADC[/E1]), and GTP cyclohydrolase I ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s136_AIMed.d16.s136.p14", "text": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH, an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "text_with_entity_marker": "METHODS: The genes for dopamine synthetic enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), and [E1]GTP cyclohydrolase I[/E1] ([E2]GCH[/E2], an enzyme critical for tetrahydrobiopterin synthesis) were contransduced into 293 cells with separate AAV vectors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GTP cyclohydrolase I", "entity_1_idx": [[126, 146]], "entity_1_idx_in_text_with_entity_marker": [130, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s137_AIMed.d16.s137.p0", "text": "Expressions of TH, AADC and GCH were detected by Western blot analysis.", "text_with_entity_marker": "Expressions of [E1]TH[/E1], [E2]AADC[/E2] and GCH were detected by Western blot analysis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[15, 17]], "entity_1_idx_in_text_with_entity_marker": [19, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[19, 23]], "entity_2_idx_in_text_with_entity_marker": [32, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s137_AIMed.d16.s137.p1", "text": "Expressions of TH, AADC and GCH were detected by Western blot analysis.", "text_with_entity_marker": "Expressions of [E1]TH[/E1], AADC and [E2]GCH[/E2] were detected by Western blot analysis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[15, 17]], "entity_1_idx_in_text_with_entity_marker": [19, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s137_AIMed.d16.s137.p2", "text": "Expressions of TH, AADC and GCH were detected by Western blot analysis.", "text_with_entity_marker": "Expressions of TH, [E1]AADC[/E1] and [E2]GCH[/E2] were detected by Western blot analysis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p0", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], [E2]AADC[/E2] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[13, 17]], "entity_2_idx_in_text_with_entity_marker": [26, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p1", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and [E2]GCH[/E2] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[22, 25]], "entity_2_idx_in_text_with_entity_marker": [35, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p2", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E2]TH[/E2], AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p3", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p4", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: [E1]TH[/E1], AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[9, 11]], "entity_1_idx_in_text_with_entity_marker": [13, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p5", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and [E2]GCH[/E2] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[22, 25]], "entity_2_idx_in_text_with_entity_marker": [35, 38], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p6", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E2]TH[/E2], AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p7", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p8", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, [E1]AADC[/E1] and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p9", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and [E1]GCH[/E1] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E2]TH[/E2], AAV-AADC and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GCH", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TH", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p10", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and [E1]GCH[/E1] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GCH", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p11", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and [E1]GCH[/E1] were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GCH", "entity_1_idx": [[22, 25]], "entity_1_idx_in_text_with_entity_marker": [26, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p12", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E1]TH[/E1], AAV-[E2]AADC[/E2] and AAV-GCH.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[112, 114]], "entity_1_idx_in_text_with_entity_marker": [116, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p13", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-[E1]TH[/E1], AAV-AADC and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[112, 114]], "entity_1_idx_in_text_with_entity_marker": [116, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s139_AIMed.d16.s139.p14", "text": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-AADC and AAV-GCH.", "text_with_entity_marker": "RESULTS: TH, AADC and GCH were effectively coexpressed in transduced cells with three separate AAV vectors, AAV-TH, AAV-[E1]AADC[/E1] and AAV-[E2]GCH[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[133, 136]], "entity_2_idx_in_text_with_entity_marker": [146, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s141_AIMed.d16.s141.p0", "text": "CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "text_with_entity_marker": "CONCLUSION: The triple transduction of [E1]TH[/E1], [E2]AADC[/E2] and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AADC", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s141_AIMed.d16.s141.p1", "text": "CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "text_with_entity_marker": "CONCLUSION: The triple transduction of [E1]TH[/E1], AADC and [E2]GCH[/E2] genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TH", "entity_1_idx": [[39, 41]], "entity_1_idx_in_text_with_entity_marker": [43, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d16.s141_AIMed.d16.s141.p2", "text": "CONCLUSION: The triple transduction of TH, AADC and GCH genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "text_with_entity_marker": "CONCLUSION: The triple transduction of TH, [E1]AADC[/E1] and [E2]GCH[/E2] genes with separate AAV vectors is effective, which might be important to gene therapy for Parkinson's disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AADC", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GCH", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1344_AIMed.d160.s1344.p0", "text": "Vascular endothelial growth factor (VEGF) expression in various cell types is induced by hypoxia and other stimuli.", "text_with_entity_marker": "[E1]Vascular endothelial growth factor[/E1] ([E2]VEGF[/E2]) expression in various cell types is induced by hypoxia and other stimuli.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Vascular endothelial growth factor", "entity_1_idx": [[0, 34]], "entity_1_idx_in_text_with_entity_marker": [4, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[36, 40]], "entity_2_idx_in_text_with_entity_marker": [49, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p0", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E2]kinase insert domain-containing receptor[/E2] (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "kinase insert domain-containing receptor", "entity_2_idx": [[139, 179]], "entity_2_idx_in_text_with_entity_marker": [152, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p1", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E2]KDR[/E2])/fetal liver kinase 1 (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p2", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/[E2]fetal liver kinase 1[/E2] (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fetal liver kinase 1", "entity_2_idx": [[186, 206]], "entity_2_idx_in_text_with_entity_marker": [199, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p3", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p4", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p5", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] ([E2]KDR[/E2])/fetal liver kinase 1 (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p6", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] (KDR)/[E2]fetal liver kinase 1[/E2] (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fetal liver kinase 1", "entity_2_idx": [[186, 206]], "entity_2_idx_in_text_with_entity_marker": [199, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p7", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] (KDR)/fetal liver kinase 1 ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p8", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] (KDR)/fetal liver kinase 1 (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p9", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E1]KDR[/E1])/[E2]fetal liver kinase 1[/E2] (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "KDR", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fetal liver kinase 1", "entity_2_idx": [[186, 206]], "entity_2_idx_in_text_with_entity_marker": [199, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p10", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E1]KDR[/E1])/fetal liver kinase 1 ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "KDR", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p11", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E1]KDR[/E1])/fetal liver kinase 1 (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "KDR", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p12", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/[E1]fetal liver kinase 1[/E1] ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fetal liver kinase 1", "entity_1_idx": [[186, 206]], "entity_1_idx_in_text_with_entity_marker": [190, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p13", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/[E1]fetal liver kinase 1[/E1] (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fetal liver kinase 1", "entity_1_idx": [[186, 206]], "entity_1_idx_in_text_with_entity_marker": [190, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p14", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 ([E1]Flk-1[/E1]) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Flk-1", "entity_1_idx": [[208, 213]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1348_AIMed.d160.s1348.p0", "text": "A VEGF model based on PDGFb indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer.", "text_with_entity_marker": "A [E1]VEGF[/E1] model based on [E2]PDGFb[/E2] indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "VEGF", "entity_1_idx": [[2, 6]], "entity_1_idx_in_text_with_entity_marker": [6, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGFb", "entity_2_idx": [[22, 27]], "entity_2_idx_in_text_with_entity_marker": [35, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1350_AIMed.d160.s1350.p0", "text": "Endothelial cell mitogenesis was abolished in mutants lacking KDR affinity; however, FLT-1 deficient mutants induced normal proliferation.", "text_with_entity_marker": "Endothelial cell mitogenesis was abolished in mutants lacking [E1]KDR[/E1] affinity; however, [E2]FLT-1[/E2] deficient mutants induced normal proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "KDR", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1352_AIMed.d160.s1352.p0", "text": "Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.", "text_with_entity_marker": "Furthermore, this mutational analysis implicates [E1]KDR[/E1], but not [E2]FLT-1[/E2], in VEGF induction of endothelial cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "KDR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[62, 67]], "entity_2_idx_in_text_with_entity_marker": [75, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1352_AIMed.d160.s1352.p1", "text": "Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.", "text_with_entity_marker": "Furthermore, this mutational analysis implicates [E1]KDR[/E1], but not FLT-1, in [E2]VEGF[/E2] induction of endothelial cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "KDR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1352_AIMed.d160.s1352.p2", "text": "Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.", "text_with_entity_marker": "Furthermore, this mutational analysis implicates KDR, but not [E1]FLT-1[/E1], in [E2]VEGF[/E2] induction of endothelial cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FLT-1", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p0", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated [E1]Stat3[/E1] but not [E2]Stat1[/E2] and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Stat3", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat1", "entity_2_idx": [[130, 135]], "entity_2_idx_in_text_with_entity_marker": [143, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p1", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated [E1]Stat3[/E1] but not Stat1 and blocked [E2]IL-10[/E2]-induced Stat3 phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Stat3", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p2", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated [E1]Stat3[/E1] but not Stat1 and blocked IL-10-induced [E2]Stat3[/E2] phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Stat3", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p3", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not [E1]Stat1[/E1] and blocked [E2]IL-10[/E2]-induced Stat3 phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Stat1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-10", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p4", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not [E1]Stat1[/E1] and blocked IL-10-induced [E2]Stat3[/E2] phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Stat1", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1575_AIMed.d185.s1575.p5", "text": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system.", "text_with_entity_marker": "Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 but not Stat1 and blocked [E1]IL-10[/E1]-induced [E2]Stat3[/E2] phosphorylation in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IL-10", "entity_1_idx": [[148, 153]], "entity_1_idx_in_text_with_entity_marker": [152, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d185.s1576_AIMed.d185.s1576.p0", "text": "In contrast, tyrosine-phosphorylated peptides containing Tyr374 or Tyr396 did not interact with Stat3 or block Stat3 activation.", "text_with_entity_marker": "In contrast, tyrosine-phosphorylated peptides containing Tyr374 or Tyr396 did not interact with [E1]Stat3[/E1] or block [E2]Stat3[/E2] activation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Stat3", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Stat3", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1935_AIMed.d223.s1935.p0", "text": "The NF-kappaB/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.", "text_with_entity_marker": "The [E1]NF-kappaB[/E1]/[E2]Rel[/E2] family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NF-kappaB", "entity_1_idx": [[4, 13]], "entity_1_idx_in_text_with_entity_marker": [8, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rel", "entity_2_idx": [[14, 17]], "entity_2_idx_in_text_with_entity_marker": [27, 30], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d223.s1942_AIMed.d223.s1942.p0", "text": "In vitro transcription assay demonstrates that E2F-1 represses NF-kappaB mediated transcription in a cell-free system.", "text_with_entity_marker": "In vitro transcription assay demonstrates that [E1]E2F-1[/E1] represses [E2]NF-kappaB[/E2] mediated transcription in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E2F-1", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappaB", "entity_2_idx": [[63, 72]], "entity_2_idx_in_text_with_entity_marker": [76, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d622.s0_BioInfer.d622.s0.p2", "text": "The herpes simplex virus type-1 UL5, UL8, and UL52 genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.", "text_with_entity_marker": "The herpes simplex virus type-1 UL5, [E1]UL8[/E1], and UL52 genes encode an essential heterotrimeric [E2]DNA helicase-primase[/E2] that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL8", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "DNA helicase-primase", "entity_2_idx": [[92, 112]], "entity_2_idx_in_text_with_entity_marker": [105, 125], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d622.s0_BioInfer.d622.s0.p4", "text": "The herpes simplex virus type-1 UL5, UL8, and UL52 genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.", "text_with_entity_marker": "The herpes simplex virus type-1 [E1]UL5[/E1], UL8, and UL52 genes encode an essential heterotrimeric [E2]DNA helicase-primase[/E2] that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL5", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "DNA helicase-primase", "entity_2_idx": [[92, 112]], "entity_2_idx_in_text_with_entity_marker": [105, 125], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d622.s0_BioInfer.d622.s0.p5", "text": "The herpes simplex virus type-1 UL5, UL8, and UL52 genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.", "text_with_entity_marker": "The herpes simplex virus type-1 UL5, UL8, and [E1]UL52[/E1] genes encode an essential heterotrimeric [E2]DNA helicase-primase[/E2] that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL52", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "DNA helicase-primase", "entity_2_idx": [[92, 112]], "entity_2_idx_in_text_with_entity_marker": [105, 125], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d415.s0_BioInfer.d415.s0.p2", "text": "MDP2 is the previously identified VRP1, which encodes verprolin, required for proper organization of the actin cytoskeleton.", "text_with_entity_marker": "MDP2 is the previously identified VRP1, which encodes [E1]verprolin[/E1], required for proper organization of the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "verprolin", "entity_1_idx": [[54, 63]], "entity_1_idx_in_text_with_entity_marker": [58, 67], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d415.s0_BioInfer.d415.s0.p4", "text": "MDP2 is the previously identified VRP1, which encodes verprolin, required for proper organization of the actin cytoskeleton.", "text_with_entity_marker": "MDP2 is the previously identified [E1]VRP1[/E1], which encodes [E2]verprolin[/E2], required for proper organization of the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "VRP1", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "verprolin", "entity_2_idx": [[54, 63]], "entity_2_idx_in_text_with_entity_marker": [67, 76], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d206.s0_BioInfer.d206.s0.p3", "text": "Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression.", "text_with_entity_marker": "Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by [E1]cyclin-dependent kinase inhibitor[/E1] [E2]p21[/E2] expression.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[90, 123]], "entity_1_idx_in_text_with_entity_marker": [94, 127], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p21", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d206.s0_BioInfer.d206.s0.p6", "text": "Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression.", "text_with_entity_marker": "Expressions of [E1]cyclin[/E1] E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor [E2]p21[/E2] expression.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin", "entity_1_idx": [[15, 21], [32, 34]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d206.s0_BioInfer.d206.s0.p8", "text": "Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression.", "text_with_entity_marker": "Expressions of [E1]cyclin E[/E1], A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor [E2]p21[/E2] expression.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin E", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d206.s0_BioInfer.d206.s0.p9", "text": "Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression.", "text_with_entity_marker": "Expressions of [E1]cyclin[/E1] E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor [E2]p21[/E2] expression.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin", "entity_1_idx": [[15, 21], [25, 26]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[124, 127]], "entity_2_idx_in_text_with_entity_marker": [137, 140], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d351.s0_BioInfer.d351.s0.p0", "text": "In reconstitution experiments, actin filaments incubated in EGTA with purified fimbrin and villin form smooth-sided bundles containing an apparently random number of filaments.", "text_with_entity_marker": "In reconstitution experiments, [E1]actin[/E1] filaments incubated in EGTA with purified [E2]fimbrin[/E2] and villin form smooth-sided bundles containing an apparently random number of filaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[79, 86]], "entity_2_idx_in_text_with_entity_marker": [92, 99], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d351.s0_BioInfer.d351.s0.p2", "text": "In reconstitution experiments, actin filaments incubated in EGTA with purified fimbrin and villin form smooth-sided bundles containing an apparently random number of filaments.", "text_with_entity_marker": "In reconstitution experiments, [E1]actin[/E1] filaments incubated in EGTA with purified fimbrin and [E2]villin[/E2] form smooth-sided bundles containing an apparently random number of filaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "villin", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d6.s0_BioInfer.d6.s0.p0", "text": "Acanthamoeba profilin affects the mechanical properties of nonfilamentous actin.", "text_with_entity_marker": "Acanthamoeba [E1]profilin[/E1] affects the mechanical properties of nonfilamentous [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[13, 21]], "entity_1_idx_in_text_with_entity_marker": [17, 25], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d6.s1_BioInfer.d6.s1.p0", "text": "In contrast, profilin had little effect on the rigidity and viscosity of actin filaments.", "text_with_entity_marker": "In contrast, [E1]profilin[/E1] had little effect on the rigidity and viscosity of [E2]actin[/E2] filaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[13, 21]], "entity_1_idx_in_text_with_entity_marker": [17, 25], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d682.s0_BioInfer.d682.s0.p1", "text": "The recombinant material is similar to authentic profilin from Acanthamoeba-based on fluorescence monitored urea denaturation, circular dichroism, actin-nucleotide exchange rate and the Kd for rabbit skeletal actin.", "text_with_entity_marker": "The recombinant material is similar to authentic [E1]profilin[/E1] from Acanthamoeba-based on fluorescence monitored urea denaturation, circular dichroism, actin-nucleotide exchange rate and the Kd for rabbit [E2]skeletal actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[49, 57]], "entity_1_idx_in_text_with_entity_marker": [53, 61], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "skeletal actin", "entity_2_idx": [[200, 214]], "entity_2_idx_in_text_with_entity_marker": [213, 227], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d235.s0_BioInfer.d235.s0.p4", "text": "Gravin is not likely to be a nonerythroid spectrin, talin, myosin, or actin-binding protein based on the lack of reactivity of antigravin with these polypeptides in immunoblots.", "text_with_entity_marker": "Gravin is not likely to be a [E1]nonerythroid spectrin[/E1], talin, myosin, or actin-binding protein based on the lack of reactivity of [E2]antigravin[/E2] with these polypeptides in immunoblots.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "nonerythroid spectrin", "entity_1_idx": [[29, 50]], "entity_1_idx_in_text_with_entity_marker": [33, 54], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "antigravin", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d235.s0_BioInfer.d235.s0.p8", "text": "Gravin is not likely to be a nonerythroid spectrin, talin, myosin, or actin-binding protein based on the lack of reactivity of antigravin with these polypeptides in immunoblots.", "text_with_entity_marker": "Gravin is not likely to be a nonerythroid spectrin, talin, [E1]myosin[/E1], or actin-binding protein based on the lack of reactivity of [E2]antigravin[/E2] with these polypeptides in immunoblots.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin", "entity_1_idx": [[59, 65]], "entity_1_idx_in_text_with_entity_marker": [63, 69], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "antigravin", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d235.s0_BioInfer.d235.s0.p13", "text": "Gravin is not likely to be a nonerythroid spectrin, talin, myosin, or actin-binding protein based on the lack of reactivity of antigravin with these polypeptides in immunoblots.", "text_with_entity_marker": "Gravin is not likely to be a nonerythroid spectrin, [E1]talin[/E1], myosin, or actin-binding protein based on the lack of reactivity of [E2]antigravin[/E2] with these polypeptides in immunoblots.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "antigravin", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d235.s0_BioInfer.d235.s0.p14", "text": "Gravin is not likely to be a nonerythroid spectrin, talin, myosin, or actin-binding protein based on the lack of reactivity of antigravin with these polypeptides in immunoblots.", "text_with_entity_marker": "Gravin is not likely to be a nonerythroid spectrin, talin, myosin, or [E1]actin-binding protein[/E1] based on the lack of reactivity of [E2]antigravin[/E2] with these polypeptides in immunoblots.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding protein", "entity_1_idx": [[70, 91]], "entity_1_idx_in_text_with_entity_marker": [74, 95], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "antigravin", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d358.s0_BioInfer.d358.s0.p0", "text": "Integrin binding may be promoted by disruption of links to the cytoskeleton, effected through depolymerisation of actin or cleavage of linking protein talin by calpain.", "text_with_entity_marker": "Integrin binding may be promoted by disruption of links to the cytoskeleton, effected through depolymerisation of actin or cleavage of linking protein [E1]talin[/E1] by [E2]calpain[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[151, 156]], "entity_1_idx_in_text_with_entity_marker": [155, 160], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "calpain", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d695.s0_BioInfer.d695.s0.p0", "text": "These data suggest that nuclear profilin can mediate a stimulus-response action on the actin cytoskeleton which is somehow linked to a phosphoinositide-signaling cascade.", "text_with_entity_marker": "These data suggest that nuclear [E1]profilin[/E1] can mediate a stimulus-response action on the [E2]actin[/E2] cytoskeleton which is somehow linked to a phosphoinositide-signaling cascade.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[32, 40]], "entity_1_idx_in_text_with_entity_marker": [36, 44], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d644.s0_BioInfer.d644.s0.p0", "text": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "text_with_entity_marker": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, [E1]villin[/E1] (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and [E2]calmodulin[/E2] (17,000 daltons).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "villin", "entity_1_idx": [[177, 183]], "entity_1_idx_in_text_with_entity_marker": [181, 187], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[256, 266]], "entity_2_idx_in_text_with_entity_marker": [269, 279], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d644.s0_BioInfer.d644.s0.p1", "text": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "text_with_entity_marker": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, [E1]villin[/E1] (95,000 daltons), [E2]fimbrin[/E2] (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "villin", "entity_1_idx": [[177, 183]], "entity_1_idx_in_text_with_entity_marker": [181, 187], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[202, 209]], "entity_2_idx_in_text_with_entity_marker": [215, 222], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d644.s0_BioInfer.d644.s0.p2", "text": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "text_with_entity_marker": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, [E1]villin[/E1] (95,000 daltons), fimbrin (68,000 daltons), [E2]actin[/E2] (43,000 daltons), and calmodulin (17,000 daltons).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "villin", "entity_1_idx": [[177, 183]], "entity_1_idx_in_text_with_entity_marker": [181, 187], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[228, 233]], "entity_2_idx_in_text_with_entity_marker": [241, 246], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d644.s0_BioInfer.d644.s0.p3", "text": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "text_with_entity_marker": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), [E1]fimbrin[/E1] (68,000 daltons), actin (43,000 daltons), and [E2]calmodulin[/E2] (17,000 daltons).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "fimbrin", "entity_1_idx": [[202, 209]], "entity_1_idx_in_text_with_entity_marker": [206, 213], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[256, 266]], "entity_2_idx_in_text_with_entity_marker": [269, 279], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d644.s0_BioInfer.d644.s0.p4", "text": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "text_with_entity_marker": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), [E1]actin[/E1] (43,000 daltons), and [E2]calmodulin[/E2] (17,000 daltons).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[228, 233]], "entity_1_idx_in_text_with_entity_marker": [232, 237], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "calmodulin", "entity_2_idx": [[256, 266]], "entity_2_idx_in_text_with_entity_marker": [269, 279], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d644.s0_BioInfer.d644.s0.p5", "text": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), fimbrin (68,000 daltons), actin (43,000 daltons), and calmodulin (17,000 daltons).", "text_with_entity_marker": "The microvillus cytoskeleton, isolated from chicken intestinal epithelial cell brush borders, is known to contain five major protein components, the 110,000-dalton polypeptide, villin (95,000 daltons), [E1]fimbrin[/E1] (68,000 daltons), [E2]actin[/E2] (43,000 daltons), and calmodulin (17,000 daltons).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "fimbrin", "entity_1_idx": [[202, 209]], "entity_1_idx_in_text_with_entity_marker": [206, 213], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[228, 233]], "entity_2_idx_in_text_with_entity_marker": [241, 246], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d561.s0_BioInfer.d561.s0.p0", "text": "The actin-binding protein profilin was isolated from Tetrahymena thermophila by affinity chromatography, and the peptide sequence was determined for part of the protein.", "text_with_entity_marker": "The [E1]actin-binding protein[/E1] [E2]profilin[/E2] was isolated from Tetrahymena thermophila by affinity chromatography, and the peptide sequence was determined for part of the protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding protein", "entity_1_idx": [[4, 25]], "entity_1_idx_in_text_with_entity_marker": [8, 29], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "profilin", "entity_2_idx": [[26, 34]], "entity_2_idx_in_text_with_entity_marker": [39, 47], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d648.s0_BioInfer.d648.s0.p0", "text": "The multifunctional protein profilin is one of the most abundant proteins in the cytoplasm and is thought to regulate actin assembly and the phosphoinositide signaling pathway.", "text_with_entity_marker": "The multifunctional protein [E1]profilin[/E1] is one of the most abundant proteins in the cytoplasm and is thought to regulate [E2]actin[/E2] assembly and the phosphoinositide signaling pathway.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[28, 36]], "entity_1_idx_in_text_with_entity_marker": [32, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d613.s0_BioInfer.d613.s0.p66", "text": "The findings suggest that M1 muscarinic receptors are involved in muscarinic receptor-mediated enhancement of IL-2 production in Jurkat cells and that the transcription factor AP-1 and pathways via mitogen-activated protein kinase (MAPK)/extracellular signal regulated protein kinase and c-Jun N-terminal kinase, but not via p38 MAPK, may be involved in the muscarinic receptor-mediated enhancement of IL-2 production.", "text_with_entity_marker": "The findings suggest that M1 muscarinic receptors are involved in muscarinic receptor-mediated enhancement of IL-2 production in Jurkat cells and that the transcription factor AP-1 and pathways via mitogen-activated protein kinase (MAPK)/extracellular signal regulated protein kinase and c-Jun N-terminal kinase, but not via [E1]p38[/E1] [E2]MAPK[/E2], may be involved in the muscarinic receptor-mediated enhancement of IL-2 production.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p38", "entity_1_idx": [[325, 328]], "entity_1_idx_in_text_with_entity_marker": [329, 332], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MAPK", "entity_2_idx": [[329, 333]], "entity_2_idx_in_text_with_entity_marker": [342, 346], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d103.s0_BioInfer.d103.s0.p1", "text": "Bistratene A causes phosphorylation of talin and redistribution of actin microfilaments in fibroblasts: possible role for PKC-delta.", "text_with_entity_marker": "Bistratene A causes phosphorylation of talin and redistribution of [E1]actin[/E1] microfilaments in fibroblasts: possible role for [E2]PKC-delta[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[67, 72]], "entity_1_idx_in_text_with_entity_marker": [71, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "PKC-delta", "entity_2_idx": [[122, 131]], "entity_2_idx_in_text_with_entity_marker": [135, 144], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d103.s0_BioInfer.d103.s0.p2", "text": "Bistratene A causes phosphorylation of talin and redistribution of actin microfilaments in fibroblasts: possible role for PKC-delta.", "text_with_entity_marker": "Bistratene A causes phosphorylation of [E1]talin[/E1] and redistribution of actin microfilaments in fibroblasts: possible role for [E2]PKC-delta[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[39, 44]], "entity_1_idx_in_text_with_entity_marker": [43, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "PKC-delta", "entity_2_idx": [[122, 131]], "entity_2_idx_in_text_with_entity_marker": [135, 144], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s0_BioInfer.d161.s0.p0", "text": "Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, thymosin beta(4), and actin form a ternary complex.", "text_with_entity_marker": "Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, [E1]thymosin beta(4)[/E1], and [E2]actin[/E2] form a ternary complex.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "thymosin beta(4)", "entity_1_idx": [[139, 155]], "entity_1_idx_in_text_with_entity_marker": [143, 159], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[161, 166]], "entity_2_idx_in_text_with_entity_marker": [174, 179], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s0_BioInfer.d161.s0.p1", "text": "Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, thymosin beta(4), and actin form a ternary complex.", "text_with_entity_marker": "Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that [E1]profilin[/E1], [E2]thymosin beta(4)[/E2], and actin form a ternary complex.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[129, 137]], "entity_1_idx_in_text_with_entity_marker": [133, 141], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "thymosin beta(4)", "entity_2_idx": [[139, 155]], "entity_2_idx_in_text_with_entity_marker": [152, 168], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s0_BioInfer.d161.s0.p2", "text": "Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, thymosin beta(4), and actin form a ternary complex.", "text_with_entity_marker": "Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that [E1]profilin[/E1], thymosin beta(4), and [E2]actin[/E2] form a ternary complex.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[129, 137]], "entity_1_idx_in_text_with_entity_marker": [133, 141], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[161, 166]], "entity_2_idx_in_text_with_entity_marker": [174, 179], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s1_BioInfer.d161.s1.p0", "text": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to actin.", "text_with_entity_marker": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why [E1]thymosin beta(4)[/E1] and profilin can bind simultaneously to [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "thymosin beta(4)", "entity_1_idx": [[204, 220]], "entity_1_idx_in_text_with_entity_marker": [208, 224], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[261, 266]], "entity_2_idx_in_text_with_entity_marker": [274, 279], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s1_BioInfer.d161.s1.p4", "text": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to actin.", "text_with_entity_marker": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and [E1]profilin[/E1] can bind simultaneously to [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[225, 233]], "entity_1_idx_in_text_with_entity_marker": [229, 237], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[261, 266]], "entity_2_idx_in_text_with_entity_marker": [274, 279], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s1_BioInfer.d161.s1.p8", "text": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to actin.", "text_with_entity_marker": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why [E1]thymosin beta(4)[/E1] and [E2]profilin[/E2] can bind simultaneously to actin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "thymosin beta(4)", "entity_1_idx": [[204, 220]], "entity_1_idx_in_text_with_entity_marker": [208, 224], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[225, 233]], "entity_2_idx_in_text_with_entity_marker": [238, 246], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d161.s1_BioInfer.d161.s1.p10", "text": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to actin.", "text_with_entity_marker": "Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between [E1]actin[/E1] and [E2]thymosin beta(4)[/E2], and explain why thymosin beta(4) and profilin can bind simultaneously to actin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[160, 165]], "entity_1_idx_in_text_with_entity_marker": [164, 169], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "thymosin beta(4)", "entity_2_idx": [[170, 186]], "entity_2_idx_in_text_with_entity_marker": [183, 199], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p22", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; [E1]alpha-catenin[/E1] binds to beta-catenin/plakoglobin and serves to link the [E2]cadherin[/E2]/catenin complex to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[70, 83]], "entity_1_idx_in_text_with_entity_marker": [74, 87], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cadherin", "entity_2_idx": [[141, 149]], "entity_2_idx_in_text_with_entity_marker": [154, 162], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p24", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the [E1]cadherin[/E1]/catenin complex to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cadherin", "entity_1_idx": [[141, 149]], "entity_1_idx_in_text_with_entity_marker": [145, 153], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p26", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; [E1]alpha-catenin[/E1] binds to beta-catenin/plakoglobin and serves to link the cadherin/[E2]catenin[/E2] complex to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[70, 83]], "entity_1_idx_in_text_with_entity_marker": [74, 87], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "catenin", "entity_2_idx": [[150, 157]], "entity_2_idx_in_text_with_entity_marker": [163, 170], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p28", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/[E1]catenin[/E1] complex to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "catenin", "entity_1_idx": [[150, 157]], "entity_1_idx_in_text_with_entity_marker": [154, 161], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p30", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; [E1]alpha-catenin[/E1] binds to beta-catenin/[E2]plakoglobin[/E2] and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[70, 83]], "entity_1_idx_in_text_with_entity_marker": [74, 87], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "plakoglobin", "entity_2_idx": [[106, 117]], "entity_2_idx_in_text_with_entity_marker": [119, 130], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p31", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; [E1]alpha-catenin[/E1] binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[70, 83]], "entity_1_idx_in_text_with_entity_marker": [74, 87], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d140.s2_BioInfer.d140.s2.p32", "text": "beta-catenin or plakoglobin is associated directly with the cadherin; alpha-catenin binds to beta-catenin/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "text_with_entity_marker": "beta-catenin or plakoglobin is associated directly with the cadherin; [E1]alpha-catenin[/E1] binds to [E2]beta-catenin[/E2]/plakoglobin and serves to link the cadherin/catenin complex to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[70, 83]], "entity_1_idx_in_text_with_entity_marker": [74, 87], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[93, 105]], "entity_2_idx_in_text_with_entity_marker": [106, 118], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d788.s0_BioInfer.d788.s0.p0", "text": "Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the actin filament.", "text_with_entity_marker": "Using the known three-dimensional structure of the homologous actin-binding domain of [E1]fimbrin[/E1], these results have enabled us to determine the likely orientation of the [E2]utrophin[/E2] actin-binding domain with respect to the actin filament.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "fimbrin", "entity_1_idx": [[86, 93]], "entity_1_idx_in_text_with_entity_marker": [90, 97], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[168, 176]], "entity_2_idx_in_text_with_entity_marker": [181, 189], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d788.s0_BioInfer.d788.s0.p1", "text": "Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the actin filament.", "text_with_entity_marker": "Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the [E1]utrophin[/E1] actin-binding domain with respect to the [E2]actin[/E2] filament.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "utrophin", "entity_1_idx": [[168, 176]], "entity_1_idx_in_text_with_entity_marker": [172, 180], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[218, 223]], "entity_2_idx_in_text_with_entity_marker": [231, 236], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d788.s0_BioInfer.d788.s0.p2", "text": "Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the actin filament.", "text_with_entity_marker": "Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the [E1]utrophin[/E1] [E2]actin[/E2]-binding domain with respect to the actin filament.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "utrophin", "entity_1_idx": [[168, 176]], "entity_1_idx_in_text_with_entity_marker": [172, 180], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[177, 182]], "entity_2_idx_in_text_with_entity_marker": [190, 195], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d788.s0_BioInfer.d788.s0.p6", "text": "Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the actin filament.", "text_with_entity_marker": "Using the known three-dimensional structure of the homologous [E1]actin[/E1]-binding domain of [E2]fimbrin[/E2], these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the actin filament.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[86, 93]], "entity_2_idx_in_text_with_entity_marker": [99, 106], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d340.s0_BioInfer.d340.s0.p1", "text": "Inhibition of actomyosin subfragment 1 ATPase activity by analog peptides of the actin-binding site around the Cys(SH1) of myosin heavy chain.", "text_with_entity_marker": "Inhibition of [E1]actomyosin[/E1] subfragment 1 [E2]ATPase[/E2] activity by analog peptides of the actin-binding site around the Cys(SH1) of myosin heavy chain.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "actomyosin", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "ATPase", "entity_2_idx": [[39, 45]], "entity_2_idx_in_text_with_entity_marker": [52, 58], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d340.s0_BioInfer.d340.s0.p2", "text": "Inhibition of actomyosin subfragment 1 ATPase activity by analog peptides of the actin-binding site around the Cys(SH1) of myosin heavy chain.", "text_with_entity_marker": "Inhibition of [E1]actomyosin[/E1] subfragment 1 ATPase activity by analog peptides of the actin-binding site around the Cys(SH1) of [E2]myosin heavy chain[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actomyosin", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "myosin heavy chain", "entity_2_idx": [[123, 141]], "entity_2_idx_in_text_with_entity_marker": [136, 154], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d340.s0_BioInfer.d340.s0.p4", "text": "Inhibition of actomyosin subfragment 1 ATPase activity by analog peptides of the actin-binding site around the Cys(SH1) of myosin heavy chain.", "text_with_entity_marker": "Inhibition of actomyosin subfragment 1 ATPase activity by analog peptides of the [E1]actin[/E1]-binding site around the Cys(SH1) of [E2]myosin heavy chain[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[81, 86]], "entity_1_idx_in_text_with_entity_marker": [85, 90], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "myosin heavy chain", "entity_2_idx": [[123, 141]], "entity_2_idx_in_text_with_entity_marker": [136, 154], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d158.s0_BioInfer.d158.s0.p0", "text": "Crystallization and preliminary crystallographic analysis of the N-terminal actin binding domain of human fimbrin.", "text_with_entity_marker": "Crystallization and preliminary crystallographic analysis of the N-terminal [E1]actin[/E1] binding domain of human [E2]fimbrin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[76, 81]], "entity_1_idx_in_text_with_entity_marker": [80, 85], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[106, 113]], "entity_2_idx_in_text_with_entity_marker": [119, 126], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p0", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: [E1]X22[/E1], titin, myosin heavy chain, [E2]actin[/E2], and desmin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "X22", "entity_1_idx": [[195, 198]], "entity_1_idx_in_text_with_entity_marker": [199, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[227, 232]], "entity_2_idx_in_text_with_entity_marker": [240, 245], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p1", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, [E1]titin[/E1], myosin heavy chain, [E2]actin[/E2], and desmin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "titin", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[227, 232]], "entity_2_idx_in_text_with_entity_marker": [240, 245], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p3", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, [E1]actin[/E1], and [E2]desmin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[227, 232]], "entity_1_idx_in_text_with_entity_marker": [231, 236], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "desmin", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p4", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, [E1]myosin heavy chain[/E1], [E2]actin[/E2], and desmin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin heavy chain", "entity_1_idx": [[207, 225]], "entity_1_idx_in_text_with_entity_marker": [211, 229], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[227, 232]], "entity_2_idx_in_text_with_entity_marker": [240, 245], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p5", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: [E1]X22[/E1], [E2]titin[/E2], myosin heavy chain, actin, and desmin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "X22", "entity_1_idx": [[195, 198]], "entity_1_idx_in_text_with_entity_marker": [199, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "titin", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p7", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: [E1]X22[/E1], titin, myosin heavy chain, actin, and [E2]desmin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "X22", "entity_1_idx": [[195, 198]], "entity_1_idx_in_text_with_entity_marker": [199, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "desmin", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p8", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: [E1]X22[/E1], titin, [E2]myosin heavy chain[/E2], actin, and desmin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "X22", "entity_1_idx": [[195, 198]], "entity_1_idx_in_text_with_entity_marker": [199, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "myosin heavy chain", "entity_2_idx": [[207, 225]], "entity_2_idx_in_text_with_entity_marker": [220, 238], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p10", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, [E1]titin[/E1], myosin heavy chain, actin, and [E2]desmin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "titin", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "desmin", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p11", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, [E1]titin[/E1], [E2]myosin heavy chain[/E2], actin, and desmin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "titin", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "myosin heavy chain", "entity_2_idx": [[207, 225]], "entity_2_idx_in_text_with_entity_marker": [220, 238], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d506.s0_BioInfer.d506.s0.p14", "text": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, myosin heavy chain, actin, and desmin.", "text_with_entity_marker": "Quantitation of the appearance of X22 banding in primary cultures of myotubes indicates that it precedes that of other myofibrillar proteins and that assembly takes place in the following order: X22, titin, [E1]myosin heavy chain[/E1], actin, and [E2]desmin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin heavy chain", "entity_1_idx": [[207, 225]], "entity_1_idx_in_text_with_entity_marker": [211, 229], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "desmin", "entity_2_idx": [[238, 244]], "entity_2_idx_in_text_with_entity_marker": [251, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d251.s0_BioInfer.d251.s0.p0", "text": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or CBP) histone acetylation activity.", "text_with_entity_marker": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit [E1]p300[/E1] (and the highly related molecule, CREB-binding protein, or CBP) [E2]histone[/E2] acetylation activity.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[115, 119]], "entity_1_idx_in_text_with_entity_marker": [119, 123], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "histone", "entity_2_idx": [[184, 191]], "entity_2_idx_in_text_with_entity_marker": [197, 204], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d251.s0_BioInfer.d251.s0.p4", "text": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or CBP) histone acetylation activity.", "text_with_entity_marker": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, [E1]CREB-binding protein[/E1], or CBP) [E2]histone[/E2] acetylation activity.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "CREB-binding protein", "entity_1_idx": [[154, 174]], "entity_1_idx_in_text_with_entity_marker": [158, 178], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "histone", "entity_2_idx": [[184, 191]], "entity_2_idx_in_text_with_entity_marker": [197, 204], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d251.s0_BioInfer.d251.s0.p5", "text": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or CBP) histone acetylation activity.", "text_with_entity_marker": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or [E1]CBP[/E1]) [E2]histone[/E2] acetylation activity.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "CBP", "entity_1_idx": [[179, 182]], "entity_1_idx_in_text_with_entity_marker": [183, 186], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "histone", "entity_2_idx": [[184, 191]], "entity_2_idx_in_text_with_entity_marker": [197, 204], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d251.s0_BioInfer.d251.s0.p6", "text": "Here, we show that EID-1 is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or CBP) histone acetylation activity.", "text_with_entity_marker": "Here, we show that [E1]EID-1[/E1] is a potent inhibitor of differentiation and link this activity to its ability to inhibit p300 (and the highly related molecule, CREB-binding protein, or CBP) [E2]histone[/E2] acetylation activity.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "EID-1", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "histone", "entity_2_idx": [[184, 191]], "entity_2_idx_in_text_with_entity_marker": [197, 204], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d706.s0_BioInfer.d706.s0.p7", "text": "The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.", "text_with_entity_marker": "The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the [E1]cell adhesion proteins[/E1] [E2]alpha-catenin[/E2], beta-catenin/Armadillo, and classical cadherin, respectively.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cell adhesion proteins", "entity_1_idx": [[83, 105]], "entity_1_idx_in_text_with_entity_marker": [87, 109], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "alpha-catenin", "entity_2_idx": [[106, 119]], "entity_2_idx_in_text_with_entity_marker": [119, 132], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d706.s0_BioInfer.d706.s0.p8", "text": "The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.", "text_with_entity_marker": "The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the [E1]cell adhesion proteins[/E1] alpha-catenin, beta-catenin/Armadillo, and [E2]classical cadherin[/E2], respectively.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cell adhesion proteins", "entity_1_idx": [[83, 105]], "entity_1_idx_in_text_with_entity_marker": [87, 109], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "classical cadherin", "entity_2_idx": [[149, 167]], "entity_2_idx_in_text_with_entity_marker": [162, 180], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d706.s0_BioInfer.d706.s0.p17", "text": "The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.", "text_with_entity_marker": "The sequences of the predicted [E1]HMP-1[/E1], HMP-2, and HMR-1 proteins are related to the cell adhesion proteins [E2]alpha-catenin[/E2], beta-catenin/Armadillo, and classical cadherin, respectively.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "HMP-1", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-catenin", "entity_2_idx": [[106, 119]], "entity_2_idx_in_text_with_entity_marker": [119, 132], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d706.s0_BioInfer.d706.s0.p19", "text": "The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.", "text_with_entity_marker": "The sequences of the predicted HMP-1, HMP-2, and [E1]HMR-1[/E1] proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and [E2]classical cadherin[/E2], respectively.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "HMR-1", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "classical cadherin", "entity_2_idx": [[149, 167]], "entity_2_idx_in_text_with_entity_marker": [162, 180], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p2", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the [E1]cyclin-dependent kinase inhibitor[/E1] [E2]p27[/E2](KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[136, 169]], "entity_1_idx_in_text_with_entity_marker": [140, 173], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p27", "entity_2_idx": [[170, 173]], "entity_2_idx_in_text_with_entity_marker": [183, 186], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p5", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the [E1]cyclin-dependent kinase inhibitor[/E1] p27([E2]KIP1[/E2]) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[136, 169]], "entity_1_idx_in_text_with_entity_marker": [140, 173], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "KIP1", "entity_2_idx": [[174, 178]], "entity_2_idx_in_text_with_entity_marker": [187, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p8", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27([E1]KIP1[/E1]) specifically bound to cyclin E and a concomitant decrease in [E2]cyclin E-associated kinase[/E2] activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "KIP1", "entity_1_idx": [[222, 226]], "entity_1_idx_in_text_with_entity_marker": [226, 230], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E-associated kinase", "entity_2_idx": [[289, 315]], "entity_2_idx_in_text_with_entity_marker": [302, 328], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p9", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor [E1]p27[/E1](KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in [E2]cyclin E-associated kinase[/E2] activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[170, 173]], "entity_1_idx_in_text_with_entity_marker": [174, 177], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E-associated kinase", "entity_2_idx": [[289, 315]], "entity_2_idx_in_text_with_entity_marker": [302, 328], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p12", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27([E1]KIP1[/E1]) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in [E2]cyclin E-associated kinase[/E2] activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "KIP1", "entity_1_idx": [[174, 178]], "entity_1_idx_in_text_with_entity_marker": [178, 182], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E-associated kinase", "entity_2_idx": [[289, 315]], "entity_2_idx_in_text_with_entity_marker": [302, 328], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p14", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in [E1]p27[/E1](KIP1) specifically bound to cyclin E and a concomitant decrease in [E2]cyclin E-associated kinase[/E2] activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[218, 221]], "entity_1_idx_in_text_with_entity_marker": [222, 225], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E-associated kinase", "entity_2_idx": [[289, 315]], "entity_2_idx_in_text_with_entity_marker": [302, 328], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p15", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor [E1]p27[/E1](KIP1) that is accompanied by an increase in p27([E2]KIP1[/E2]) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[170, 173]], "entity_1_idx_in_text_with_entity_marker": [174, 177], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p16", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27([E1]KIP1[/E1]) specifically bound to [E2]cyclin E[/E2] and a concomitant decrease in cyclin E-associated kinase activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "KIP1", "entity_1_idx": [[222, 226]], "entity_1_idx_in_text_with_entity_marker": [226, 230], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[250, 258]], "entity_2_idx_in_text_with_entity_marker": [263, 271], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p18", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27([E1]KIP1[/E1]) that is accompanied by an increase in p27([E2]KIP1[/E2]) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "KIP1", "entity_1_idx": [[174, 178]], "entity_1_idx_in_text_with_entity_marker": [178, 182], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "KIP1", "entity_2_idx": [[222, 226]], "entity_2_idx_in_text_with_entity_marker": [235, 239], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d345.s0_BioInfer.d345.s0.p22", "text": "In investigating the mechanism by which pRb induces senescence, we have found that pRb causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor p27(KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "text_with_entity_marker": "In investigating the mechanism by which pRb induces senescence, we have found that [E1]pRb[/E1] causes a posttranscriptional accumulation of the cyclin-dependent kinase inhibitor [E2]p27[/E2](KIP1) that is accompanied by an increase in p27(KIP1) specifically bound to cyclin E and a concomitant decrease in cyclin E-associated kinase activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "pRb", "entity_1_idx": [[83, 86]], "entity_1_idx_in_text_with_entity_marker": [87, 90], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[170, 173]], "entity_2_idx_in_text_with_entity_marker": [183, 186], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d818.s0_BioInfer.d818.s0.p1", "text": "We propose that profilin may act by forming, during the critical period of cerebellar development, a reserve pool of monomeric actin that can easily be mobilized in cell regions such as growth cones or synaptic junctions where filamentous actin is highly concentrated.", "text_with_entity_marker": "We propose that [E1]profilin[/E1] may act by forming, during the critical period of cerebellar development, a reserve pool of monomeric [E2]actin[/E2] that can easily be mobilized in cell regions such as growth cones or synaptic junctions where filamentous actin is highly concentrated.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[16, 24]], "entity_1_idx_in_text_with_entity_marker": [20, 28], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[127, 132]], "entity_2_idx_in_text_with_entity_marker": [140, 145], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d412.s0_BioInfer.d412.s0.p0", "text": "Mammalian LIM-kinases (LIMKs) phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Mammalian LIM-kinases ([E1]LIMKs[/E1]) phosphorylate cofilin and induce [E2]actin[/E2] cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIMKs", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d412.s0_BioInfer.d412.s0.p1", "text": "Mammalian LIM-kinases (LIMKs) phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Mammalian [E1]LIM-kinases[/E1] (LIMKs) phosphorylate cofilin and induce [E2]actin[/E2] cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIM-kinases", "entity_1_idx": [[10, 21]], "entity_1_idx_in_text_with_entity_marker": [14, 25], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d412.s0_BioInfer.d412.s0.p4", "text": "Mammalian LIM-kinases (LIMKs) phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Mammalian LIM-kinases ([E1]LIMKs[/E1]) phosphorylate [E2]cofilin[/E2] and induce actin cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIMKs", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[44, 51]], "entity_2_idx_in_text_with_entity_marker": [57, 64], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d412.s0_BioInfer.d412.s0.p5", "text": "Mammalian LIM-kinases (LIMKs) phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Mammalian [E1]LIM-kinases[/E1] (LIMKs) phosphorylate [E2]cofilin[/E2] and induce actin cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIM-kinases", "entity_1_idx": [[10, 21]], "entity_1_idx_in_text_with_entity_marker": [14, 25], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[44, 51]], "entity_2_idx_in_text_with_entity_marker": [57, 64], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d45.s0_BioInfer.d45.s0.p2", "text": "Although platelets contain only 1 profilin for every 5-10 actin molecules, these complex reactions may allow substoichiometric profilin to have an important influence on actin assembly.", "text_with_entity_marker": "Although platelets contain only 1 profilin for every 5-10 actin molecules, these complex reactions may allow substoichiometric [E1]profilin[/E1] to have an important influence on [E2]actin[/E2] assembly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[127, 135]], "entity_1_idx_in_text_with_entity_marker": [131, 139], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d45.s1_BioInfer.d45.s1.p0", "text": "Kinetic simulation showed that the profilin exchanges between actin monomers on a subsecond time scale that allows it to catalyze nucleotide exchange.", "text_with_entity_marker": "Kinetic simulation showed that the [E1]profilin[/E1] exchanges between [E2]actin[/E2] monomers on a subsecond time scale that allows it to catalyze nucleotide exchange.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[35, 43]], "entity_1_idx_in_text_with_entity_marker": [39, 47], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[62, 67]], "entity_2_idx_in_text_with_entity_marker": [75, 80], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d45.s2_BioInfer.d45.s2.p4", "text": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; profilin inhibits the elongation of platelet actin much more strongly than muscle actin; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "text_with_entity_marker": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; [E1]profilin[/E1] inhibits the elongation of platelet actin much more strongly than [E2]muscle actin[/E2]; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[207, 215]], "entity_1_idx_in_text_with_entity_marker": [211, 219], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "muscle actin", "entity_2_idx": [[282, 294]], "entity_2_idx_in_text_with_entity_marker": [295, 307], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d45.s2_BioInfer.d45.s2.p5", "text": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; profilin inhibits the elongation of platelet actin much more strongly than muscle actin; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "text_with_entity_marker": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; [E1]profilin[/E1] inhibits the elongation of [E2]platelet actin[/E2] much more strongly than muscle actin; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[207, 215]], "entity_1_idx_in_text_with_entity_marker": [211, 219], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "platelet actin", "entity_2_idx": [[243, 257]], "entity_2_idx_in_text_with_entity_marker": [256, 270], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d45.s2_BioInfer.d45.s2.p6", "text": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; profilin inhibits the elongation of platelet actin much more strongly than muscle actin; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "text_with_entity_marker": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: [E1]profilin[/E1] has different effects on elongation at the two ends of [E2]actin[/E2] filaments; profilin inhibits the elongation of platelet actin much more strongly than muscle actin; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[126, 134]], "entity_1_idx_in_text_with_entity_marker": [130, 138], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d45.s2_BioInfer.d45.s2.p15", "text": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; profilin inhibits the elongation of platelet actin much more strongly than muscle actin; and simple formation of 1:1 complexes of actin with profilin cannot account for the strong inhibition of spontaneous polymerization.", "text_with_entity_marker": "On the other hand, polymerization assays give disparate results that are inconsistent with the binding assays and each other: profilin has different effects on elongation at the two ends of actin filaments; profilin inhibits the elongation of platelet actin much more strongly than muscle actin; and simple formation of 1:1 complexes of [E1]actin[/E1] with [E2]profilin[/E2] cannot account for the strong inhibition of spontaneous polymerization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[337, 342]], "entity_1_idx_in_text_with_entity_marker": [341, 346], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[348, 356]], "entity_2_idx_in_text_with_entity_marker": [361, 369], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d57.s0_BioInfer.d57.s0.p0", "text": "Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the spleen actin (beta, gamma) which appears to regulate the interaction with profilin.", "text_with_entity_marker": "Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the [E1]spleen actin[/E1] (beta, gamma) which appears to regulate the interaction with [E2]profilin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "spleen actin", "entity_1_idx": [[201, 213], [221, 226]], "entity_1_idx_in_text_with_entity_marker": [205, 217], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[275, 283]], "entity_2_idx_in_text_with_entity_marker": [288, 296], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d57.s0_BioInfer.d57.s0.p1", "text": "Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the spleen actin (beta, gamma) which appears to regulate the interaction with profilin.", "text_with_entity_marker": "Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the [E1]spleen actin[/E1] (beta, gamma) which appears to regulate the interaction with [E2]profilin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "spleen actin", "entity_1_idx": [[201, 213], [215, 219]], "entity_1_idx_in_text_with_entity_marker": [205, 217], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[275, 283]], "entity_2_idx_in_text_with_entity_marker": [288, 296], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d57.s1_BioInfer.d57.s1.p3", "text": "The interaction between calf spleen profilin and actin depends critically on the status of the C-terminus of the actin, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.", "text_with_entity_marker": "The interaction between calf [E1]spleen[/E1] profilin and actin depends critically on the status of the C-terminus of the [E2]actin[/E2], and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "spleen", "entity_1_idx": [[29, 35], [49, 54]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d57.s1_BioInfer.d57.s1.p4", "text": "The interaction between calf spleen profilin and actin depends critically on the status of the C-terminus of the actin, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.", "text_with_entity_marker": "The interaction between calf [E1]spleen profilin[/E1] and actin depends critically on the status of the C-terminus of the [E2]actin[/E2], and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "spleen profilin", "entity_1_idx": [[29, 44]], "entity_1_idx_in_text_with_entity_marker": [33, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[113, 118]], "entity_2_idx_in_text_with_entity_marker": [126, 131], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d57.s1_BioInfer.d57.s1.p5", "text": "The interaction between calf spleen profilin and actin depends critically on the status of the C-terminus of the actin, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.", "text_with_entity_marker": "The interaction between calf [E1-E2]spleen[/E1] profilin[/E2] and actin depends critically on the status of the C-terminus of the actin, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "spleen", "entity_1_idx": [[29, 35], [49, 54]], "entity_1_idx_in_text_with_entity_marker": [36, 42], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "spleen[/E1] profilin", "entity_2_idx": [[29, 44]], "entity_2_idx_in_text_with_entity_marker": [36, 56], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d306.s0_BioInfer.d306.s0.p0", "text": "In a blot overlay experiment, purified 125I-labeled recombinant profilin bound not only to plant actin, but also to mammalian actin, demonstrating that cytoskeletal components from distantly related organisms with divergent primary structures can be compatible.", "text_with_entity_marker": "In a blot overlay experiment, purified 125I-labeled recombinant [E1]profilin[/E1] bound not only to plant [E2]actin[/E2], but also to mammalian actin, demonstrating that cytoskeletal components from distantly related organisms with divergent primary structures can be compatible.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[64, 72]], "entity_1_idx_in_text_with_entity_marker": [68, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[97, 102]], "entity_2_idx_in_text_with_entity_marker": [110, 115], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d306.s0_BioInfer.d306.s0.p1", "text": "In a blot overlay experiment, purified 125I-labeled recombinant profilin bound not only to plant actin, but also to mammalian actin, demonstrating that cytoskeletal components from distantly related organisms with divergent primary structures can be compatible.", "text_with_entity_marker": "In a blot overlay experiment, purified 125I-labeled recombinant [E1]profilin[/E1] bound not only to plant actin, but also to mammalian [E2]actin[/E2], demonstrating that cytoskeletal components from distantly related organisms with divergent primary structures can be compatible.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[64, 72]], "entity_1_idx_in_text_with_entity_marker": [68, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d634.s0_BioInfer.d634.s0.p38", "text": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.", "text_with_entity_marker": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating [E1]caspases[/E1]-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and [E2]TRAIL-R2[/E2]) are controversial.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "caspases", "entity_1_idx": [[102, 110], [117, 120]], "entity_1_idx_in_text_with_entity_marker": [106, 114], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAIL-R2", "entity_2_idx": [[204, 212]], "entity_2_idx_in_text_with_entity_marker": [217, 225], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d634.s0_BioInfer.d634.s0.p39", "text": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.", "text_with_entity_marker": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating [E1]caspases-8[/E1] and -10 in death signaling by the two death-inducing [E2]TRAIL receptors[/E2] 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "caspases-8", "entity_1_idx": [[102, 112]], "entity_1_idx_in_text_with_entity_marker": [106, 116], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAIL receptors", "entity_2_idx": [[166, 181], [188, 189]], "entity_2_idx_in_text_with_entity_marker": [179, 194], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d634.s0_BioInfer.d634.s0.p40", "text": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.", "text_with_entity_marker": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating [E1]caspases-8[/E1] and -10 in death signaling by the two death-inducing [E2]TRAIL receptors 1[/E2] and 2 (TRAIL-R1 and TRAIL-R2) are controversial.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "caspases-8", "entity_1_idx": [[102, 112]], "entity_1_idx_in_text_with_entity_marker": [106, 116], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAIL receptors 1", "entity_2_idx": [[166, 183]], "entity_2_idx_in_text_with_entity_marker": [179, 196], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d634.s0_BioInfer.d634.s0.p41", "text": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.", "text_with_entity_marker": "The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating [E1]caspases-8[/E1] and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and [E2]TRAIL-R2[/E2]) are controversial.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "caspases-8", "entity_1_idx": [[102, 112]], "entity_1_idx_in_text_with_entity_marker": [106, 116], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAIL-R2", "entity_2_idx": [[204, 212]], "entity_2_idx_in_text_with_entity_marker": [217, 225], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p0", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or [E1]NCF2[/E1] promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and [E2]ICSBP[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NCF2", "entity_1_idx": [[127, 131]], "entity_1_idx_in_text_with_entity_marker": [131, 135], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "ICSBP", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p1", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the [E1]CREBbinding protein[/E1]), to the CYBB or [E2]NCF2[/E2] promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CREBbinding protein", "entity_1_idx": [[90, 109]], "entity_1_idx_in_text_with_entity_marker": [94, 113], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "NCF2", "entity_2_idx": [[127, 131]], "entity_2_idx_in_text_with_entity_marker": [140, 144], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p2", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or [E1]NCF2[/E1] promoter is the molecular mechanism of transcriptional activation by [E2]PU.1[/E2], IRF1, and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NCF2", "entity_1_idx": [[127, 131]], "entity_1_idx_in_text_with_entity_marker": [131, 135], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "PU.1", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p3", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or [E1]NCF2[/E1] promoter is the molecular mechanism of transcriptional activation by PU.1, [E2]IRF1[/E2], and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NCF2", "entity_1_idx": [[127, 131]], "entity_1_idx_in_text_with_entity_marker": [131, 135], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "IRF1", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p4", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, [E1]CBP[/E1] (the CREBbinding protein), to the CYBB or [E2]NCF2[/E2] promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[81, 84]], "entity_1_idx_in_text_with_entity_marker": [85, 88], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "NCF2", "entity_2_idx": [[127, 131]], "entity_2_idx_in_text_with_entity_marker": [140, 144], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p10", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the [E1]CYBB[/E1] or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and [E2]ICSBP[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CYBB", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "ICSBP", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p14", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the [E1]CREBbinding protein[/E1]), to the [E2]CYBB[/E2] or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CREBbinding protein", "entity_1_idx": [[90, 109]], "entity_1_idx_in_text_with_entity_marker": [94, 113], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CYBB", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p17", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the [E1]CYBB[/E1] or NCF2 promoter is the molecular mechanism of transcriptional activation by [E2]PU.1[/E2], IRF1, and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CYBB", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "PU.1", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p19", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the [E1]CYBB[/E1] or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, [E2]IRF1[/E2], and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CYBB", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "IRF1", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d372.s0_BioInfer.d372.s0.p20", "text": "In these investigations, we determine that recruitment of a coactivator protein, CBP (the CREBbinding protein), to the CYBB or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "text_with_entity_marker": "In these investigations, we determine that recruitment of a coactivator protein, [E1]CBP[/E1] (the CREBbinding protein), to the [E2]CYBB[/E2] or NCF2 promoter is the molecular mechanism of transcriptional activation by PU.1, IRF1, and ICSBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[81, 84]], "entity_1_idx_in_text_with_entity_marker": [85, 88], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CYBB", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d822.s0_BioInfer.d822.s0.p0", "text": "We speculate that fimbrin may help maintain the parallel growth of actin filaments within the stereocilia.", "text_with_entity_marker": "We speculate that [E1]fimbrin[/E1] may help maintain the parallel growth of [E2]actin[/E2] filaments within the stereocilia.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "fimbrin", "entity_1_idx": [[18, 25]], "entity_1_idx_in_text_with_entity_marker": [22, 29], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p3", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein ([E1]DRP[/E1] or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "DRP", "entity_1_idx": [[99, 102]], "entity_1_idx_in_text_with_entity_marker": [103, 106], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p4", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein ([E2]DRP[/E2] or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "DRP", "entity_2_idx": [[99, 102]], "entity_2_idx_in_text_with_entity_marker": [112, 115], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p7", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human [E1]dystrophin related protein[/E1] (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "dystrophin related protein", "entity_1_idx": [[71, 97]], "entity_1_idx_in_text_with_entity_marker": [75, 101], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p8", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human [E2]dystrophin related protein[/E2] (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "dystrophin related protein", "entity_2_idx": [[71, 97]], "entity_2_idx_in_text_with_entity_marker": [84, 110], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p10", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the [E1]87K postsynaptic protein[/E1] from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "87K postsynaptic protein", "entity_1_idx": [[124, 148]], "entity_1_idx_in_text_with_entity_marker": [128, 152], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p11", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein (DRP or utrophin) and the [E2]87K postsynaptic protein[/E2] from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "87K postsynaptic protein", "entity_2_idx": [[124, 148]], "entity_2_idx_in_text_with_entity_marker": [137, 161], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p12", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or [E1]utrophin[/E1]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated [E2]beta 1-syntrophin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "utrophin", "entity_1_idx": [[106, 114]], "entity_1_idx_in_text_with_entity_marker": [110, 118], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[202, 219]], "entity_2_idx_in_text_with_entity_marker": [215, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d376.s0_BioInfer.d376.s0.p13", "text": "In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "text_with_entity_marker": "In this recombinant expression system, the [E1]dystrophin[/E1] relatives, human dystrophin related protein (DRP or [E2]utrophin[/E2]) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[43, 53]], "entity_1_idx_in_text_with_entity_marker": [47, 57], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[106, 114]], "entity_2_idx_in_text_with_entity_marker": [119, 127], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d459.s0_BioInfer.d459.s0.p0", "text": "Once the actin monomer is bound to the filament, the profilin is released, and is available to bind to additional actin monomers.", "text_with_entity_marker": "Once the actin monomer is bound to the filament, the [E1]profilin[/E1] is released, and is available to bind to additional [E2]actin[/E2] monomers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[53, 61]], "entity_1_idx_in_text_with_entity_marker": [57, 65], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d395.s1_BioInfer.d395.s1.p0", "text": "Native profilin, purified from extracts of lung epithelial cells by affinity binding to a poly-L-proline matrix, stimulated the actin-saturated RSV transcription by 2.5- to 3-fold.", "text_with_entity_marker": "Native [E1]profilin[/E1], purified from extracts of lung epithelial cells by affinity binding to a poly-L-proline matrix, stimulated the [E2]actin[/E2]-saturated RSV transcription by 2.5- to 3-fold.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[7, 15]], "entity_1_idx_in_text_with_entity_marker": [11, 19], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d720.s0_BioInfer.d720.s0.p5", "text": "The sites on the myosin heavy chain that interact with actin and are responsible for force generation are ill-defined: crosslinking and experiments with isolated domains of the myosin head implicate regions in both the 50K and 20K (molecular weights in thousands) domains of the myosin head (subfragment 1, S1) in this process.", "text_with_entity_marker": "The sites on the [E1]myosin heavy chain[/E1] that interact with [E2]actin[/E2] and are responsible for force generation are ill-defined: crosslinking and experiments with isolated domains of the myosin head implicate regions in both the 50K and 20K (molecular weights in thousands) domains of the myosin head (subfragment 1, S1) in this process.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin heavy chain", "entity_1_idx": [[17, 35]], "entity_1_idx_in_text_with_entity_marker": [21, 39], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d743.s0_BioInfer.d743.s0.p0", "text": "This paper describes the structural and biochemical characterization of talin, a protein localized to various cellular sites where bundles of actin filaments attach to the plasma membrane.", "text_with_entity_marker": "This paper describes the structural and biochemical characterization of [E1]talin[/E1], a protein localized to various cellular sites where bundles of [E2]actin[/E2] filaments attach to the plasma membrane.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d119.s0_BioInfer.d119.s0.p0", "text": "By site-directed mutagenesis of profilin II from Dictyostelium discoideum the point mutations K114E and W3N were generated by PCR thus changing actin and poly-(L)-proline-binding activity respectively.", "text_with_entity_marker": "By site-directed mutagenesis of [E1]profilin II[/E1] from Dictyostelium discoideum the point mutations K114E and W3N were generated by PCR thus changing [E2]actin[/E2] and poly-(L)-proline-binding activity respectively.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin II", "entity_1_idx": [[32, 43]], "entity_1_idx_in_text_with_entity_marker": [36, 47], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d119.s1_BioInfer.d119.s1.p0", "text": "The K114E profilin exhibited a profound decrease in its ability to interact with actin, whereas binding to poly-(L)-proline was essentially unchanged.", "text_with_entity_marker": "The [E1]K114E profilin[/E1] exhibited a profound decrease in its ability to interact with [E2]actin[/E2], whereas binding to poly-(L)-proline was essentially unchanged.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "K114E profilin", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d431.s0_BioInfer.d431.s0.p0", "text": "[Molecular functions of cofilin which regulates reorganization of actin cytoskeleton].", "text_with_entity_marker": "[Molecular functions of [E1]cofilin[/E1] which regulates reorganization of [E2]actin[/E2] cytoskeleton].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[24, 31]], "entity_1_idx_in_text_with_entity_marker": [28, 35], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p16", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of [E1]profilin[/E1] on [E2]actin[/E2] polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[136, 144]], "entity_1_idx_in_text_with_entity_marker": [140, 148], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d309.s0_BioInfer.d309.s0.p1", "text": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of cyclin D1.", "text_with_entity_marker": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the [E1]cyclin-dependent kinase inhibitor[/E1] p16([E2]INK4A[/E2]) and/or up-regulation of cyclin D1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[114, 147]], "entity_1_idx_in_text_with_entity_marker": [118, 151], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "INK4A", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d309.s0_BioInfer.d309.s0.p3", "text": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of cyclin D1.", "text_with_entity_marker": "Inactivation of the [E1]Rb[/E1] pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16([E2]INK4A[/E2]) and/or up-regulation of cyclin D1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[20, 22]], "entity_1_idx_in_text_with_entity_marker": [24, 26], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "INK4A", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d309.s0_BioInfer.d309.s0.p6", "text": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of cyclin D1.", "text_with_entity_marker": "Inactivation of the [E1]Rb[/E1] pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of [E2]cyclin D1[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[20, 22]], "entity_1_idx_in_text_with_entity_marker": [24, 26], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin D1", "entity_2_idx": [[183, 192]], "entity_2_idx_in_text_with_entity_marker": [196, 205], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d309.s0_BioInfer.d309.s0.p7", "text": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of cyclin D1.", "text_with_entity_marker": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the [E1]cyclin-dependent kinase inhibitor[/E1] [E2]p16[/E2](INK4A) and/or up-regulation of cyclin D1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[114, 147]], "entity_1_idx_in_text_with_entity_marker": [118, 151], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p16", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d309.s0_BioInfer.d309.s0.p9", "text": "Inactivation of the Rb pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor p16(INK4A) and/or up-regulation of cyclin D1.", "text_with_entity_marker": "Inactivation of the [E1]Rb[/E1] pathway in non-small cell lung carcinoma (NSCLC) occurs mostly through inactivation of the cyclin-dependent kinase inhibitor [E2]p16[/E2](INK4A) and/or up-regulation of cyclin D1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[20, 22]], "entity_1_idx_in_text_with_entity_marker": [24, 26], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p16", "entity_2_idx": [[148, 151]], "entity_2_idx_in_text_with_entity_marker": [161, 164], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d546.s0_BioInfer.d546.s0.p5", "text": "Specific antibodies to myosin heavy chain isoforms (SM1, SM2, SMemb), caldesmon, and alpha-smooth muscle actin and cDNAs for SMemb were used.", "text_with_entity_marker": "Specific antibodies to [E1]myosin heavy chain[/E1] isoforms ([E2]SM1[/E2], SM2, SMemb), caldesmon, and alpha-smooth muscle actin and cDNAs for SMemb were used.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin heavy chain", "entity_1_idx": [[23, 41]], "entity_1_idx_in_text_with_entity_marker": [27, 45], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "SM1", "entity_2_idx": [[52, 55]], "entity_2_idx_in_text_with_entity_marker": [65, 68], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d546.s0_BioInfer.d546.s0.p17", "text": "Specific antibodies to myosin heavy chain isoforms (SM1, SM2, SMemb), caldesmon, and alpha-smooth muscle actin and cDNAs for SMemb were used.", "text_with_entity_marker": "Specific antibodies to [E1]myosin heavy chain[/E1] isoforms (SM1, [E2]SM2[/E2], SMemb), caldesmon, and alpha-smooth muscle actin and cDNAs for SMemb were used.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin heavy chain", "entity_1_idx": [[23, 41]], "entity_1_idx_in_text_with_entity_marker": [27, 45], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "SM2", "entity_2_idx": [[57, 60]], "entity_2_idx_in_text_with_entity_marker": [70, 73], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d546.s0_BioInfer.d546.s0.p20", "text": "Specific antibodies to myosin heavy chain isoforms (SM1, SM2, SMemb), caldesmon, and alpha-smooth muscle actin and cDNAs for SMemb were used.", "text_with_entity_marker": "Specific antibodies to [E1]myosin heavy chain[/E1] isoforms (SM1, SM2, [E2]SMemb[/E2]), caldesmon, and alpha-smooth muscle actin and cDNAs for SMemb were used.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "myosin heavy chain", "entity_1_idx": [[23, 41]], "entity_1_idx_in_text_with_entity_marker": [27, 45], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "SMemb", "entity_2_idx": [[62, 67]], "entity_2_idx_in_text_with_entity_marker": [75, 80], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d711.s0_BioInfer.d711.s0.p0", "text": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "text_with_entity_marker": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with [E1]actin-binding proteins[/E1] such as gelsolin and [E2]profilin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding proteins", "entity_1_idx": [[326, 348]], "entity_1_idx_in_text_with_entity_marker": [330, 352], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "profilin", "entity_2_idx": [[370, 378]], "entity_2_idx_in_text_with_entity_marker": [383, 391], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d711.s0_BioInfer.d711.s0.p9", "text": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "text_with_entity_marker": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of [E1]actin[/E1] in RBL cells, possibly through the interaction of the polyphosphoinositides with [E2]actin-binding proteins[/E2] such as gelsolin and profilin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[239, 244]], "entity_1_idx_in_text_with_entity_marker": [243, 248], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin-binding proteins", "entity_2_idx": [[326, 348]], "entity_2_idx_in_text_with_entity_marker": [339, 361], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d711.s0_BioInfer.d711.s0.p10", "text": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "text_with_entity_marker": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with [E1]actin-binding proteins[/E1] such as [E2]gelsolin[/E2] and profilin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding proteins", "entity_1_idx": [[326, 348]], "entity_1_idx_in_text_with_entity_marker": [330, 352], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "gelsolin", "entity_2_idx": [[357, 365]], "entity_2_idx_in_text_with_entity_marker": [370, 378], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d711.s0_BioInfer.d711.s0.p13", "text": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "text_with_entity_marker": "These results suggest that activation of PKC precedes the activation of [E1]PI[/E1] and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of [E2]actin[/E2] in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "PI", "entity_1_idx": [[72, 74], [83, 90]], "entity_1_idx_in_text_with_entity_marker": [76, 78], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d711.s0_BioInfer.d711.s0.p16", "text": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "text_with_entity_marker": "These results suggest that activation of [E1]PKC[/E1] precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of [E2]actin[/E2] in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[41, 44]], "entity_1_idx_in_text_with_entity_marker": [45, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d711.s0_BioInfer.d711.s0.p18", "text": "These results suggest that activation of PKC precedes the activation of PI and PIP kinases and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of actin in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "text_with_entity_marker": "These results suggest that activation of PKC precedes the activation of PI and [E1]PIP kinases[/E1] and that under certain circumstances activation of the kinases and the increased synthesis of PIP and PIP2 may be involved in the polymerization of [E2]actin[/E2] in RBL cells, possibly through the interaction of the polyphosphoinositides with actin-binding proteins such as gelsolin and profilin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "PIP kinases", "entity_1_idx": [[79, 90]], "entity_1_idx_in_text_with_entity_marker": [83, 94], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[239, 244]], "entity_2_idx_in_text_with_entity_marker": [252, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d567.s0_BioInfer.d567.s0.p0", "text": "The CREB binding domain of CBP is sufficient to contact to c-Jun in vitro.", "text_with_entity_marker": "The [E1]CREB[/E1] binding domain of [E2]CBP[/E2] is sufficient to contact to c-Jun in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CREB", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CBP", "entity_2_idx": [[27, 30]], "entity_2_idx_in_text_with_entity_marker": [40, 43], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d567.s0_BioInfer.d567.s0.p1", "text": "The CREB binding domain of CBP is sufficient to contact to c-Jun in vitro.", "text_with_entity_marker": "The CREB binding domain of [E1]CBP[/E1] is sufficient to contact to [E2]c-Jun[/E2] in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d636.s0_BioInfer.d636.s0.p0", "text": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.", "text_with_entity_marker": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: [E1]actin[/E1], villin, fimbrin and [E2]brush border myosin-I[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[89, 94]], "entity_1_idx_in_text_with_entity_marker": [93, 98], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "brush border myosin-I", "entity_2_idx": [[116, 137]], "entity_2_idx_in_text_with_entity_marker": [129, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d636.s0_BioInfer.d636.s0.p1", "text": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.", "text_with_entity_marker": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: [E1]actin[/E1], [E2]villin[/E2], fimbrin and brush border myosin-I.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[89, 94]], "entity_1_idx_in_text_with_entity_marker": [93, 98], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "villin", "entity_2_idx": [[96, 102]], "entity_2_idx_in_text_with_entity_marker": [109, 115], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d636.s0_BioInfer.d636.s0.p2", "text": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.", "text_with_entity_marker": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: [E1]actin[/E1], villin, [E2]fimbrin[/E2] and brush border myosin-I.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[89, 94]], "entity_1_idx_in_text_with_entity_marker": [93, 98], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d636.s0_BioInfer.d636.s0.p3", "text": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.", "text_with_entity_marker": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, [E1]villin[/E1], fimbrin and [E2]brush border myosin-I[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "villin", "entity_1_idx": [[96, 102]], "entity_1_idx_in_text_with_entity_marker": [100, 106], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "brush border myosin-I", "entity_2_idx": [[116, 137]], "entity_2_idx_in_text_with_entity_marker": [129, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d636.s0_BioInfer.d636.s0.p4", "text": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.", "text_with_entity_marker": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, [E1]fimbrin[/E1] and [E2]brush border myosin-I[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "fimbrin", "entity_1_idx": [[104, 111]], "entity_1_idx_in_text_with_entity_marker": [108, 115], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "brush border myosin-I", "entity_2_idx": [[116, 137]], "entity_2_idx_in_text_with_entity_marker": [129, 150], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d636.s0_BioInfer.d636.s0.p5", "text": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, villin, fimbrin and brush border myosin-I.", "text_with_entity_marker": "The isolated intestinal microvillus cytoskeleton (core) consists of four major proteins: actin, [E1]villin[/E1], [E2]fimbrin[/E2] and brush border myosin-I.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "villin", "entity_1_idx": [[96, 102]], "entity_1_idx_in_text_with_entity_marker": [100, 106], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d833.s0_BioInfer.d833.s0.p30", "text": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "text_with_entity_marker": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, [E1]vinculin[/E1] and [E2]alpha-actinin[/E2] appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "vinculin", "entity_1_idx": [[124, 132]], "entity_1_idx_in_text_with_entity_marker": [128, 136], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-actinin", "entity_2_idx": [[137, 150]], "entity_2_idx_in_text_with_entity_marker": [150, 163], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d833.s0_BioInfer.d833.s0.p31", "text": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "text_with_entity_marker": "Within 1 hour of raising the concentration of calcium ions, integrins, [E1]cadherins[/E1], alpha-catenin, beta-catenin, plakoglobin, vinculin and [E2]alpha-actinin[/E2] appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cadherins", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-actinin", "entity_2_idx": [[137, 150]], "entity_2_idx_in_text_with_entity_marker": [150, 163], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d833.s0_BioInfer.d833.s0.p32", "text": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "text_with_entity_marker": "Within 1 hour of raising the concentration of calcium ions, [E1]integrins[/E1], cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and [E2]alpha-actinin[/E2] appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "integrins", "entity_1_idx": [[60, 69]], "entity_1_idx_in_text_with_entity_marker": [64, 73], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-actinin", "entity_2_idx": [[137, 150]], "entity_2_idx_in_text_with_entity_marker": [150, 163], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d833.s0_BioInfer.d833.s0.p33", "text": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "text_with_entity_marker": "Within 1 hour of raising the concentration of calcium ions, integrins, [E1]cadherins[/E1], alpha-catenin, beta-catenin, plakoglobin, [E2]vinculin[/E2] and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cadherins", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "vinculin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d833.s0_BioInfer.d833.s0.p34", "text": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "text_with_entity_marker": "Within 1 hour of raising the concentration of calcium ions, [E1]integrins[/E1], cadherins, alpha-catenin, beta-catenin, plakoglobin, [E2]vinculin[/E2] and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "integrins", "entity_1_idx": [[60, 69]], "entity_1_idx_in_text_with_entity_marker": [64, 73], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "vinculin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d833.s0_BioInfer.d833.s0.p35", "text": "Within 1 hour of raising the concentration of calcium ions, integrins, cadherins, alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "text_with_entity_marker": "Within 1 hour of raising the concentration of calcium ions, [E1]integrins[/E1], [E2]cadherins[/E2], alpha-catenin, beta-catenin, plakoglobin, vinculin and alpha-actinin appeared to accumulate at cell-cell borders, whereas the focal contact proteins, paxillin and talin, did not.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "integrins", "entity_1_idx": [[60, 69]], "entity_1_idx_in_text_with_entity_marker": [64, 73], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cadherins", "entity_2_idx": [[71, 80]], "entity_2_idx_in_text_with_entity_marker": [84, 93], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d187.s0_BioInfer.d187.s0.p0", "text": "Effects of single amino acid substitutions in the actin-binding site on the biological activity of bovine profilin I.", "text_with_entity_marker": "Effects of single amino acid substitutions in the [E1]actin[/E1]-binding site on the biological activity of bovine [E2]profilin I[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin I", "entity_2_idx": [[106, 116]], "entity_2_idx_in_text_with_entity_marker": [119, 129], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d187.s1_BioInfer.d187.s1.p1", "text": "However, these mutants displayed a lower affinity for actin than wild-type profilin, suggesting that additional putative bonds created this way cannot increase profilin's affinity for actin.", "text_with_entity_marker": "However, these mutants displayed a lower affinity for [E1]actin[/E1] than wild-type [E2]profilin[/E2], suggesting that additional putative bonds created this way cannot increase profilin's affinity for actin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[75, 83]], "entity_2_idx_in_text_with_entity_marker": [88, 96], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d187.s1_BioInfer.d187.s1.p4", "text": "However, these mutants displayed a lower affinity for actin than wild-type profilin, suggesting that additional putative bonds created this way cannot increase profilin's affinity for actin.", "text_with_entity_marker": "However, these mutants displayed a lower affinity for actin than wild-type profilin, suggesting that additional putative bonds created this way cannot increase [E1]profilin[/E1]'s affinity for [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[160, 168]], "entity_1_idx_in_text_with_entity_marker": [164, 172], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[184, 189]], "entity_2_idx_in_text_with_entity_marker": [197, 202], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d187.s2_BioInfer.d187.s2.p0", "text": "These results emphasize the highly conserved biological function of profilins with low sequence homology, and correlate specifically their actin-binding capacity with cell motility and proliferation.", "text_with_entity_marker": "These results emphasize the highly conserved biological function of [E1]profilins[/E1] with low sequence homology, and correlate specifically their [E2]actin[/E2]-binding capacity with cell motility and proliferation.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilins", "entity_1_idx": [[68, 77]], "entity_1_idx_in_text_with_entity_marker": [72, 81], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p1", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of [E1]LIM-kinase[/E1] by ROCK and consequently increased phosphorylation of [E2]cofilin[/E2] by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIM-kinase", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[112, 119]], "entity_2_idx_in_text_with_entity_marker": [125, 132], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p2", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of [E1]LIM-kinase[/E1] by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIM-kinase", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p4", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of [E1]LIM-kinase[/E1] by [E2]ROCK[/E2] and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIM-kinase", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "ROCK", "entity_2_idx": [[61, 65]], "entity_2_idx_in_text_with_entity_marker": [74, 78], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p5", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of [E1]cofilin[/E1] by [E2]LIM-kinase[/E2] contribute to Rho-induced reorganization of the actin cytoskeleton.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cofilin", "entity_1_idx": [[112, 119]], "entity_1_idx_in_text_with_entity_marker": [116, 123], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "LIM-kinase", "entity_2_idx": [[123, 133]], "entity_2_idx_in_text_with_entity_marker": [136, 146], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p6", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by [E1]LIM-kinase[/E1] contribute to Rho-induced reorganization of the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIM-kinase", "entity_1_idx": [[123, 133]], "entity_1_idx_in_text_with_entity_marker": [127, 137], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p9", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of [E1]cofilin[/E1] by LIM-kinase contribute to Rho-induced reorganization of the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[112, 119]], "entity_1_idx_in_text_with_entity_marker": [116, 123], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p11", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of LIM-kinase by [E1]ROCK[/E1] and consequently increased phosphorylation of [E2]cofilin[/E2] by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ROCK", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[112, 119]], "entity_2_idx_in_text_with_entity_marker": [125, 132], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p12", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to [E1]Rho[/E1]-induced reorganization of the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Rho", "entity_1_idx": [[148, 151]], "entity_1_idx_in_text_with_entity_marker": [152, 155], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d709.s0_BioInfer.d709.s0.p13", "text": "These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.", "text_with_entity_marker": "These results indicate that phosphorylation of LIM-kinase by [E1]ROCK[/E1] and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ROCK", "entity_1_idx": [[61, 65]], "entity_1_idx_in_text_with_entity_marker": [65, 69], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[182, 187]], "entity_2_idx_in_text_with_entity_marker": [195, 200], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d312.s0_BioInfer.d312.s0.p2", "text": "In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with TNF-alpha led to a 2.4-fold increase in net actin protein synthesis and a 3.3-fold increase in net myosin heavy chain synthesis.", "text_with_entity_marker": "In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with [E1]TNF-alpha[/E1] led to a 2.4-fold increase in net actin protein synthesis and a 3.3-fold increase in net [E2]myosin heavy chain[/E2] synthesis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[97, 106]], "entity_1_idx_in_text_with_entity_marker": [101, 110], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "myosin heavy chain", "entity_2_idx": [[196, 214]], "entity_2_idx_in_text_with_entity_marker": [209, 227], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d312.s0_BioInfer.d312.s0.p4", "text": "In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with TNF-alpha led to a 2.4-fold increase in net actin protein synthesis and a 3.3-fold increase in net myosin heavy chain synthesis.", "text_with_entity_marker": "In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with [E1]TNF-alpha[/E1] led to a 2.4-fold increase in net [E2]actin[/E2] protein synthesis and a 3.3-fold increase in net myosin heavy chain synthesis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[97, 106]], "entity_1_idx_in_text_with_entity_marker": [101, 110], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d100.s2_BioInfer.d100.s2.p6", "text": "Here, we show that PRP5 (a DEAD box helicase-like protein), PRP9, and PRP11 are each required for the U2 snRNP to bind to the pre-spliceosome during spliceosome assembly in vitro.", "text_with_entity_marker": "Here, we show that [E1]PRP5[/E1] (a [E2]DEAD box helicase[/E2]-like protein), PRP9, and PRP11 are each required for the U2 snRNP to bind to the pre-spliceosome during spliceosome assembly in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PRP5", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "DEAD box helicase", "entity_2_idx": [[27, 44]], "entity_2_idx_in_text_with_entity_marker": [40, 57], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d487.s0_BioInfer.d487.s0.p0", "text": "Phosphorylation of the headpiece domain could regulate the actin binding and bundling properties of fimbrin, or it could regulate the interaction of fimbrin with other proteins.", "text_with_entity_marker": "Phosphorylation of the headpiece domain could regulate the [E1]actin[/E1] binding and bundling properties of [E2]fimbrin[/E2], or it could regulate the interaction of fimbrin with other proteins.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[100, 107]], "entity_2_idx_in_text_with_entity_marker": [113, 120], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d487.s0_BioInfer.d487.s0.p2", "text": "Phosphorylation of the headpiece domain could regulate the actin binding and bundling properties of fimbrin, or it could regulate the interaction of fimbrin with other proteins.", "text_with_entity_marker": "Phosphorylation of the headpiece domain could regulate the actin binding and bundling properties of [E1]fimbrin[/E1], or it could regulate the interaction of [E2]fimbrin[/E2] with other proteins.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "fimbrin", "entity_1_idx": [[100, 107]], "entity_1_idx_in_text_with_entity_marker": [104, 111], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p0", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the [E1]BNI1[/E1], GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "BNI1", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "actin", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p1", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking [E1]Cdc42p[/E1] to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Cdc42p", "entity_1_idx": [[97, 103]], "entity_1_idx_in_text_with_entity_marker": [101, 107], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p2", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the BNI1, GIC1, and [E1]GIC2[/E1] gene products also appear to be involved in linking Cdc42p to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "GIC2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "actin", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p3", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the BNI1, [E1]GIC1[/E1], and GIC2 gene products also appear to be involved in linking Cdc42p to the [E2]actin[/E2] cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "GIC1", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "actin", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p4", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the [E1]BNI1[/E1], GIC1, and GIC2 gene products also appear to be involved in linking [E2]Cdc42p[/E2] to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "BNI1", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "Cdc42p", "entity_2_idx": [[97, 103]], "entity_2_idx_in_text_with_entity_marker": [110, 116], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p7", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the BNI1, GIC1, and [E1]GIC2[/E1] gene products also appear to be involved in linking [E2]Cdc42p[/E2] to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "GIC2", "entity_1_idx": [[40, 44]], "entity_1_idx_in_text_with_entity_marker": [44, 48], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "Cdc42p", "entity_2_idx": [[97, 103]], "entity_2_idx_in_text_with_entity_marker": [110, 116], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d217.s0_BioInfer.d217.s0.p8", "text": "From previous work, the BNI1, GIC1, and GIC2 gene products also appear to be involved in linking Cdc42p to the actin cytoskeleton.", "text_with_entity_marker": "From previous work, the BNI1, [E1]GIC1[/E1], and GIC2 gene products also appear to be involved in linking [E2]Cdc42p[/E2] to the actin cytoskeleton.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "GIC1", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "Cdc42p", "entity_2_idx": [[97, 103]], "entity_2_idx_in_text_with_entity_marker": [110, 116], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d527.s0_BioInfer.d527.s0.p15", "text": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between MSH2 and RAD1, RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "text_with_entity_marker": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between [E1]MSH2[/E1] and RAD1, RAD2, RAD3, RAD10, RAD14, and [E2]RAD25[/E2] subsequently were demonstrated by two-hybrid analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[125, 129]], "entity_1_idx_in_text_with_entity_marker": [129, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD25", "entity_2_idx": [[170, 175]], "entity_2_idx_in_text_with_entity_marker": [183, 188], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d527.s0_BioInfer.d527.s0.p16", "text": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between MSH2 and RAD1, RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "text_with_entity_marker": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between [E1]MSH2[/E1] and RAD1, RAD2, [E2]RAD3[/E2], RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[125, 129]], "entity_1_idx_in_text_with_entity_marker": [129, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD3", "entity_2_idx": [[146, 150]], "entity_2_idx_in_text_with_entity_marker": [159, 163], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d527.s0_BioInfer.d527.s0.p17", "text": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between MSH2 and RAD1, RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "text_with_entity_marker": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between [E1]MSH2[/E1] and RAD1, RAD2, RAD3, [E2]RAD10[/E2], RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[125, 129]], "entity_1_idx_in_text_with_entity_marker": [129, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD10", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d527.s0_BioInfer.d527.s0.p18", "text": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between MSH2 and RAD1, RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "text_with_entity_marker": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between [E1]MSH2[/E1] and [E2]RAD1[/E2], RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[125, 129]], "entity_1_idx_in_text_with_entity_marker": [129, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD1", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d527.s0_BioInfer.d527.s0.p19", "text": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between MSH2 and RAD1, RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "text_with_entity_marker": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between [E1]MSH2[/E1] and RAD1, [E2]RAD2[/E2], RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[125, 129]], "entity_1_idx_in_text_with_entity_marker": [129, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD2", "entity_2_idx": [[140, 144]], "entity_2_idx_in_text_with_entity_marker": [153, 157], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d527.s0_BioInfer.d527.s0.p20", "text": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between MSH2 and RAD1, RAD2, RAD3, RAD10, RAD14, and RAD25 subsequently were demonstrated by two-hybrid analysis.", "text_with_entity_marker": "Saccharomyces cerevisiae RAD14 was identified in a two-hybrid screen using MSH2 as \"bait,\" and pairwise interactions between [E1]MSH2[/E1] and RAD1, RAD2, RAD3, RAD10, [E2]RAD14[/E2], and RAD25 subsequently were demonstrated by two-hybrid analysis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[125, 129]], "entity_1_idx_in_text_with_entity_marker": [129, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD14", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p1", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and [E1]alpha 1-syntrophin[/E1] interact with peptides encoding the syntrophin-binding region of dystrophin, [E2]utrophin[/E2]/dystrophin related protein, and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha 1-syntrophin", "entity_1_idx": [[133, 151]], "entity_1_idx_in_text_with_entity_marker": [137, 155], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[229, 237]], "entity_2_idx_in_text_with_entity_marker": [242, 250], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p3", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and [E1]alpha 1-syntrophin[/E1] interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/[E2]dystrophin related protein[/E2], and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha 1-syntrophin", "entity_1_idx": [[133, 151]], "entity_1_idx_in_text_with_entity_marker": [137, 155], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "dystrophin related protein", "entity_2_idx": [[238, 264]], "entity_2_idx_in_text_with_entity_marker": [251, 277], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p4", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and [E1]alpha 1-syntrophin[/E1] interact with peptides encoding the syntrophin-binding region of [E2]dystrophin[/E2], utrophin/dystrophin related protein, and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha 1-syntrophin", "entity_1_idx": [[133, 151]], "entity_1_idx_in_text_with_entity_marker": [137, 155], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[217, 227]], "entity_2_idx_in_text_with_entity_marker": [230, 240], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p5", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and [E1]alpha 1-syntrophin[/E1] interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo [E2]87K[/E2] protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha 1-syntrophin", "entity_1_idx": [[133, 151]], "entity_1_idx_in_text_with_entity_marker": [137, 155], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "87K", "entity_2_idx": [[282, 285]], "entity_2_idx_in_text_with_entity_marker": [295, 298], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p7", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like [E1]beta 1-syntrophin[/E1], both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, [E2]utrophin[/E2]/dystrophin related protein, and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[97, 114]], "entity_1_idx_in_text_with_entity_marker": [101, 118], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[229, 237]], "entity_2_idx_in_text_with_entity_marker": [242, 250], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p9", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like [E1]beta 1-syntrophin[/E1], both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/[E2]dystrophin related protein[/E2], and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[97, 114]], "entity_1_idx_in_text_with_entity_marker": [101, 118], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "dystrophin related protein", "entity_2_idx": [[238, 264]], "entity_2_idx_in_text_with_entity_marker": [251, 277], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p10", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like [E1]beta 1-syntrophin[/E1], both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of [E2]dystrophin[/E2], utrophin/dystrophin related protein, and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[97, 114]], "entity_1_idx_in_text_with_entity_marker": [101, 118], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[217, 227]], "entity_2_idx_in_text_with_entity_marker": [230, 240], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p11", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like [E1]beta 1-syntrophin[/E1], both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo [E2]87K[/E2] protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[97, 114]], "entity_1_idx_in_text_with_entity_marker": [101, 118], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "87K", "entity_2_idx": [[282, 285]], "entity_2_idx_in_text_with_entity_marker": [295, 298], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p17", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both [E1]beta 2-[/E1] and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, [E2]utrophin[/E2]/dystrophin related protein, and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta 2-", "entity_1_idx": [[121, 128], [141, 151]], "entity_1_idx_in_text_with_entity_marker": [125, 132], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "utrophin", "entity_2_idx": [[229, 237]], "entity_2_idx_in_text_with_entity_marker": [242, 250], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d211.s0_BioInfer.d211.s0.p19", "text": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.", "text_with_entity_marker": "Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the [E1]syntrophin[/E1]-binding region of [E2]dystrophin[/E2], utrophin/dystrophin related protein, and the Torpedo 87K protein.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "syntrophin", "entity_1_idx": [[188, 198]], "entity_1_idx_in_text_with_entity_marker": [192, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[217, 227]], "entity_2_idx_in_text_with_entity_marker": [230, 240], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d67.s0_BioInfer.d67.s0.p6", "text": "A null mutation of the actin gene (ACT1) is lethal, but null mutations in the tropomyosin (TPM1), fimbrin (SAC6), Abp1p (ABP1), and capping protein (CAP1 and CAP2) genes have relatively mild or no effects.", "text_with_entity_marker": "A null mutation of the actin gene (ACT1) is lethal, but null mutations in the tropomyosin (TPM1), fimbrin (SAC6), Abp1p (ABP1), and [E1]capping protein[/E1] (CAP1 and [E2]CAP2[/E2]) genes have relatively mild or no effects.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "capping protein", "entity_1_idx": [[132, 147]], "entity_1_idx_in_text_with_entity_marker": [136, 151], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CAP2", "entity_2_idx": [[158, 162]], "entity_2_idx_in_text_with_entity_marker": [171, 175], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d67.s0_BioInfer.d67.s0.p41", "text": "A null mutation of the actin gene (ACT1) is lethal, but null mutations in the tropomyosin (TPM1), fimbrin (SAC6), Abp1p (ABP1), and capping protein (CAP1 and CAP2) genes have relatively mild or no effects.", "text_with_entity_marker": "A null mutation of the actin gene (ACT1) is lethal, but null mutations in the tropomyosin (TPM1), fimbrin (SAC6), Abp1p (ABP1), and [E1]capping protein[/E1] ([E2]CAP1[/E2] and CAP2) genes have relatively mild or no effects.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "capping protein", "entity_1_idx": [[132, 147]], "entity_1_idx_in_text_with_entity_marker": [136, 151], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CAP1", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d782.s0_BioInfer.d782.s0.p4", "text": "Unexpectedly, treatment with the actin-depolymerizing drug latrunculin-A disrupted the medial region targeting pattern, and cells deficient in the actin-binding proteins tropomyosin and profilin also did not exhibit medial GFP-Cdc42p staining.", "text_with_entity_marker": "Unexpectedly, treatment with the actin-depolymerizing drug latrunculin-A disrupted the medial region targeting pattern, and cells deficient in the [E1]actin-binding proteins[/E1] tropomyosin and [E2]profilin[/E2] also did not exhibit medial GFP-Cdc42p staining.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding proteins", "entity_1_idx": [[147, 169]], "entity_1_idx_in_text_with_entity_marker": [151, 173], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "profilin", "entity_2_idx": [[186, 194]], "entity_2_idx_in_text_with_entity_marker": [199, 207], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d782.s0_BioInfer.d782.s0.p8", "text": "Unexpectedly, treatment with the actin-depolymerizing drug latrunculin-A disrupted the medial region targeting pattern, and cells deficient in the actin-binding proteins tropomyosin and profilin also did not exhibit medial GFP-Cdc42p staining.", "text_with_entity_marker": "Unexpectedly, treatment with the actin-depolymerizing drug latrunculin-A disrupted the medial region targeting pattern, and cells deficient in the [E1]actin-binding proteins[/E1] [E2]tropomyosin[/E2] and profilin also did not exhibit medial GFP-Cdc42p staining.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding proteins", "entity_1_idx": [[147, 169]], "entity_1_idx_in_text_with_entity_marker": [151, 173], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "tropomyosin", "entity_2_idx": [[170, 181]], "entity_2_idx_in_text_with_entity_marker": [183, 194], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p0", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that [E1]TGFbeta[/E1] regulates [E2]clusterin[/E2] gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "TGFbeta", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "clusterin", "entity_2_idx": [[55, 64]], "entity_2_idx_in_text_with_entity_marker": [68, 77], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p1", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that [E1]TGFbeta[/E1] regulates clusterin gene expression through an AP-1 site and its cognate transcription factor [E2]AP-1[/E2], and requires the involvement of protein kinase C.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TGFbeta", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p2", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that [E1]TGFbeta[/E1] regulates clusterin gene expression through an [E2]AP-1[/E2] site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TGFbeta", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[92, 96]], "entity_2_idx_in_text_with_entity_marker": [105, 109], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p3", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that [E1]TGFbeta[/E1] regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of [E2]protein kinase C[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TGFbeta", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[177, 193]], "entity_2_idx_in_text_with_entity_marker": [190, 206], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p4", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that TGFbeta regulates [E1]clusterin[/E1] gene expression through an AP-1 site and its cognate transcription factor [E2]AP-1[/E2], and requires the involvement of protein kinase C.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "clusterin", "entity_1_idx": [[55, 64]], "entity_1_idx_in_text_with_entity_marker": [59, 68], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p5", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that TGFbeta regulates [E1]clusterin[/E1] gene expression through an [E2]AP-1[/E2] site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "clusterin", "entity_1_idx": [[55, 64]], "entity_1_idx_in_text_with_entity_marker": [59, 68], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[92, 96]], "entity_2_idx_in_text_with_entity_marker": [105, 109], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d768.s0_BioInfer.d768.s0.p7", "text": "Together these results indicate that TGFbeta regulates clusterin gene expression through an AP-1 site and its cognate transcription factor AP-1, and requires the involvement of protein kinase C.", "text_with_entity_marker": "Together these results indicate that TGFbeta regulates clusterin gene expression through an [E1]AP-1[/E1] site and its cognate transcription factor [E2]AP-1[/E2], and requires the involvement of protein kinase C.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AP-1", "entity_1_idx": [[92, 96]], "entity_1_idx_in_text_with_entity_marker": [96, 100], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d792.s0_BioInfer.d792.s0.p0", "text": "VASP, in turn, provides the ABM-2 sequences [XPPPPP, X = G, P, L, S, A] for binding profilin, an actin-regulatory protein that stimulates actin filament assembly.", "text_with_entity_marker": "[E1]VASP[/E1], in turn, provides the ABM-2 sequences [XPPPPP, X = G, P, L, S, A] for binding [E2]profilin[/E2], an actin-regulatory protein that stimulates actin filament assembly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "VASP", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[84, 92]], "entity_2_idx_in_text_with_entity_marker": [97, 105], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d792.s0_BioInfer.d792.s0.p1", "text": "VASP, in turn, provides the ABM-2 sequences [XPPPPP, X = G, P, L, S, A] for binding profilin, an actin-regulatory protein that stimulates actin filament assembly.", "text_with_entity_marker": "VASP, in turn, provides the ABM-2 sequences [XPPPPP, X = G, P, L, S, A] for binding [E1]profilin[/E1], an [E2]actin[/E2]-regulatory protein that stimulates actin filament assembly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[84, 92]], "entity_1_idx_in_text_with_entity_marker": [88, 96], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[97, 102]], "entity_2_idx_in_text_with_entity_marker": [110, 115], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d792.s0_BioInfer.d792.s0.p2", "text": "VASP, in turn, provides the ABM-2 sequences [XPPPPP, X = G, P, L, S, A] for binding profilin, an actin-regulatory protein that stimulates actin filament assembly.", "text_with_entity_marker": "VASP, in turn, provides the ABM-2 sequences [XPPPPP, X = G, P, L, S, A] for binding [E1]profilin[/E1], an actin-regulatory protein that stimulates [E2]actin[/E2] filament assembly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[84, 92]], "entity_1_idx_in_text_with_entity_marker": [88, 96], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[138, 143]], "entity_2_idx_in_text_with_entity_marker": [151, 156], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p5", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the [E1]p27[/E1] [E2]cyclin-dependent kinase inhibitor[/E2] (CKI).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[237, 240]], "entity_1_idx_in_text_with_entity_marker": [241, 244], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase inhibitor", "entity_2_idx": [[241, 274]], "entity_2_idx_in_text_with_entity_marker": [254, 287], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p11", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the [E1]p27[/E1] cyclin-dependent kinase inhibitor ([E2]CKI[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p27", "entity_1_idx": [[237, 240]], "entity_1_idx_in_text_with_entity_marker": [241, 244], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CKI", "entity_2_idx": [[276, 279]], "entity_2_idx_in_text_with_entity_marker": [289, 292], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p13", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of [E1]Ras[/E1] with [E2]Myc[/E2] allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[102, 105]], "entity_1_idx_in_text_with_entity_marker": [106, 109], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Myc", "entity_2_idx": [[111, 114]], "entity_2_idx_in_text_with_entity_marker": [124, 127], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p17", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with [E1]Myc[/E1] allows the generation of [E2]cyclin E-dependent kinase[/E2] activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Myc", "entity_1_idx": [[111, 114]], "entity_1_idx_in_text_with_entity_marker": [115, 118], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E-dependent kinase", "entity_2_idx": [[140, 165]], "entity_2_idx_in_text_with_entity_marker": [153, 178], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p21", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of [E1]Ras[/E1] with Myc allows the generation of [E2]cyclin E-dependent kinase[/E2] activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[102, 105]], "entity_1_idx_in_text_with_entity_marker": [106, 109], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E-dependent kinase", "entity_2_idx": [[140, 165]], "entity_2_idx_in_text_with_entity_marker": [153, 178], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p22", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of [E1]Ras[/E1] alone will not induce G1 [E2]CDK[/E2] activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CDK", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d266.s0_BioInfer.d266.s0.p27", "text": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of cyclin E-dependent kinase activity and the induction of S phase, coincident with the loss of the p27 cyclin-dependent kinase inhibitor (CKI).", "text_with_entity_marker": "However, although expression of Ras alone will not induce G1 CDK activity or S phase, coexpression of Ras with Myc allows the generation of [E1]cyclin E-dependent kinase[/E1] activity and the induction of S phase, coincident with the loss of the [E2]p27[/E2] cyclin-dependent kinase inhibitor (CKI).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin E-dependent kinase", "entity_1_idx": [[140, 165]], "entity_1_idx_in_text_with_entity_marker": [144, 169], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[237, 240]], "entity_2_idx_in_text_with_entity_marker": [250, 253], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d375.s0_BioInfer.d375.s0.p0", "text": "In this model, profilin can bind both to actin monomers with a Kd of about 5 microM and to the barbed end of actin filaments with a Kd of about 50-100 microM.", "text_with_entity_marker": "In this model, [E1]profilin[/E1] can bind both to [E2]actin[/E2] monomers with a Kd of about 5 microM and to the barbed end of actin filaments with a Kd of about 50-100 microM.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[41, 46]], "entity_2_idx_in_text_with_entity_marker": [54, 59], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d375.s0_BioInfer.d375.s0.p1", "text": "In this model, profilin can bind both to actin monomers with a Kd of about 5 microM and to the barbed end of actin filaments with a Kd of about 50-100 microM.", "text_with_entity_marker": "In this model, [E1]profilin[/E1] can bind both to actin monomers with a Kd of about 5 microM and to the barbed end of [E2]actin[/E2] filaments with a Kd of about 50-100 microM.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[109, 114]], "entity_2_idx_in_text_with_entity_marker": [122, 127], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d375.s1_BioInfer.d375.s1.p0", "text": "Quantitative analysis of the effect of Acanthamoeba profilin on actin filament nucleation and elongation.", "text_with_entity_marker": "Quantitative analysis of the effect of Acanthamoeba [E1]profilin[/E1] on [E2]actin[/E2] filament nucleation and elongation.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[52, 60]], "entity_1_idx_in_text_with_entity_marker": [56, 64], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d375.s2_BioInfer.d375.s2.p0", "text": "The current view of the mechanism of action of Acanthamoeba profilin is that it binds to actin monomers, forming a complex that cannot polymerize [Tobacman, L. S., & Korn, E. D. (1982) J. Biol. Chem. 257, 4166-4170; Tseng, P., & Pollard, T. D. (1982) J. Cell Biol. 94, 213-218; Tobacman, L. S., Brenner, S. L., & Korn, E. D. (1983) J. Biol. Chem. 258, 8806-8812].", "text_with_entity_marker": "The current view of the mechanism of action of Acanthamoeba [E1]profilin[/E1] is that it binds to [E2]actin[/E2] monomers, forming a complex that cannot polymerize [Tobacman, L. S., & Korn, E. D. (1982) J. Biol. Chem. 257, 4166-4170; Tseng, P., & Pollard, T. D. (1982) J. Cell Biol. 94, 213-218; Tobacman, L. S., Brenner, S. L., & Korn, E. D. (1983) J. Biol. Chem. 258, 8806-8812].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[60, 68]], "entity_1_idx_in_text_with_entity_marker": [64, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[89, 94]], "entity_2_idx_in_text_with_entity_marker": [102, 107], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d375.s3_BioInfer.d375.s3.p1", "text": "This model includes two different Kd's--one for profilin bound to actin monomers and one for profilin bound to an actin molecule at the barbed end of a filament.", "text_with_entity_marker": "This model includes two different Kd's--one for [E1]profilin[/E1] bound to [E2]actin[/E2] monomers and one for profilin bound to an actin molecule at the barbed end of a filament.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d375.s3_BioInfer.d375.s3.p4", "text": "This model includes two different Kd's--one for profilin bound to actin monomers and one for profilin bound to an actin molecule at the barbed end of a filament.", "text_with_entity_marker": "This model includes two different Kd's--one for profilin bound to actin monomers and one for [E1]profilin[/E1] bound to an [E2]actin[/E2] molecule at the barbed end of a filament.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p0", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: [E1]BUD1[/E1]/RSR1, BUD2, [E2]BUD3[/E2], BUD4 and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD1", "entity_1_idx": [[136, 140]], "entity_1_idx_in_text_with_entity_marker": [140, 144], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD3", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p1", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: [E1]BUD1[/E1]/RSR1, [E2]BUD2[/E2], BUD3, BUD4 and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD1", "entity_1_idx": [[136, 140]], "entity_1_idx_in_text_with_entity_marker": [140, 144], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD2", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p2", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: [E1]BUD1[/E1]/RSR1, BUD2, BUD3, BUD4 and [E2]BUD5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD1", "entity_1_idx": [[136, 140]], "entity_1_idx_in_text_with_entity_marker": [140, 144], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD5", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p3", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: [E1]BUD1[/E1]/RSR1, BUD2, BUD3, [E2]BUD4[/E2] and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD1", "entity_1_idx": [[136, 140]], "entity_1_idx_in_text_with_entity_marker": [140, 144], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD4", "entity_2_idx": [[159, 163]], "entity_2_idx_in_text_with_entity_marker": [172, 176], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p4", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: [E1]BUD1[/E1]/[E2]RSR1[/E2], BUD2, BUD3, BUD4 and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD1", "entity_1_idx": [[136, 140]], "entity_1_idx_in_text_with_entity_marker": [140, 144], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "RSR1", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p5", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, [E1]BUD2[/E1], [E2]BUD3[/E2], BUD4 and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD2", "entity_1_idx": [[147, 151]], "entity_1_idx_in_text_with_entity_marker": [151, 155], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "BUD3", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p6", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, [E1]BUD3[/E1], BUD4 and [E2]BUD5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD3", "entity_1_idx": [[153, 157]], "entity_1_idx_in_text_with_entity_marker": [157, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "BUD5", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p7", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, [E1]BUD3[/E1], [E2]BUD4[/E2] and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD3", "entity_1_idx": [[153, 157]], "entity_1_idx_in_text_with_entity_marker": [157, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "BUD4", "entity_2_idx": [[159, 163]], "entity_2_idx_in_text_with_entity_marker": [172, 176], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p8", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/[E1]RSR1[/E1], BUD2, [E2]BUD3[/E2], BUD4 and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RSR1", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD3", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p9", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, [E1]BUD2[/E1], BUD3, BUD4 and [E2]BUD5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD2", "entity_1_idx": [[147, 151]], "entity_1_idx_in_text_with_entity_marker": [151, 155], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "BUD5", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p10", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, [E1]BUD2[/E1], BUD3, [E2]BUD4[/E2] and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD2", "entity_1_idx": [[147, 151]], "entity_1_idx_in_text_with_entity_marker": [151, 155], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "BUD4", "entity_2_idx": [[159, 163]], "entity_2_idx_in_text_with_entity_marker": [172, 176], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p11", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/[E1]RSR1[/E1], [E2]BUD2[/E2], BUD3, BUD4 and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RSR1", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD2", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p12", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, [E1]BUD4[/E1] and [E2]BUD5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "BUD4", "entity_1_idx": [[159, 163]], "entity_1_idx_in_text_with_entity_marker": [163, 167], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "BUD5", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p13", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/[E1]RSR1[/E1], BUD2, BUD3, BUD4 and [E2]BUD5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RSR1", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD5", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d116.s0_BioInfer.d116.s0.p14", "text": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD5.", "text_with_entity_marker": "Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/[E1]RSR1[/E1], BUD2, BUD3, [E2]BUD4[/E2] and BUD5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RSR1", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "BUD4", "entity_2_idx": [[159, 163]], "entity_2_idx_in_text_with_entity_marker": [172, 176], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d21.s0_BioInfer.d21.s0.p0", "text": "Actophorin and profilin have opposite effects on the rate of exchange of nucleotide bound to actin monomers.", "text_with_entity_marker": "Actophorin and [E1]profilin[/E1] have opposite effects on the rate of exchange of nucleotide bound to [E2]actin[/E2] monomers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilin", "entity_1_idx": [[15, 23]], "entity_1_idx_in_text_with_entity_marker": [19, 27], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d21.s0_BioInfer.d21.s0.p1", "text": "Actophorin and profilin have opposite effects on the rate of exchange of nucleotide bound to actin monomers.", "text_with_entity_marker": "[E1]Actophorin[/E1] and profilin have opposite effects on the rate of exchange of nucleotide bound to [E2]actin[/E2] monomers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Actophorin", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d21.s0_BioInfer.d21.s0.p2", "text": "Actophorin and profilin have opposite effects on the rate of exchange of nucleotide bound to actin monomers.", "text_with_entity_marker": "[E1]Actophorin[/E1] and [E2]profilin[/E2] have opposite effects on the rate of exchange of nucleotide bound to actin monomers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Actophorin", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[15, 23]], "entity_2_idx_in_text_with_entity_marker": [28, 36], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s0_BioInfer.d90.s0.p0", "text": "BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (E-cadherin, alpha-catenin, and beta-catenin) has been reported to be associated with tumor metastasis.", "text_with_entity_marker": "BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules ([E1]E-cadherin[/E1], alpha-catenin, and [E2]beta-catenin[/E2]) has been reported to be associated with tumor metastasis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[75, 85]], "entity_1_idx_in_text_with_entity_marker": [79, 89], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[106, 118]], "entity_2_idx_in_text_with_entity_marker": [119, 131], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s0_BioInfer.d90.s0.p1", "text": "BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (E-cadherin, alpha-catenin, and beta-catenin) has been reported to be associated with tumor metastasis.", "text_with_entity_marker": "BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules ([E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], and beta-catenin) has been reported to be associated with tumor metastasis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[75, 85]], "entity_1_idx_in_text_with_entity_marker": [79, 89], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[87, 100]], "entity_2_idx_in_text_with_entity_marker": [100, 113], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s0_BioInfer.d90.s0.p2", "text": "BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (E-cadherin, alpha-catenin, and beta-catenin) has been reported to be associated with tumor metastasis.", "text_with_entity_marker": "BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (E-cadherin, [E1]alpha-catenin[/E1], and [E2]beta-catenin[/E2]) has been reported to be associated with tumor metastasis.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[87, 100]], "entity_1_idx_in_text_with_entity_marker": [91, 104], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[106, 118]], "entity_2_idx_in_text_with_entity_marker": [119, 131], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s1_BioInfer.d90.s1.p0", "text": "In this study, we evaluated the prognostic significance of E-cadherin, alpha-catenin, and beta-catenin expressions in the metastatic foci of patients with colorectal carcinoma.", "text_with_entity_marker": "In this study, we evaluated the prognostic significance of [E1]E-cadherin[/E1], alpha-catenin, and [E2]beta-catenin[/E2] expressions in the metastatic foci of patients with colorectal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[59, 69]], "entity_1_idx_in_text_with_entity_marker": [63, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[90, 102]], "entity_2_idx_in_text_with_entity_marker": [103, 115], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s1_BioInfer.d90.s1.p1", "text": "In this study, we evaluated the prognostic significance of E-cadherin, alpha-catenin, and beta-catenin expressions in the metastatic foci of patients with colorectal carcinoma.", "text_with_entity_marker": "In this study, we evaluated the prognostic significance of [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], and beta-catenin expressions in the metastatic foci of patients with colorectal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[59, 69]], "entity_1_idx_in_text_with_entity_marker": [63, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[71, 84]], "entity_2_idx_in_text_with_entity_marker": [84, 97], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s1_BioInfer.d90.s1.p2", "text": "In this study, we evaluated the prognostic significance of E-cadherin, alpha-catenin, and beta-catenin expressions in the metastatic foci of patients with colorectal carcinoma.", "text_with_entity_marker": "In this study, we evaluated the prognostic significance of E-cadherin, [E1]alpha-catenin[/E1], and [E2]beta-catenin[/E2] expressions in the metastatic foci of patients with colorectal carcinoma.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[71, 84]], "entity_1_idx_in_text_with_entity_marker": [75, 88], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[90, 102]], "entity_2_idx_in_text_with_entity_marker": [103, 115], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s2_BioInfer.d90.s2.p0", "text": "RESULTS: Reduced normal expression of E-cadherin, alpha-catenin, and beta-catenin in comparison with normal epithelium was detected in 78 primary tumors, respectively.", "text_with_entity_marker": "RESULTS: Reduced normal expression of [E1]E-cadherin[/E1], alpha-catenin, and [E2]beta-catenin[/E2] in comparison with normal epithelium was detected in 78 primary tumors, respectively.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[38, 48]], "entity_1_idx_in_text_with_entity_marker": [42, 52], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[69, 81]], "entity_2_idx_in_text_with_entity_marker": [82, 94], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s2_BioInfer.d90.s2.p1", "text": "RESULTS: Reduced normal expression of E-cadherin, alpha-catenin, and beta-catenin in comparison with normal epithelium was detected in 78 primary tumors, respectively.", "text_with_entity_marker": "RESULTS: Reduced normal expression of [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], and beta-catenin in comparison with normal epithelium was detected in 78 primary tumors, respectively.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[38, 48]], "entity_1_idx_in_text_with_entity_marker": [42, 52], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[50, 63]], "entity_2_idx_in_text_with_entity_marker": [63, 76], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d90.s2_BioInfer.d90.s2.p2", "text": "RESULTS: Reduced normal expression of E-cadherin, alpha-catenin, and beta-catenin in comparison with normal epithelium was detected in 78 primary tumors, respectively.", "text_with_entity_marker": "RESULTS: Reduced normal expression of E-cadherin, [E1]alpha-catenin[/E1], and [E2]beta-catenin[/E2] in comparison with normal epithelium was detected in 78 primary tumors, respectively.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[50, 63]], "entity_1_idx_in_text_with_entity_marker": [54, 67], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[69, 81]], "entity_2_idx_in_text_with_entity_marker": [82, 94], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d834.s0_BioInfer.d834.s0.p0", "text": "Within the sieve-tube exudate, profilin was present in 15-fold molar excess to actin.", "text_with_entity_marker": "Within the sieve-tube exudate, [E1]profilin[/E1] was present in 15-fold molar excess to [E2]actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilin", "entity_1_idx": [[31, 39]], "entity_1_idx_in_text_with_entity_marker": [35, 43], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[79, 84]], "entity_2_idx_in_text_with_entity_marker": [92, 97], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s0_BioInfer.d280.s0.p0", "text": "However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "text_with_entity_marker": "However, when all of the four proteins ([E1]E-cadherin[/E1], alpha-catenin, [E2]beta-catenin[/E2], and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[67, 79]], "entity_2_idx_in_text_with_entity_marker": [80, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s0_BioInfer.d280.s0.p1", "text": "However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "text_with_entity_marker": "However, when all of the four proteins (E-cadherin, alpha-catenin, [E1]beta-catenin[/E1], and [E2]gamma-catenin[/E2]) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[67, 79]], "entity_1_idx_in_text_with_entity_marker": [71, 83], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[85, 98]], "entity_2_idx_in_text_with_entity_marker": [98, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s0_BioInfer.d280.s0.p2", "text": "However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "text_with_entity_marker": "However, when all of the four proteins (E-cadherin, [E1]alpha-catenin[/E1], [E2]beta-catenin[/E2], and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[52, 65]], "entity_1_idx_in_text_with_entity_marker": [56, 69], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[67, 79]], "entity_2_idx_in_text_with_entity_marker": [80, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s0_BioInfer.d280.s0.p3", "text": "However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "text_with_entity_marker": "However, when all of the four proteins ([E1]E-cadherin[/E1], alpha-catenin, beta-catenin, and [E2]gamma-catenin[/E2]) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[85, 98]], "entity_2_idx_in_text_with_entity_marker": [98, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s0_BioInfer.d280.s0.p4", "text": "However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "text_with_entity_marker": "However, when all of the four proteins ([E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[40, 50]], "entity_1_idx_in_text_with_entity_marker": [44, 54], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[52, 65]], "entity_2_idx_in_text_with_entity_marker": [65, 78], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s0_BioInfer.d280.s0.p5", "text": "However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "text_with_entity_marker": "However, when all of the four proteins (E-cadherin, [E1]alpha-catenin[/E1], beta-catenin, and [E2]gamma-catenin[/E2]) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presence of metastases.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[52, 65]], "entity_1_idx_in_text_with_entity_marker": [56, 69], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[85, 98]], "entity_2_idx_in_text_with_entity_marker": [98, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s1_BioInfer.d280.s1.p0", "text": "Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for alpha-catenin, in 50 (55.6 per cent) for beta-catenin, and in 50 (55.6 per cent) for gamma-catenin.", "text_with_entity_marker": "Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for alpha-catenin, in 50 (55.6 per cent) for [E1]beta-catenin[/E1], and in 50 (55.6 per cent) for [E2]gamma-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[132, 144]], "entity_1_idx_in_text_with_entity_marker": [136, 148], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[176, 189]], "entity_2_idx_in_text_with_entity_marker": [189, 202], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s1_BioInfer.d280.s1.p1", "text": "Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for alpha-catenin, in 50 (55.6 per cent) for beta-catenin, and in 50 (55.6 per cent) for gamma-catenin.", "text_with_entity_marker": "Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for [E1]alpha-catenin[/E1], in 50 (55.6 per cent) for [E2]beta-catenin[/E2], and in 50 (55.6 per cent) for gamma-catenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[91, 104]], "entity_1_idx_in_text_with_entity_marker": [95, 108], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[132, 144]], "entity_2_idx_in_text_with_entity_marker": [145, 157], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d280.s1_BioInfer.d280.s1.p2", "text": "Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for alpha-catenin, in 50 (55.6 per cent) for beta-catenin, and in 50 (55.6 per cent) for gamma-catenin.", "text_with_entity_marker": "Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for [E1]alpha-catenin[/E1], in 50 (55.6 per cent) for beta-catenin, and in 50 (55.6 per cent) for [E2]gamma-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[91, 104]], "entity_1_idx_in_text_with_entity_marker": [95, 108], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[176, 189]], "entity_2_idx_in_text_with_entity_marker": [189, 202], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p10", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/[E1]MORT-1[/E1], RIP) and TRAF domain-containing proteins (TRAF-1, [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MORT-1", "entity_1_idx": [[73, 79]], "entity_1_idx_in_text_with_entity_marker": [77, 83], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p11", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/[E1]MORT-1[/E1], RIP) and TRAF domain-containing proteins ([E2]TRAF-1[/E2], TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MORT-1", "entity_1_idx": [[73, 79]], "entity_1_idx_in_text_with_entity_marker": [77, 83], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAF-1", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p12", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/[E1]MORT-1[/E1], RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MORT-1", "entity_1_idx": [[73, 79]], "entity_1_idx_in_text_with_entity_marker": [77, 83], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p13", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain ([E1]TNF-RI[/E1], Fas, TRADD, FADD/[E2]MORT-1[/E2], RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-RI", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MORT-1", "entity_2_idx": [[73, 79]], "entity_2_idx_in_text_with_entity_marker": [86, 92], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p14", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, [E1]TRADD[/E1], FADD/[E2]MORT-1[/E2], RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MORT-1", "entity_2_idx": [[73, 79]], "entity_2_idx_in_text_with_entity_marker": [86, 92], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p15", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, [E1]Fas[/E1], TRADD, FADD/[E2]MORT-1[/E2], RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MORT-1", "entity_2_idx": [[73, 79]], "entity_2_idx_in_text_with_entity_marker": [86, 92], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p16", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/[E1]MORT-1[/E1], [E2]RIP[/E2]) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MORT-1", "entity_1_idx": [[73, 79]], "entity_1_idx_in_text_with_entity_marker": [77, 83], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[81, 84]], "entity_2_idx_in_text_with_entity_marker": [94, 97], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p17", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, [E1]FADD[/E1]/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p18", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, [E1]FADD[/E1]/MORT-1, RIP) and TRAF domain-containing proteins ([E2]TRAF-1[/E2], TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAF-1", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p19", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, [E1]FADD[/E1]/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p20", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain ([E1]TNF-RI[/E1], Fas, TRADD, [E2]FADD[/E2]/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-RI", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FADD", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p21", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, [E1]TRADD[/E1], [E2]FADD[/E2]/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FADD", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p22", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, [E1]Fas[/E1], TRADD, [E2]FADD[/E2]/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FADD", "entity_2_idx": [[68, 72]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p23", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, [E1]FADD[/E1]/MORT-1, [E2]RIP[/E2]) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[68, 72]], "entity_1_idx_in_text_with_entity_marker": [72, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RIP", "entity_2_idx": [[81, 84]], "entity_2_idx_in_text_with_entity_marker": [94, 97], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p24", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins ([E1]TRAF-1[/E1], [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRAF-1", "entity_1_idx": [[123, 129]], "entity_1_idx_in_text_with_entity_marker": [127, 133], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p25", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, [E1]TRAF-2[/E1], [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRAF-2", "entity_1_idx": [[131, 137]], "entity_1_idx_in_text_with_entity_marker": [135, 141], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p26", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain ([E1]TNF-RI[/E1], Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-RI", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p27", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, [E1]TRADD[/E1], FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p28", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, [E1]Fas[/E1], TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p29", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, [E1]RIP[/E1]) and TRAF domain-containing proteins (TRAF-1, [E2]TRAF-2[/E2], TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RIP", "entity_1_idx": [[81, 84]], "entity_1_idx_in_text_with_entity_marker": [85, 88], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-2", "entity_2_idx": [[131, 137]], "entity_2_idx_in_text_with_entity_marker": [144, 150], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d393.s0_BioInfer.d393.s0.p0", "text": "Isolation of human skeletal muscle myosin heavy chain and actin for measurement of fractional synthesis rates.", "text_with_entity_marker": "Isolation of human [E1]skeletal muscle myosin heavy chain[/E1] and [E2]actin[/E2] for measurement of fractional synthesis rates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "skeletal muscle myosin heavy chain", "entity_1_idx": [[19, 53]], "entity_1_idx_in_text_with_entity_marker": [23, 57], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[58, 63]], "entity_2_idx_in_text_with_entity_marker": [71, 76], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d393.s1_BioInfer.d393.s1.p0", "text": "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), we have developed a simple method to isolate myosin heavy chain (MHC) and actin from small (60-80 mg) human skeletal muscle samples for the determination of their fractional synthesis rates.", "text_with_entity_marker": "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), we have developed a simple method to isolate [E1]myosin heavy chain[/E1] (MHC) and [E2]actin[/E2] from small (60-80 mg) human skeletal muscle samples for the determination of their fractional synthesis rates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[121, 139]], "entity_1_idx_in_text_with_entity_marker": [125, 143], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d393.s1_BioInfer.d393.s1.p1", "text": "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), we have developed a simple method to isolate myosin heavy chain (MHC) and actin from small (60-80 mg) human skeletal muscle samples for the determination of their fractional synthesis rates.", "text_with_entity_marker": "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), we have developed a simple method to isolate myosin heavy chain ([E1]MHC[/E1]) and [E2]actin[/E2] from small (60-80 mg) human skeletal muscle samples for the determination of their fractional synthesis rates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MHC", "entity_1_idx": [[141, 144]], "entity_1_idx_in_text_with_entity_marker": [145, 148], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d393.s1_BioInfer.d393.s1.p2", "text": "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), we have developed a simple method to isolate myosin heavy chain (MHC) and actin from small (60-80 mg) human skeletal muscle samples for the determination of their fractional synthesis rates.", "text_with_entity_marker": "Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), we have developed a simple method to isolate [E1]myosin heavy chain[/E1] ([E2]MHC[/E2]) and actin from small (60-80 mg) human skeletal muscle samples for the determination of their fractional synthesis rates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[121, 139]], "entity_1_idx_in_text_with_entity_marker": [125, 143], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MHC", "entity_2_idx": [[141, 144]], "entity_2_idx_in_text_with_entity_marker": [154, 157], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p10", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous [E1]myogenin[/E1] and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the [E2]skeletal muscle actin[/E2], or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myogenin", "entity_1_idx": [[138, 146]], "entity_1_idx_in_text_with_entity_marker": [142, 150], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "skeletal muscle actin", "entity_2_idx": [[223, 244]], "entity_2_idx_in_text_with_entity_marker": [236, 257], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p11", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, [E1]MRF4[/E1], [E2]Myf5[/E2], the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MRF4", "entity_1_idx": [[207, 211]], "entity_1_idx_in_text_with_entity_marker": [211, 215], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Myf5", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p12", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous [E1]MyoD1[/E1], MRF4, [E2]Myf5[/E2], the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MyoD1", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Myf5", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p13", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and [E1]myosin light chain 2[/E1] gene but not the endogenous MyoD1, MRF4, [E2]Myf5[/E2], the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin light chain 2", "entity_1_idx": [[151, 171]], "entity_1_idx_in_text_with_entity_marker": [155, 175], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Myf5", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p14", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous [E1]myogenin[/E1] and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, [E2]Myf5[/E2], the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myogenin", "entity_1_idx": [[138, 146]], "entity_1_idx_in_text_with_entity_marker": [142, 150], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Myf5", "entity_2_idx": [[213, 217]], "entity_2_idx_in_text_with_entity_marker": [226, 230], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p15", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous [E1]MyoD1[/E1], [E2]MRF4[/E2], Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MyoD1", "entity_1_idx": [[200, 205]], "entity_1_idx_in_text_with_entity_marker": [204, 209], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MRF4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p16", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and [E1]myosin light chain 2[/E1] gene but not the endogenous MyoD1, [E2]MRF4[/E2], Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin light chain 2", "entity_1_idx": [[151, 171]], "entity_1_idx_in_text_with_entity_marker": [155, 175], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MRF4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p17", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous [E1]myogenin[/E1] and myosin light chain 2 gene but not the endogenous MyoD1, [E2]MRF4[/E2], Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myogenin", "entity_1_idx": [[138, 146]], "entity_1_idx_in_text_with_entity_marker": [142, 150], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MRF4", "entity_2_idx": [[207, 211]], "entity_2_idx_in_text_with_entity_marker": [220, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p18", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and [E1]myosin light chain 2[/E1] gene but not the endogenous [E2]MyoD1[/E2], MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin light chain 2", "entity_1_idx": [[151, 171]], "entity_1_idx_in_text_with_entity_marker": [155, 175], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD1", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d557.s0_BioInfer.d557.s0.p19", "text": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous myogenin and myosin light chain 2 gene but not the endogenous MyoD1, MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "text_with_entity_marker": "Surprisingly, although maintained in mitogen-rich medium, this ectopic expression was associated with a transactivation of the endogenous [E1]myogenin[/E1] and myosin light chain 2 gene but not the endogenous [E2]MyoD1[/E2], MRF4, Myf5, the skeletal muscle actin, or the myosin heavy chain genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myogenin", "entity_1_idx": [[138, 146]], "entity_1_idx_in_text_with_entity_marker": [142, 150], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD1", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p0", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and [E1]CD44[/E1], with additional reverse transcription-[E2]polymerase[/E2] chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CD44", "entity_1_idx": [[231, 235]], "entity_1_idx_in_text_with_entity_marker": [235, 239], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "polymerase", "entity_2_idx": [[275, 285]], "entity_2_idx_in_text_with_entity_marker": [288, 298], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p1", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, [E1]alpha-catenin[/E1], beta-catenin, and [E2]CD44[/E2], with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[198, 211]], "entity_1_idx_in_text_with_entity_marker": [202, 215], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CD44", "entity_2_idx": [[231, 235]], "entity_2_idx_in_text_with_entity_marker": [244, 248], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p2", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of [E1]cell adhesion molecules[/E1] and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and [E2]CD44[/E2], with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cell adhesion molecules", "entity_1_idx": [[60, 83]], "entity_1_idx_in_text_with_entity_marker": [64, 87], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CD44", "entity_2_idx": [[231, 235]], "entity_2_idx_in_text_with_entity_marker": [244, 248], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p3", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for [E1]E-cadherin[/E1], alpha-catenin, beta-catenin, and [E2]CD44[/E2], with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[186, 196]], "entity_1_idx_in_text_with_entity_marker": [190, 200], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CD44", "entity_2_idx": [[231, 235]], "entity_2_idx_in_text_with_entity_marker": [244, 248], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p4", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, [E1]beta-catenin[/E1], and [E2]CD44[/E2], with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[213, 225]], "entity_1_idx_in_text_with_entity_marker": [217, 229], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CD44", "entity_2_idx": [[231, 235]], "entity_2_idx_in_text_with_entity_marker": [244, 248], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p5", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, [E1]alpha-catenin[/E1], beta-catenin, and CD44, with additional reverse transcription-[E2]polymerase[/E2] chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[198, 211]], "entity_1_idx_in_text_with_entity_marker": [202, 215], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "polymerase", "entity_2_idx": [[275, 285]], "entity_2_idx_in_text_with_entity_marker": [288, 298], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p6", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of [E1]cell adhesion molecules[/E1] and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-[E2]polymerase[/E2] chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cell adhesion molecules", "entity_1_idx": [[60, 83]], "entity_1_idx_in_text_with_entity_marker": [64, 87], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "polymerase", "entity_2_idx": [[275, 285]], "entity_2_idx_in_text_with_entity_marker": [288, 298], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p7", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for [E1]E-cadherin[/E1], alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-[E2]polymerase[/E2] chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[186, 196]], "entity_1_idx_in_text_with_entity_marker": [190, 200], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "polymerase", "entity_2_idx": [[275, 285]], "entity_2_idx_in_text_with_entity_marker": [288, 298], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p8", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, [E1]beta-catenin[/E1], and CD44, with additional reverse transcription-[E2]polymerase[/E2] chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[213, 225]], "entity_1_idx_in_text_with_entity_marker": [217, 229], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "polymerase", "entity_2_idx": [[275, 285]], "entity_2_idx_in_text_with_entity_marker": [288, 298], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p9", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of [E1]cell adhesion molecules[/E1] and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, [E2]alpha-catenin[/E2], beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cell adhesion molecules", "entity_1_idx": [[60, 83]], "entity_1_idx_in_text_with_entity_marker": [64, 87], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[198, 211]], "entity_2_idx_in_text_with_entity_marker": [211, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p10", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[186, 196]], "entity_1_idx_in_text_with_entity_marker": [190, 200], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[198, 211]], "entity_2_idx_in_text_with_entity_marker": [211, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p11", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, [E1]alpha-catenin[/E1], [E2]beta-catenin[/E2], and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[198, 211]], "entity_1_idx_in_text_with_entity_marker": [202, 215], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[213, 225]], "entity_2_idx_in_text_with_entity_marker": [226, 238], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p12", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of [E1]cell adhesion molecules[/E1] and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for [E2]E-cadherin[/E2], alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cell adhesion molecules", "entity_1_idx": [[60, 83]], "entity_1_idx_in_text_with_entity_marker": [64, 87], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "E-cadherin", "entity_2_idx": [[186, 196]], "entity_2_idx_in_text_with_entity_marker": [199, 209], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p13", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of [E1]cell adhesion molecules[/E1] and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, [E2]beta-catenin[/E2], and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cell adhesion molecules", "entity_1_idx": [[60, 83]], "entity_1_idx_in_text_with_entity_marker": [64, 87], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[213, 225]], "entity_2_idx_in_text_with_entity_marker": [226, 238], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d763.s0_BioInfer.d763.s0.p14", "text": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for E-cadherin, alpha-catenin, beta-catenin, and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "text_with_entity_marker": "To clarify the relation between alteration of expression of cell adhesion molecules and progression of extrahepatic bile duct carcinomas 55 cases were immunohistochemically examined for [E1]E-cadherin[/E1], alpha-catenin, [E2]beta-catenin[/E2], and CD44, with additional reverse transcription-polymerase chain reaction and Southern blotting hybridization (RT-PCR/SBH) assays.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[186, 196]], "entity_1_idx_in_text_with_entity_marker": [190, 200], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[213, 225]], "entity_2_idx_in_text_with_entity_marker": [226, 238], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p0", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, [E1]alpha-actinin[/E1] and [E2]vinculin[/E2] that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-actinin", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[161, 169]], "entity_2_idx_in_text_with_entity_marker": [174, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p1", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, [E1]plakoglobin[/E1], p120, [E2]alpha-actinin[/E2] and vinculin that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "plakoglobin", "entity_1_idx": [[124, 135]], "entity_1_idx_in_text_with_entity_marker": [128, 139], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-actinin", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p2", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, [E1]p120[/E1], [E2]alpha-actinin[/E2] and vinculin that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p120", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-actinin", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p3", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, [E1]alpha-catenin[/E1], beta-catenin, plakoglobin, p120, [E2]alpha-actinin[/E2] and vinculin that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[95, 108]], "entity_1_idx_in_text_with_entity_marker": [99, 112], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-actinin", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p4", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, [E1]beta-catenin[/E1], plakoglobin, p120, [E2]alpha-actinin[/E2] and vinculin that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[110, 122]], "entity_1_idx_in_text_with_entity_marker": [114, 126], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-actinin", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p5", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of [E1]N-cadherin[/E1], alpha-catenin, beta-catenin, plakoglobin, p120, [E2]alpha-actinin[/E2] and vinculin that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N-cadherin", "entity_1_idx": [[83, 93]], "entity_1_idx_in_text_with_entity_marker": [87, 97], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-actinin", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p6", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, [E1]plakoglobin[/E1], p120, alpha-actinin and [E2]vinculin[/E2] that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "plakoglobin", "entity_1_idx": [[124, 135]], "entity_1_idx_in_text_with_entity_marker": [128, 139], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[161, 169]], "entity_2_idx_in_text_with_entity_marker": [174, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p7", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, [E1]p120[/E1], alpha-actinin and [E2]vinculin[/E2] that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p120", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[161, 169]], "entity_2_idx_in_text_with_entity_marker": [174, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p8", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, [E1]alpha-catenin[/E1], beta-catenin, plakoglobin, p120, alpha-actinin and [E2]vinculin[/E2] that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[95, 108]], "entity_1_idx_in_text_with_entity_marker": [99, 112], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[161, 169]], "entity_2_idx_in_text_with_entity_marker": [174, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d227.s0_BioInfer.d227.s0.p9", "text": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.", "text_with_entity_marker": "Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, [E1]beta-catenin[/E1], plakoglobin, p120, alpha-actinin and [E2]vinculin[/E2] that were equivalent to epithelioid cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[110, 122]], "entity_1_idx_in_text_with_entity_marker": [114, 126], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[161, 169]], "entity_2_idx_in_text_with_entity_marker": [174, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d528.s0_BioInfer.d528.s0.p0", "text": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "text_with_entity_marker": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as [E1]actin[/E1] (43 kDa Mr), myosin heavy chain (195 kDa Mr), [E2]spectrin[/E2] (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[125, 130]], "entity_1_idx_in_text_with_entity_marker": [129, 134], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "spectrin", "entity_2_idx": [[177, 185]], "entity_2_idx_in_text_with_entity_marker": [190, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d528.s0_BioInfer.d528.s0.p1", "text": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "text_with_entity_marker": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), [E1]spectrin[/E1] (235 and 240 kDa Mr), and [E2]tubulin[/E2] (51-54 kDa Mr).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "spectrin", "entity_1_idx": [[177, 185]], "entity_1_idx_in_text_with_entity_marker": [181, 189], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "tubulin", "entity_2_idx": [[212, 219]], "entity_2_idx_in_text_with_entity_marker": [225, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d528.s0_BioInfer.d528.s0.p2", "text": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "text_with_entity_marker": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), [E1]myosin heavy chain[/E1] (195 kDa Mr), [E2]spectrin[/E2] (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[144, 162]], "entity_1_idx_in_text_with_entity_marker": [148, 166], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "spectrin", "entity_2_idx": [[177, 185]], "entity_2_idx_in_text_with_entity_marker": [190, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d528.s0_BioInfer.d528.s0.p3", "text": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "text_with_entity_marker": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as [E1]actin[/E1] (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and [E2]tubulin[/E2] (51-54 kDa Mr).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[125, 130]], "entity_1_idx_in_text_with_entity_marker": [129, 134], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "tubulin", "entity_2_idx": [[212, 219]], "entity_2_idx_in_text_with_entity_marker": [225, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d528.s0_BioInfer.d528.s0.p4", "text": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "text_with_entity_marker": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as [E1]actin[/E1] (43 kDa Mr), [E2]myosin heavy chain[/E2] (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[125, 130]], "entity_1_idx_in_text_with_entity_marker": [129, 134], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy chain", "entity_2_idx": [[144, 162]], "entity_2_idx_in_text_with_entity_marker": [157, 175], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d528.s0_BioInfer.d528.s0.p5", "text": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), myosin heavy chain (195 kDa Mr), spectrin (235 and 240 kDa Mr), and tubulin (51-54 kDa Mr).", "text_with_entity_marker": "SDS-PAGE analysis of growth cone cytoskeletons revealed the presence of several major bands, identified by their mobility as actin (43 kDa Mr), [E1]myosin heavy chain[/E1] (195 kDa Mr), spectrin (235 and 240 kDa Mr), and [E2]tubulin[/E2] (51-54 kDa Mr).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[144, 162]], "entity_1_idx_in_text_with_entity_marker": [148, 166], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "tubulin", "entity_2_idx": [[212, 219]], "entity_2_idx_in_text_with_entity_marker": [225, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p40", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), [E1]haemagglutinin neuraminidase[/E1] (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and [E2]non-structural[/E2] (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin neuraminidase", "entity_1_idx": [[183, 211], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [187, 215], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "non-structural", "entity_2_idx": [[324, 338], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [337, 351], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p41", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), [E1]phosphoprotein[/E1] (P; 49 kDa), matrix (M; 43 kDa) and [E2]non-structural[/E2] (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[273, 287], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [277, 291], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "non-structural", "entity_2_idx": [[324, 338], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [337, 351], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p42", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein ([E1]P[/E1]; 49 kDa), matrix (M; 43 kDa) and [E2]non-structural[/E2] (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[289, 290]], "entity_1_idx_in_text_with_entity_marker": [293, 294], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "non-structural", "entity_2_idx": [[324, 338], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [337, 351], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p43", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and [E1]non-structural[/E1] ([E2]V[/E2]; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "non-structural", "entity_1_idx": [[324, 338], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [328, 342], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "V", "entity_2_idx": [[340, 341]], "entity_2_idx_in_text_with_entity_marker": [353, 354], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p44", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid ([E1]N[/E1]; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and [E2]non-structural[/E2] (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[240, 241]], "entity_1_idx_in_text_with_entity_marker": [244, 245], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "non-structural", "entity_2_idx": [[324, 338], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [337, 351], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p45", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix ([E1]M[/E1]; 43 kDa) and [E2]non-structural[/E2] (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[309, 310]], "entity_1_idx_in_text_with_entity_marker": [313, 314], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "non-structural", "entity_2_idx": [[324, 338], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [337, 351], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p46", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase ([E1]HN[/E1]; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), [E2]matrix[/E2] (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HN", "entity_1_idx": [[213, 215]], "entity_1_idx_in_text_with_entity_marker": [217, 219], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[301, 307], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [314, 320], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p47", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the [E1]large[/E1] (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), [E2]matrix[/E2] (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "large", "entity_1_idx": [[163, 168], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[301, 307], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [314, 320], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p48", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), [E1]nucleocapsid[/E1] (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), [E2]matrix[/E2] (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[226, 238], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [230, 242], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[301, 307], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [314, 320], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p49", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), [E1]haemagglutinin neuraminidase[/E1] (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), [E2]matrix[/E2] (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin neuraminidase", "entity_1_idx": [[183, 211], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [187, 215], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[301, 307], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [314, 320], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d500.s0_BioInfer.d500.s0.p0", "text": "Proteolytic activity was not detected with casein, actin, or myosin heavy-chain substrates.", "text_with_entity_marker": "Proteolytic activity was not detected with casein, [E1]actin[/E1], or [E2]myosin heavy-chain[/E2] substrates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy-chain", "entity_2_idx": [[61, 79]], "entity_2_idx_in_text_with_entity_marker": [74, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d500.s0_BioInfer.d500.s0.p1", "text": "Proteolytic activity was not detected with casein, actin, or myosin heavy-chain substrates.", "text_with_entity_marker": "Proteolytic activity was not detected with [E1]casein[/E1], [E2]actin[/E2], or myosin heavy-chain substrates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "casein", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d500.s0_BioInfer.d500.s0.p2", "text": "Proteolytic activity was not detected with casein, actin, or myosin heavy-chain substrates.", "text_with_entity_marker": "Proteolytic activity was not detected with [E1]casein[/E1], actin, or [E2]myosin heavy-chain[/E2] substrates.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "casein", "entity_1_idx": [[43, 49]], "entity_1_idx_in_text_with_entity_marker": [47, 53], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy-chain", "entity_2_idx": [[61, 79]], "entity_2_idx_in_text_with_entity_marker": [74, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s2_BioInfer.d33.s2.p4", "text": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "text_with_entity_marker": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of [E1]alpha-catenin[/E1], [E2]beta-catenin[/E2], gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[115, 128]], "entity_1_idx_in_text_with_entity_marker": [119, 132], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[130, 142]], "entity_2_idx_in_text_with_entity_marker": [143, 155], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s2_BioInfer.d33.s2.p5", "text": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "text_with_entity_marker": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, [E1]beta-catenin[/E1], gamma-catenin and [E2]E-cadherin[/E2] in 68 TCC and 14 normal bladder biopsies.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[130, 142]], "entity_1_idx_in_text_with_entity_marker": [134, 146], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "E-cadherin", "entity_2_idx": [[162, 172]], "entity_2_idx_in_text_with_entity_marker": [175, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s2_BioInfer.d33.s2.p6", "text": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "text_with_entity_marker": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, [E1]beta-catenin[/E1], [E2]gamma-catenin[/E2] and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[130, 142]], "entity_1_idx_in_text_with_entity_marker": [134, 146], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[144, 157]], "entity_2_idx_in_text_with_entity_marker": [157, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s2_BioInfer.d33.s2.p7", "text": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "text_with_entity_marker": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of [E1]alpha-catenin[/E1], beta-catenin, gamma-catenin and [E2]E-cadherin[/E2] in 68 TCC and 14 normal bladder biopsies.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[115, 128]], "entity_1_idx_in_text_with_entity_marker": [119, 132], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "E-cadherin", "entity_2_idx": [[162, 172]], "entity_2_idx_in_text_with_entity_marker": [175, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s2_BioInfer.d33.s2.p8", "text": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "text_with_entity_marker": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of [E1]alpha-catenin[/E1], beta-catenin, [E2]gamma-catenin[/E2] and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[115, 128]], "entity_1_idx_in_text_with_entity_marker": [119, 132], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[144, 157]], "entity_2_idx_in_text_with_entity_marker": [157, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s2_BioInfer.d33.s2.p9", "text": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.", "text_with_entity_marker": "MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, [E1]gamma-catenin[/E1] and [E2]E-cadherin[/E2] in 68 TCC and 14 normal bladder biopsies.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "gamma-catenin", "entity_1_idx": [[144, 157]], "entity_1_idx_in_text_with_entity_marker": [148, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "E-cadherin", "entity_2_idx": [[162, 172]], "entity_2_idx_in_text_with_entity_marker": [175, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s3_BioInfer.d33.s3.p0", "text": "RESULTS: E-cadherin, alpha-catenin, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "text_with_entity_marker": "RESULTS: E-cadherin, [E1]alpha-catenin[/E1], beta-catenin and [E2]gamma-catenin[/E2] were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[21, 34]], "entity_1_idx_in_text_with_entity_marker": [25, 38], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[53, 66]], "entity_2_idx_in_text_with_entity_marker": [66, 79], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s3_BioInfer.d33.s3.p1", "text": "RESULTS: E-cadherin, alpha-catenin, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "text_with_entity_marker": "RESULTS: [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[21, 34]], "entity_2_idx_in_text_with_entity_marker": [34, 47], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s3_BioInfer.d33.s3.p2", "text": "RESULTS: E-cadherin, alpha-catenin, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "text_with_entity_marker": "RESULTS: E-cadherin, [E1]alpha-catenin[/E1], [E2]beta-catenin[/E2] and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[21, 34]], "entity_1_idx_in_text_with_entity_marker": [25, 38], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[36, 48]], "entity_2_idx_in_text_with_entity_marker": [49, 61], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s3_BioInfer.d33.s3.p3", "text": "RESULTS: E-cadherin, alpha-catenin, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "text_with_entity_marker": "RESULTS: [E1]E-cadherin[/E1], alpha-catenin, beta-catenin and [E2]gamma-catenin[/E2] were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[53, 66]], "entity_2_idx_in_text_with_entity_marker": [66, 79], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p40", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), [E1]phosphoprotein[/E1] (P) and [E2]matrix[/E2] (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[96, 110], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [100, 114], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[119, 125], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p41", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and [E1]matrix[/E1] (M) proteins of MV and the H, [E2]F[/E2], NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix", "entity_1_idx": [[119, 125], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [123, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F", "entity_2_idx": [[156, 157], [168, 176]], "entity_2_idx_in_text_with_entity_marker": [169, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p42", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin ([E1]H[/E1]), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and [E2]matrix[/E2] (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "H", "entity_1_idx": [[53, 54]], "entity_1_idx_in_text_with_entity_marker": [57, 58], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[119, 125], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p43", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein ([E1]P[/E1]) and [E2]matrix[/E2] (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[112, 113]], "entity_1_idx_in_text_with_entity_marker": [116, 117], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[119, 125], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p44", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P) and [E2]matrix[/E2] (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[91, 93]], "entity_1_idx_in_text_with_entity_marker": [95, 97], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[119, 125], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [132, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p45", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and [E1]matrix[/E1] ([E2]M[/E2]) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix", "entity_1_idx": [[119, 125], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [123, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[127, 128]], "entity_2_idx_in_text_with_entity_marker": [140, 141], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p46", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the [E1]haemagglutinin[/E1] (H), fusion (F), [E2]nucleocapsid protein[/E2] (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin", "entity_1_idx": [[37, 51], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [41, 55], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "nucleocapsid protein", "entity_2_idx": [[69, 89], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [82, 102], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p47", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the [E1]haemagglutinin[/E1] (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the [E2]H[/E2], F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin", "entity_1_idx": [[37, 51], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [41, 55], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "H", "entity_2_idx": [[153, 154], [168, 176]], "entity_2_idx_in_text_with_entity_marker": [166, 167], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p48", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the [E1]haemagglutinin[/E1] (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin", "entity_1_idx": [[37, 51], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [41, 55], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p49", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the [E1]haemagglutinin[/E1] (H), fusion (F), nucleocapsid protein (NP), [E2]phosphoprotein[/E2] (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin", "entity_1_idx": [[37, 51], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [41, 55], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[96, 110], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [109, 123], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p15", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, [E1]ribonuclease[/E1] protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, [E2]FADD[/E2], TRADD, RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ribonuclease", "entity_1_idx": [[57, 69]], "entity_1_idx_in_text_with_entity_marker": [61, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FADD", "entity_2_idx": [[167, 171]], "entity_2_idx_in_text_with_entity_marker": [180, 184], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p16", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, [E1]ribonuclease[/E1] protection assay was used with specific antisense RNA probes for Fas, [E2]Fas ligand[/E2], TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ribonuclease", "entity_1_idx": [[57, 69]], "entity_1_idx_in_text_with_entity_marker": [61, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Fas ligand", "entity_2_idx": [[140, 150]], "entity_2_idx_in_text_with_entity_marker": [153, 163], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p17", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, [E1]ribonuclease[/E1] protection assay was used with specific antisense RNA probes for Fas, Fas ligand, [E2]TNFR-1[/E2], TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ribonuclease", "entity_1_idx": [[57, 69]], "entity_1_idx_in_text_with_entity_marker": [61, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TNFR-1", "entity_2_idx": [[152, 158]], "entity_2_idx_in_text_with_entity_marker": [165, 171], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p18", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, [E1]ribonuclease[/E1] protection assay was used with specific antisense RNA probes for [E2]Fas[/E2], Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ribonuclease", "entity_1_idx": [[57, 69]], "entity_1_idx_in_text_with_entity_marker": [61, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Fas", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p19", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, [E1]FAF[/E1], [E2]FAP[/E2], and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FAF", "entity_1_idx": [[185, 188]], "entity_1_idx_in_text_with_entity_marker": [189, 192], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAP", "entity_2_idx": [[190, 193]], "entity_2_idx_in_text_with_entity_marker": [203, 206], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p20", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, [E1]TRADD[/E1], RIP, [E2]FAF[/E2], FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[173, 178]], "entity_1_idx_in_text_with_entity_marker": [177, 182], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAF", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p21", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, [E1]RIP[/E1], [E2]FAF[/E2], FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RIP", "entity_1_idx": [[180, 183]], "entity_1_idx_in_text_with_entity_marker": [184, 187], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAF", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p22", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, [E1]FAF[/E1], FAP, and [E2]caspase-8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FAF", "entity_1_idx": [[185, 188]], "entity_1_idx_in_text_with_entity_marker": [189, 192], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[199, 208]], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p23", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, [E1]FADD[/E1], TRADD, RIP, [E2]FAF[/E2], FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[167, 171]], "entity_1_idx_in_text_with_entity_marker": [171, 175], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAF", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p24", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, [E1]Fas ligand[/E1], TNFR-1, TRAIL, FADD, TRADD, RIP, [E2]FAF[/E2], FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas ligand", "entity_1_idx": [[140, 150]], "entity_1_idx_in_text_with_entity_marker": [144, 154], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAF", "entity_2_idx": [[185, 188]], "entity_2_idx_in_text_with_entity_marker": [198, 201], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p35", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, [E1]TRADD[/E1], RIP, FAF, FAP, and [E2]caspase-8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[173, 178]], "entity_1_idx_in_text_with_entity_marker": [177, 182], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[199, 208]], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p36", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, [E1]FADD[/E1], [E2]TRADD[/E2], RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[167, 171]], "entity_1_idx_in_text_with_entity_marker": [171, 175], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRADD", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p37", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, [E1]Fas ligand[/E1], TNFR-1, TRAIL, FADD, [E2]TRADD[/E2], RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas ligand", "entity_1_idx": [[140, 150]], "entity_1_idx_in_text_with_entity_marker": [144, 154], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRADD", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p38", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, [E1]TNFR-1[/E1], TRAIL, FADD, [E2]TRADD[/E2], RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFR-1", "entity_1_idx": [[152, 158]], "entity_1_idx_in_text_with_entity_marker": [156, 162], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRADD", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p39", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for [E1]Fas[/E1], Fas ligand, TNFR-1, TRAIL, FADD, [E2]TRADD[/E2], RIP, FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRADD", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p40", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, [E1]RIP[/E1], FAF, FAP, and [E2]caspase-8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RIP", "entity_1_idx": [[180, 183]], "entity_1_idx_in_text_with_entity_marker": [184, 187], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[199, 208]], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p41", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, [E1]FADD[/E1], TRADD, [E2]RIP[/E2], FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[167, 171]], "entity_1_idx_in_text_with_entity_marker": [171, 175], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RIP", "entity_2_idx": [[180, 183]], "entity_2_idx_in_text_with_entity_marker": [193, 196], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p42", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, [E1]Fas ligand[/E1], TNFR-1, TRAIL, FADD, TRADD, [E2]RIP[/E2], FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas ligand", "entity_1_idx": [[140, 150]], "entity_1_idx_in_text_with_entity_marker": [144, 154], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RIP", "entity_2_idx": [[180, 183]], "entity_2_idx_in_text_with_entity_marker": [193, 196], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p43", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, [E1]TNFR-1[/E1], TRAIL, FADD, TRADD, [E2]RIP[/E2], FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNFR-1", "entity_1_idx": [[152, 158]], "entity_1_idx_in_text_with_entity_marker": [156, 162], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RIP", "entity_2_idx": [[180, 183]], "entity_2_idx_in_text_with_entity_marker": [193, 196], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s1_BioInfer.d148.s1.p44", "text": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for Fas, Fas ligand, TNFR-1, TRAIL, FADD, TRADD, RIP, FAF, FAP, and caspase-8.", "text_with_entity_marker": "To detect the expression of apoptosis-related molecules, ribonuclease protection assay was used with specific antisense RNA probes for [E1]Fas[/E1], Fas ligand, TNFR-1, TRAIL, FADD, TRADD, [E2]RIP[/E2], FAF, FAP, and caspase-8.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RIP", "entity_2_idx": [[180, 183]], "entity_2_idx_in_text_with_entity_marker": [193, 196], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p0", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not [E1]E-cadherin[/E1], p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[22, 32]], "entity_1_idx_in_text_with_entity_marker": [26, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[198, 210]], "entity_2_idx_in_text_with_entity_marker": [211, 223], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p1", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not E-cadherin, [E1]p120[/E1](cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p120", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[198, 210]], "entity_2_idx_in_text_with_entity_marker": [211, 223], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p2", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "[E1]beta-catenin[/E1], but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[198, 210]], "entity_2_idx_in_text_with_entity_marker": [211, 223], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p3", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not E-cadherin, p120([E1]cas[/E1]) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cas", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[198, 210]], "entity_2_idx_in_text_with_entity_marker": [211, 223], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p4", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when [E1]proteasome[/E1]-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "proteasome", "entity_1_idx": [[86, 96]], "entity_1_idx_in_text_with_entity_marker": [90, 100], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[198, 210]], "entity_2_idx_in_text_with_entity_marker": [211, 223], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p5", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not E-cadherin, p120(cas) or [E1]alpha-catenin[/E1], becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[47, 60]], "entity_1_idx_in_text_with_entity_marker": [51, 64], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[198, 210]], "entity_2_idx_in_text_with_entity_marker": [211, 223], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p6", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not [E1]E-cadherin[/E1], [E2]p120[/E2](cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[22, 32]], "entity_1_idx_in_text_with_entity_marker": [26, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "p120", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p7", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "[E1]beta-catenin[/E1], but not [E2]E-cadherin[/E2], p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "E-cadherin", "entity_2_idx": [[22, 32]], "entity_2_idx_in_text_with_entity_marker": [35, 45], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p8", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not [E1]E-cadherin[/E1], p120([E2]cas[/E2]) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[22, 32]], "entity_1_idx_in_text_with_entity_marker": [26, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "cas", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d253.s1_BioInfer.d253.s1.p9", "text": "beta-catenin, but not E-cadherin, p120(cas) or alpha-catenin, becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "text_with_entity_marker": "beta-catenin, but not [E1]E-cadherin[/E1], p120(cas) or alpha-catenin, becomes stabilized when [E2]proteasome[/E2]-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[22, 32]], "entity_1_idx_in_text_with_entity_marker": [26, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "proteasome", "entity_2_idx": [[86, 96]], "entity_2_idx_in_text_with_entity_marker": [99, 109], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d591.s0_BioInfer.d591.s0.p0", "text": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, vinculin and actin.", "text_with_entity_marker": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the [E1]fibronectin receptor[/E1], talin, [E2]vinculin[/E2] and actin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fibronectin receptor", "entity_1_idx": [[205, 225]], "entity_1_idx_in_text_with_entity_marker": [209, 229], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[234, 242]], "entity_2_idx_in_text_with_entity_marker": [247, 255], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d591.s0_BioInfer.d591.s0.p1", "text": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, vinculin and actin.", "text_with_entity_marker": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, [E1]vinculin[/E1] and [E2]actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vinculin", "entity_1_idx": [[234, 242]], "entity_1_idx_in_text_with_entity_marker": [238, 246], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d591.s0_BioInfer.d591.s0.p2", "text": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, vinculin and actin.", "text_with_entity_marker": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, [E1]talin[/E1], [E2]vinculin[/E2] and actin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "talin", "entity_1_idx": [[227, 232]], "entity_1_idx_in_text_with_entity_marker": [231, 236], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[234, 242]], "entity_2_idx_in_text_with_entity_marker": [247, 255], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d591.s0_BioInfer.d591.s0.p3", "text": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, vinculin and actin.", "text_with_entity_marker": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the [E1]fibronectin receptor[/E1], talin, vinculin and [E2]actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fibronectin receptor", "entity_1_idx": [[205, 225]], "entity_1_idx_in_text_with_entity_marker": [209, 229], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d591.s0_BioInfer.d591.s0.p4", "text": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, vinculin and actin.", "text_with_entity_marker": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the [E1]fibronectin receptor[/E1], [E2]talin[/E2], vinculin and actin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fibronectin receptor", "entity_1_idx": [[205, 225]], "entity_1_idx_in_text_with_entity_marker": [209, 229], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "talin", "entity_2_idx": [[227, 232]], "entity_2_idx_in_text_with_entity_marker": [240, 245], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d591.s0_BioInfer.d591.s0.p5", "text": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, vinculin and actin.", "text_with_entity_marker": "The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, [E1]talin[/E1], vinculin and [E2]actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "talin", "entity_1_idx": [[227, 232]], "entity_1_idx_in_text_with_entity_marker": [231, 236], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p30", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, [E1]M[/E1] and [E2]fusion protein[/E2] (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[280, 281]], "entity_1_idx_in_text_with_entity_marker": [284, 285], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fusion protein", "entity_2_idx": [[286, 300]], "entity_2_idx_in_text_with_entity_marker": [299, 313], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p31", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, [E1]M[/E1] and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[280, 281]], "entity_1_idx_in_text_with_entity_marker": [284, 285], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p32", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, [E1]M[/E1] and fusion protein (F0) gene sequences; and another, F0 and [E2]hemagglutinin-neuraminidase protein[/E2] (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[280, 281]], "entity_1_idx_in_text_with_entity_marker": [284, 285], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "hemagglutinin-neuraminidase protein", "entity_2_idx": [[342, 377]], "entity_2_idx_in_text_with_entity_marker": [355, 390], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p33", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein ([E1]NP[/E1]) and [E2]phosphoprotein[/E2] (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[176, 178]], "entity_1_idx_in_text_with_entity_marker": [180, 182], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[184, 198]], "entity_2_idx_in_text_with_entity_marker": [197, 211], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p34", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and [E1]phosphoprotein[/E1] (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, [E2]F0[/E2] and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[184, 198]], "entity_1_idx_in_text_with_entity_marker": [188, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[335, 337]], "entity_2_idx_in_text_with_entity_marker": [348, 350], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p35", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and [E1]phosphoprotein[/E1] (P) gene sequences; another, P and membrane protein ([E2]M[/E2]) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[184, 198]], "entity_1_idx_in_text_with_entity_marker": [188, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[252, 253]], "entity_2_idx_in_text_with_entity_marker": [265, 266], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p36", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and [E1]phosphoprotein[/E1] ([E2]P[/E2]) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[184, 198]], "entity_1_idx_in_text_with_entity_marker": [188, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[200, 201]], "entity_2_idx_in_text_with_entity_marker": [213, 214], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p37", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and [E1]phosphoprotein[/E1] (P) gene sequences; another, P and [E2]membrane protein[/E2] (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[184, 198]], "entity_1_idx_in_text_with_entity_marker": [188, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "membrane protein", "entity_2_idx": [[234, 250]], "entity_2_idx_in_text_with_entity_marker": [247, 263], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p38", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and [E1]phosphoprotein[/E1] (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein ([E2]F0[/E2]) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[184, 198]], "entity_1_idx_in_text_with_entity_marker": [188, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[302, 304]], "entity_2_idx_in_text_with_entity_marker": [315, 317], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p39", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and [E1]phosphoprotein[/E1] (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and [E2]fusion protein[/E2] (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[184, 198]], "entity_1_idx_in_text_with_entity_marker": [188, 202], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fusion protein", "entity_2_idx": [[286, 300]], "entity_2_idx_in_text_with_entity_marker": [299, 313], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p60", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein ([E1]M[/E1]) gene sequences; another, M and [E2]fusion protein[/E2] (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[252, 253]], "entity_1_idx_in_text_with_entity_marker": [256, 257], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fusion protein", "entity_2_idx": [[286, 300]], "entity_2_idx_in_text_with_entity_marker": [299, 313], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p61", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein ([E1]M[/E1]) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[252, 253]], "entity_1_idx_in_text_with_entity_marker": [256, 257], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p62", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein ([E1]M[/E1]) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and [E2]hemagglutinin-neuraminidase protein[/E2] (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[252, 253]], "entity_1_idx_in_text_with_entity_marker": [256, 257], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "hemagglutinin-neuraminidase protein", "entity_2_idx": [[342, 377]], "entity_2_idx_in_text_with_entity_marker": [355, 390], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p63", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein ([E1]P[/E1]) gene sequences; another, P and [E2]membrane protein[/E2] (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[200, 201]], "entity_1_idx_in_text_with_entity_marker": [204, 205], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "membrane protein", "entity_2_idx": [[234, 250]], "entity_2_idx_in_text_with_entity_marker": [247, 263], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p64", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein ([E1]P[/E1]) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein ([E2]F0[/E2]) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[200, 201]], "entity_1_idx_in_text_with_entity_marker": [204, 205], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[302, 304]], "entity_2_idx_in_text_with_entity_marker": [315, 317], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p65", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein ([E1]P[/E1]) gene sequences; another, P and membrane protein (M) gene sequences; another, M and [E2]fusion protein[/E2] (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[200, 201]], "entity_1_idx_in_text_with_entity_marker": [204, 205], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fusion protein", "entity_2_idx": [[286, 300]], "entity_2_idx_in_text_with_entity_marker": [299, 313], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p66", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein ([E1]P[/E1]) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[200, 201]], "entity_1_idx_in_text_with_entity_marker": [204, 205], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p67", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein ([E1]P[/E1]) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and [E2]hemagglutinin-neuraminidase protein[/E2] (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[200, 201]], "entity_1_idx_in_text_with_entity_marker": [204, 205], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "hemagglutinin-neuraminidase protein", "entity_2_idx": [[342, 377]], "entity_2_idx_in_text_with_entity_marker": [355, 390], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p68", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and [E1]membrane protein[/E1] (M) gene sequences; another, M and fusion protein ([E2]F0[/E2]) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "membrane protein", "entity_1_idx": [[234, 250]], "entity_1_idx_in_text_with_entity_marker": [238, 254], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[302, 304]], "entity_2_idx_in_text_with_entity_marker": [315, 317], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p69", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and [E1]membrane protein[/E1] (M) gene sequences; another, M and [E2]fusion protein[/E2] (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "membrane protein", "entity_1_idx": [[234, 250]], "entity_1_idx_in_text_with_entity_marker": [238, 254], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fusion protein", "entity_2_idx": [[286, 300]], "entity_2_idx_in_text_with_entity_marker": [299, 313], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p70", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and [E1]membrane protein[/E1] (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "membrane protein", "entity_1_idx": [[234, 250]], "entity_1_idx_in_text_with_entity_marker": [238, 254], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p71", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and [E1]membrane protein[/E1] (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and [E2]hemagglutinin-neuraminidase protein[/E2] (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "membrane protein", "entity_1_idx": [[234, 250]], "entity_1_idx_in_text_with_entity_marker": [238, 254], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "hemagglutinin-neuraminidase protein", "entity_2_idx": [[342, 377]], "entity_2_idx_in_text_with_entity_marker": [355, 390], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p72", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and [E1]fusion protein[/E1] ([E2]F0[/E2]) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion protein", "entity_1_idx": [[286, 300]], "entity_1_idx_in_text_with_entity_marker": [290, 304], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[302, 304]], "entity_2_idx_in_text_with_entity_marker": [315, 317], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p73", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein ([E1]F0[/E1]) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F0", "entity_1_idx": [[302, 304]], "entity_1_idx_in_text_with_entity_marker": [306, 308], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p74", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein ([E1]F0[/E1]) gene sequences; and another, F0 and [E2]hemagglutinin-neuraminidase protein[/E2] (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F0", "entity_1_idx": [[302, 304]], "entity_1_idx_in_text_with_entity_marker": [306, 308], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "hemagglutinin-neuraminidase protein", "entity_2_idx": [[342, 377]], "entity_2_idx_in_text_with_entity_marker": [355, 390], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p75", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and [E1]fusion protein[/E1] (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion protein", "entity_1_idx": [[286, 300]], "entity_1_idx_in_text_with_entity_marker": [290, 304], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p76", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and [E1]fusion protein[/E1] (F0) gene sequences; and another, F0 and [E2]hemagglutinin-neuraminidase protein[/E2] (HN) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion protein", "entity_1_idx": [[286, 300]], "entity_1_idx_in_text_with_entity_marker": [290, 304], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "hemagglutinin-neuraminidase protein", "entity_2_idx": [[342, 377]], "entity_2_idx_in_text_with_entity_marker": [355, 390], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d121.s0_BioInfer.d121.s0.p77", "text": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.", "text_with_entity_marker": "By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and [E1]hemagglutinin-neuraminidase protein[/E1] ([E2]HN[/E2]) gene sequences.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "hemagglutinin-neuraminidase protein", "entity_1_idx": [[342, 377]], "entity_1_idx_in_text_with_entity_marker": [346, 381], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[379, 381]], "entity_2_idx_in_text_with_entity_marker": [392, 394], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d513.s0_BioInfer.d513.s0.p0", "text": "Reduced expression of E-cadherin, alpha-catenin, and beta-catenin was observed in 64% (87 of 135), 50% (43 of 86), and 58% (50 of 86) of the specimens tested, respectively.", "text_with_entity_marker": "Reduced expression of [E1]E-cadherin[/E1], alpha-catenin, and [E2]beta-catenin[/E2] was observed in 64% (87 of 135), 50% (43 of 86), and 58% (50 of 86) of the specimens tested, respectively.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[22, 32]], "entity_1_idx_in_text_with_entity_marker": [26, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[53, 65]], "entity_2_idx_in_text_with_entity_marker": [66, 78], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d513.s0_BioInfer.d513.s0.p1", "text": "Reduced expression of E-cadherin, alpha-catenin, and beta-catenin was observed in 64% (87 of 135), 50% (43 of 86), and 58% (50 of 86) of the specimens tested, respectively.", "text_with_entity_marker": "Reduced expression of [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], and beta-catenin was observed in 64% (87 of 135), 50% (43 of 86), and 58% (50 of 86) of the specimens tested, respectively.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[22, 32]], "entity_1_idx_in_text_with_entity_marker": [26, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[34, 47]], "entity_2_idx_in_text_with_entity_marker": [47, 60], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d513.s0_BioInfer.d513.s0.p2", "text": "Reduced expression of E-cadherin, alpha-catenin, and beta-catenin was observed in 64% (87 of 135), 50% (43 of 86), and 58% (50 of 86) of the specimens tested, respectively.", "text_with_entity_marker": "Reduced expression of E-cadherin, [E1]alpha-catenin[/E1], and [E2]beta-catenin[/E2] was observed in 64% (87 of 135), 50% (43 of 86), and 58% (50 of 86) of the specimens tested, respectively.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[34, 47]], "entity_1_idx_in_text_with_entity_marker": [38, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[53, 65]], "entity_2_idx_in_text_with_entity_marker": [66, 78], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p50", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), [E1]fusion[/E1] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[78, 84], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p51", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p52", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid ([E1]N[/E1]), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[42, 43]], "entity_1_idx_in_text_with_entity_marker": [46, 47], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p53", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion ([E1]F[/E1]), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[86, 87]], "entity_1_idx_in_text_with_entity_marker": [90, 91], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p54", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of [E1]nucleocapsid[/E1] (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[28, 40], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [32, 44], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p55", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), [E1]matrix[/E1] (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix", "entity_1_idx": [[66, 72], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p56", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), [E1]phosphoprotein[/E1] (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[46, 60], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [50, 64], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p57", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and [E1]large protein[/E1] (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "large protein", "entity_1_idx": [[94, 107]], "entity_1_idx_in_text_with_entity_marker": [98, 111], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p58", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix ([E1]M[/E1]), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[74, 75]], "entity_1_idx_in_text_with_entity_marker": [78, 79], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p59", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position [E1]N[/E1]: 1301-1700, P: 1751-2190, [E2]M[/E2]: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[245, 246]], "entity_1_idx_in_text_with_entity_marker": [249, 250], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "M", "entity_2_idx": [[273, 274]], "entity_2_idx_in_text_with_entity_marker": [286, 287], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d277.s0_BioInfer.d277.s0.p0", "text": "However, there were no changes in the expression of E-cadherin, alpha-catenin, and beta-catenin.", "text_with_entity_marker": "However, there were no changes in the expression of [E1]E-cadherin[/E1], alpha-catenin, and [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[52, 62]], "entity_1_idx_in_text_with_entity_marker": [56, 66], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[83, 95]], "entity_2_idx_in_text_with_entity_marker": [96, 108], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d277.s0_BioInfer.d277.s0.p1", "text": "However, there were no changes in the expression of E-cadherin, alpha-catenin, and beta-catenin.", "text_with_entity_marker": "However, there were no changes in the expression of [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], and beta-catenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[52, 62]], "entity_1_idx_in_text_with_entity_marker": [56, 66], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[64, 77]], "entity_2_idx_in_text_with_entity_marker": [77, 90], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d277.s0_BioInfer.d277.s0.p2", "text": "However, there were no changes in the expression of E-cadherin, alpha-catenin, and beta-catenin.", "text_with_entity_marker": "However, there were no changes in the expression of E-cadherin, [E1]alpha-catenin[/E1], and [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[64, 77]], "entity_1_idx_in_text_with_entity_marker": [68, 81], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[83, 95]], "entity_2_idx_in_text_with_entity_marker": [96, 108], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d437.s0_BioInfer.d437.s0.p0", "text": "Moreover, in the presence of cofilin, rapid interconversion of monomeric and polymeric forms of actin can be induced by simply changing the pH of the medium.", "text_with_entity_marker": "Moreover, in the presence of [E1]cofilin[/E1], rapid interconversion of monomeric and polymeric forms of [E2]actin[/E2] can be induced by simply changing the pH of the medium.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cofilin", "entity_1_idx": [[29, 36]], "entity_1_idx_in_text_with_entity_marker": [33, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[96, 101]], "entity_2_idx_in_text_with_entity_marker": [109, 114], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p0", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, [E1]RAD51[/E1], RAD52, and [E2]RAD5[/E2] genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD51", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD5", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p1", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, [E1]RAD52[/E1], and [E2]RAD5[/E2] genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD52", "entity_1_idx": [[94, 99]], "entity_1_idx_in_text_with_entity_marker": [98, 103], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD5", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p2", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and [E1]rad18[/E1] mutants is dependent on the RAD1, RAD51, RAD52, and [E2]RAD5[/E2] genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad18", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD5", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p3", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the [E1]RAD1[/E1], RAD51, RAD52, and [E2]RAD5[/E2] genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD1", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD5", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p4", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in [E1]rad5[/E1] and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and [E2]RAD5[/E2] genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad5", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD5", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p5", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, [E1]RAD51[/E1], [E2]RAD52[/E2], and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD51", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[94, 99]], "entity_2_idx_in_text_with_entity_marker": [107, 112], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p6", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and [E1]rad18[/E1] mutants is dependent on the RAD1, [E2]RAD51[/E2], RAD52, and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad18", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD51", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p7", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the [E1]RAD1[/E1], [E2]RAD51[/E2], RAD52, and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD1", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD51", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p8", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in [E1]rad5[/E1] and rad18 mutants is dependent on the RAD1, [E2]RAD51[/E2], RAD52, and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad5", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD51", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p9", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and [E1]rad18[/E1] mutants is dependent on the RAD1, RAD51, [E2]RAD52[/E2], and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad18", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[94, 99]], "entity_2_idx_in_text_with_entity_marker": [107, 112], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p10", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the [E1]RAD1[/E1], RAD51, [E2]RAD52[/E2], and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD1", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[94, 99]], "entity_2_idx_in_text_with_entity_marker": [107, 112], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p11", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in [E1]rad5[/E1] and rad18 mutants is dependent on the RAD1, RAD51, [E2]RAD52[/E2], and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad5", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[94, 99]], "entity_2_idx_in_text_with_entity_marker": [107, 112], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p12", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in rad5 and [E1]rad18[/E1] mutants is dependent on the [E2]RAD1[/E2], RAD51, RAD52, and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad18", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD1", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p13", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in [E1]rad5[/E1] and [E2]rad18[/E2] mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad5", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "rad18", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d624.s0_BioInfer.d624.s0.p14", "text": "The high recombination levels seen in rad5 and rad18 mutants is dependent on the RAD1, RAD51, RAD52, and RAD5 genes.", "text_with_entity_marker": "The high recombination levels seen in [E1]rad5[/E1] and rad18 mutants is dependent on the [E2]RAD1[/E2], RAD51, RAD52, and RAD5 genes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "rad5", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD1", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d830.s0_BioInfer.d830.s0.p0", "text": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "text_with_entity_marker": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of [E1]ADF[/E1] and actin are down-regulated compared with [E2]cofilin[/E2] and 19 other proteins selected at random.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ADF", "entity_1_idx": [[118, 121]], "entity_1_idx_in_text_with_entity_marker": [122, 125], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "cofilin", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d830.s0_BioInfer.d830.s0.p1", "text": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "text_with_entity_marker": "When the [E1]actin[/E1] monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of [E2]ADF[/E2] and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "ADF", "entity_2_idx": [[118, 121]], "entity_2_idx_in_text_with_entity_marker": [131, 134], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d830.s0_BioInfer.d830.s0.p2", "text": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "text_with_entity_marker": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of [E1]ADF[/E1] and [E2]actin[/E2] are down-regulated compared with cofilin and 19 other proteins selected at random.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ADF", "entity_1_idx": [[118, 121]], "entity_1_idx_in_text_with_entity_marker": [122, 125], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d830.s0_BioInfer.d830.s0.p3", "text": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "text_with_entity_marker": "When the [E1]actin[/E1] monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with [E2]cofilin[/E2] and 19 other proteins selected at random.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "cofilin", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d830.s0_BioInfer.d830.s0.p4", "text": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "text_with_entity_marker": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and [E1]actin[/E1] are down-regulated compared with [E2]cofilin[/E2] and 19 other proteins selected at random.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[126, 131]], "entity_1_idx_in_text_with_entity_marker": [130, 135], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "cofilin", "entity_2_idx": [[165, 172]], "entity_2_idx_in_text_with_entity_marker": [178, 185], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d830.s0_BioInfer.d830.s0.p5", "text": "When the actin monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and actin are down-regulated compared with cofilin and 19 other proteins selected at random.", "text_with_entity_marker": "When the [E1]actin[/E1] monomer pool in untransfected myoblasts is increased 70% by treatment with latrunculin A, synthesis of ADF and [E2]actin[/E2] are down-regulated compared with cofilin and 19 other proteins selected at random.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[126, 131]], "entity_2_idx_in_text_with_entity_marker": [139, 144], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d197.s0_BioInfer.d197.s0.p0", "text": "Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families.", "text_with_entity_marker": "Exclusion of [E1]cardiac myosin heavy chain[/E1] and [E2]actin[/E2] gene involvement in hypertrophic cardiomyopathy of several French families.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cardiac myosin heavy chain", "entity_1_idx": [[13, 39]], "entity_1_idx_in_text_with_entity_marker": [17, 43], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[44, 49]], "entity_2_idx_in_text_with_entity_marker": [57, 62], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d17.s0_BioInfer.d17.s0.p0", "text": "Actin expression was reduced by 25-50%, relative to that of myosin heavy chain, in smooth muscle of KO mice, without any change in the relative distribution of the actin isoforms.", "text_with_entity_marker": "[E1]Actin[/E1] expression was reduced by 25-50%, relative to that of myosin heavy chain, in smooth muscle of KO mice, without any change in the relative distribution of the [E2]actin[/E2] isoforms.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Actin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[164, 169]], "entity_2_idx_in_text_with_entity_marker": [177, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d17.s0_BioInfer.d17.s0.p1", "text": "Actin expression was reduced by 25-50%, relative to that of myosin heavy chain, in smooth muscle of KO mice, without any change in the relative distribution of the actin isoforms.", "text_with_entity_marker": "[E1]Actin[/E1] expression was reduced by 25-50%, relative to that of [E2]myosin heavy chain[/E2], in smooth muscle of KO mice, without any change in the relative distribution of the actin isoforms.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Actin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy chain", "entity_2_idx": [[60, 78]], "entity_2_idx_in_text_with_entity_marker": [73, 91], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d17.s0_BioInfer.d17.s0.p2", "text": "Actin expression was reduced by 25-50%, relative to that of myosin heavy chain, in smooth muscle of KO mice, without any change in the relative distribution of the actin isoforms.", "text_with_entity_marker": "Actin expression was reduced by 25-50%, relative to that of [E1]myosin heavy chain[/E1], in smooth muscle of KO mice, without any change in the relative distribution of the [E2]actin[/E2] isoforms.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[60, 78]], "entity_1_idx_in_text_with_entity_marker": [64, 82], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[164, 169]], "entity_2_idx_in_text_with_entity_marker": [177, 182], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p40", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), [E1]small hydrophobic[/E1] (SH) protein, haemagglutinin-neuraminidase (HN) protein and [E2]large[/E2] (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "small hydrophobic", "entity_1_idx": [[142, 159], [165, 172]], "entity_1_idx_in_text_with_entity_marker": [146, 163], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "large", "entity_2_idx": [[220, 225], [230, 237]], "entity_2_idx_in_text_with_entity_marker": [233, 238], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p41", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein ([E1]M[/E1]), fusion protein (F), [E2]small hydrophobic[/E2] (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[118, 119]], "entity_1_idx_in_text_with_entity_marker": [122, 123], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "small hydrophobic", "entity_2_idx": [[142, 159], [165, 172]], "entity_2_idx_in_text_with_entity_marker": [155, 172], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p42", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), [E1]small hydrophobic[/E1] (SH) protein, haemagglutinin-neuraminidase ([E2]HN[/E2]) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "small hydrophobic", "entity_1_idx": [[142, 159], [165, 172]], "entity_1_idx_in_text_with_entity_marker": [146, 163], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[204, 206]], "entity_2_idx_in_text_with_entity_marker": [217, 219], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p43", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), [E2]small hydrophobic[/E2] (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "small hydrophobic", "entity_2_idx": [[142, 159], [165, 172]], "entity_2_idx_in_text_with_entity_marker": [155, 172], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p44", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, [E1]matrix protein[/E1] (M), fusion protein (F), [E2]small hydrophobic[/E2] (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix protein", "entity_1_idx": [[102, 116]], "entity_1_idx_in_text_with_entity_marker": [106, 120], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "small hydrophobic", "entity_2_idx": [[142, 159], [165, 172]], "entity_2_idx_in_text_with_entity_marker": [155, 172], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p45", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), [E1]small hydrophobic[/E1] (SH) protein, [E2]haemagglutinin-neuraminidase[/E2] (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "small hydrophobic", "entity_1_idx": [[142, 159], [165, 172]], "entity_1_idx_in_text_with_entity_marker": [146, 163], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "haemagglutinin-neuraminidase", "entity_2_idx": [[174, 202], [208, 215]], "entity_2_idx_in_text_with_entity_marker": [187, 215], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p46", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein ([E1]P[/E1]), V protein, matrix protein (M), fusion protein (F), [E2]small hydrophobic[/E2] (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[87, 88]], "entity_1_idx_in_text_with_entity_marker": [91, 92], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "small hydrophobic", "entity_2_idx": [[142, 159], [165, 172]], "entity_2_idx_in_text_with_entity_marker": [155, 172], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p47", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), [E1]small hydrophobic[/E1] ([E2]SH[/E2]) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "small hydrophobic", "entity_1_idx": [[142, 159], [165, 172]], "entity_1_idx_in_text_with_entity_marker": [146, 163], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "SH", "entity_2_idx": [[161, 163]], "entity_2_idx_in_text_with_entity_marker": [174, 176], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p48", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein ([E1]F[/E1]), [E2]small hydrophobic[/E2] (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[138, 139]], "entity_1_idx_in_text_with_entity_marker": [142, 143], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "small hydrophobic", "entity_2_idx": [[142, 159], [165, 172]], "entity_2_idx_in_text_with_entity_marker": [155, 172], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p49", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), [E1]small hydrophobic[/E1] (SH) protein, haemagglutinin-neuraminidase (HN) protein and large ([E2]L[/E2]) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "small hydrophobic", "entity_1_idx": [[142, 159], [165, 172]], "entity_1_idx_in_text_with_entity_marker": [146, 163], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "L", "entity_2_idx": [[227, 228]], "entity_2_idx_in_text_with_entity_marker": [240, 241], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d205.s0_BioInfer.d205.s0.p0", "text": "Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.", "text_with_entity_marker": "Expression of [E1]E-cadherin[/E1], alpha-catenin and [E2]beta-catenin[/E2] in normal ovarian surface epithelium and epithelial ovarian cancers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[44, 56]], "entity_2_idx_in_text_with_entity_marker": [57, 69], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d205.s0_BioInfer.d205.s0.p1", "text": "Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.", "text_with_entity_marker": "Expression of [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2] and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[14, 24]], "entity_1_idx_in_text_with_entity_marker": [18, 28], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[26, 39]], "entity_2_idx_in_text_with_entity_marker": [39, 52], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d205.s0_BioInfer.d205.s0.p2", "text": "Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers.", "text_with_entity_marker": "Expression of E-cadherin, [E1]alpha-catenin[/E1] and [E2]beta-catenin[/E2] in normal ovarian surface epithelium and epithelial ovarian cancers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[26, 39]], "entity_1_idx_in_text_with_entity_marker": [30, 43], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[44, 56]], "entity_2_idx_in_text_with_entity_marker": [57, 69], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d397.s1_BioInfer.d397.s1.p0", "text": "Regulation of myosin heavy chain and actin isogenes expression during cardiac growth.", "text_with_entity_marker": "Regulation of [E1]myosin heavy chain[/E1] and [E2]actin[/E2] isogenes expression during cardiac growth.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[14, 32]], "entity_1_idx_in_text_with_entity_marker": [18, 36], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d397.s2_BioInfer.d397.s2.p0", "text": "The cardiac ventricular myosin heavy chain phenotype is developmentally and hormonally regulated, but less is known concerning the actin phenotype.", "text_with_entity_marker": "The [E1]cardiac ventricular myosin heavy chain[/E1] phenotype is developmentally and hormonally regulated, but less is known concerning the [E2]actin[/E2] phenotype.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cardiac ventricular myosin heavy chain", "entity_1_idx": [[4, 42]], "entity_1_idx_in_text_with_entity_marker": [8, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p20", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], [E2]Factor-XIIIa[/E2], alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Factor-XIIIa", "entity_2_idx": [[49, 61]], "entity_2_idx_in_text_with_entity_marker": [62, 74], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p21", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for [E2]desmin[/E2], calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "desmin", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p22", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], Factor-XIIIa, alpha-smooth muscle actin and [E2]CD34[/E2], but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CD34", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p23", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, [E2]high molecular weight caldesmon[/E2], smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "high molecular weight caldesmon", "entity_2_idx": [[134, 165]], "entity_2_idx_in_text_with_entity_marker": [147, 178], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p24", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, [E2]calponin[/E2], high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "calponin", "entity_2_idx": [[124, 132]], "entity_2_idx_in_text_with_entity_marker": [137, 145], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p25", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, [E2]collagen type IV[/E2], laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "collagen type IV", "entity_2_idx": [[201, 217]], "entity_2_idx_in_text_with_entity_marker": [214, 230], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p26", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for [E1]vimentin[/E1], Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, [E2]laminin[/E2] and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vimentin", "entity_1_idx": [[39, 47]], "entity_1_idx_in_text_with_entity_marker": [43, 51], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "laminin", "entity_2_idx": [[219, 226]], "entity_2_idx_in_text_with_entity_marker": [232, 239], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p27", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for vimentin, [E1]Factor-XIIIa[/E1], [E2]alpha-smooth muscle actin[/E2] and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Factor-XIIIa", "entity_1_idx": [[49, 61]], "entity_1_idx_in_text_with_entity_marker": [53, 65], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-smooth muscle actin", "entity_2_idx": [[63, 88]], "entity_2_idx_in_text_with_entity_marker": [76, 101], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p28", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for vimentin, Factor-XIIIa, [E1]alpha-smooth muscle actin[/E1] and CD34, but negative for [E2]desmin[/E2], calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-smooth muscle actin", "entity_1_idx": [[63, 88]], "entity_1_idx_in_text_with_entity_marker": [67, 92], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "desmin", "entity_2_idx": [[116, 122]], "entity_2_idx_in_text_with_entity_marker": [129, 135], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d651.s0_BioInfer.d651.s0.p29", "text": "The neoplastic cells were positive for vimentin, Factor-XIIIa, alpha-smooth muscle actin and CD34, but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "text_with_entity_marker": "The neoplastic cells were positive for vimentin, Factor-XIIIa, [E1]alpha-smooth muscle actin[/E1] and [E2]CD34[/E2], but negative for desmin, calponin, high molecular weight caldesmon, smooth muscle myosin heavy chain, collagen type IV, laminin and S-100 protein.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-smooth muscle actin", "entity_1_idx": [[63, 88]], "entity_1_idx_in_text_with_entity_marker": [67, 92], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CD34", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d600.s0_BioInfer.d600.s0.p0", "text": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "text_with_entity_marker": "The core, isolated in the absence of free Ca2+, contains five major proteins: the [E1]actin[/E1] (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and [E2]fimbrin[/E2] (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[82, 87]], "entity_1_idx_in_text_with_entity_marker": [86, 91], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fimbrin", "entity_2_idx": [[156, 163]], "entity_2_idx_in_text_with_entity_marker": [169, 176], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d600.s0_BioInfer.d600.s0.p1", "text": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "text_with_entity_marker": "The core, isolated in the absence of free Ca2+, contains five major proteins: the [E1]actin[/E1] (Mr 43 000) that makes up the filaments, the [E2]villin[/E2] (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[82, 87]], "entity_1_idx_in_text_with_entity_marker": [86, 91], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "villin", "entity_2_idx": [[133, 139]], "entity_2_idx_in_text_with_entity_marker": [146, 152], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d600.s0_BioInfer.d600.s0.p2", "text": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "text_with_entity_marker": "The core, isolated in the absence of free Ca2+, contains five major proteins: the [E1]actin[/E1] (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-[E2]calmodulin[/E2] complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[82, 87]], "entity_1_idx_in_text_with_entity_marker": [86, 91], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "calmodulin", "entity_2_idx": [[247, 257]], "entity_2_idx_in_text_with_entity_marker": [260, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d600.s0_BioInfer.d600.s0.p3", "text": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "text_with_entity_marker": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the [E1]villin[/E1] (Mr 95 000) and [E2]fimbrin[/E2] (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "villin", "entity_1_idx": [[133, 139]], "entity_1_idx_in_text_with_entity_marker": [137, 143], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fimbrin", "entity_2_idx": [[156, 163]], "entity_2_idx_in_text_with_entity_marker": [169, 176], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d600.s0_BioInfer.d600.s0.p4", "text": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "text_with_entity_marker": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and [E1]fimbrin[/E1] (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-[E2]calmodulin[/E2] complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fimbrin", "entity_1_idx": [[156, 163]], "entity_1_idx_in_text_with_entity_marker": [160, 167], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "calmodulin", "entity_2_idx": [[247, 257]], "entity_2_idx_in_text_with_entity_marker": [260, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d600.s0_BioInfer.d600.s0.p5", "text": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the villin (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-calmodulin complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "text_with_entity_marker": "The core, isolated in the absence of free Ca2+, contains five major proteins: the actin (Mr 43 000) that makes up the filaments, the [E1]villin[/E1] (Mr 95 000) and fimbrin (Mr 68 000) that cross-link the filaments together, and the 110 000 Mr polypeptide-[E2]calmodulin[/E2] complex that makes up cross-filaments which project laterally from the core and link it to the inner surface of the microvillus membrane.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "villin", "entity_1_idx": [[133, 139]], "entity_1_idx_in_text_with_entity_marker": [137, 143], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "calmodulin", "entity_2_idx": [[247, 257]], "entity_2_idx_in_text_with_entity_marker": [260, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d288.s1_BioInfer.d288.s1.p0", "text": "In this study, we demonstrate using viscosity, sedimentation, and actin assembly rate assays that yeast cofilin (16 kD) possesses all of these properties.", "text_with_entity_marker": "In this study, we demonstrate using viscosity, sedimentation, and [E1]actin[/E1] assembly rate assays that yeast [E2]cofilin[/E2] (16 kD) possesses all of these properties.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[66, 71]], "entity_1_idx_in_text_with_entity_marker": [70, 75], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "cofilin", "entity_2_idx": [[104, 111]], "entity_2_idx_in_text_with_entity_marker": [117, 124], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d669.s0_BioInfer.d669.s0.p0", "text": "The product of UL38 has been shown to be essential for capsid assembly, but no role has previously been assigned to the product of UL18.", "text_with_entity_marker": "The product of [E1]UL38[/E1] has been shown to be essential for capsid assembly, but no role has previously been assigned to the product of [E2]UL18[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL38", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL18", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p0", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of [E1]CD53[/E1] with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag [E2]CD69[/E2], increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD53", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "pm0107494", "entity_1_type_id": 125, "entity_2": "CD69", "entity_2_idx": [[226, 230]], "entity_2_idx_in_text_with_entity_marker": [239, 243], "entity_2_type": "pm0115739", "entity_2_type_id": 126}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p1", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of [E1]CD53[/E1] with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and [E2]c-myc[/E2] protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD53", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "pm0107494", "entity_1_type_id": 125, "entity_2": "c-myc", "entity_2_idx": [[281, 286]], "entity_2_idx_in_text_with_entity_marker": [294, 299], "entity_2_type": "pm0104123", "entity_2_type_id": 127}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p1", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular [E1]IL-2[/E1] and IL-4, potentiated the DNA synthesis induced by cross-linking of [E2]CD53[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-2", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "pm0110478", "entity_1_type_id": 128, "entity_2": "CD53", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "pm0107494", "entity_2_type_id": 125}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s1_HPRD50.d33.s1.p2", "text": "However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53", "text_with_entity_marker": "However, cytokines, in particular IL-2 and [E1]IL-4[/E1], potentiated the DNA synthesis induced by cross-linking of [E2]CD53[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-4", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "pm0106845", "entity_1_type_id": 129, "entity_2": "CD53", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "pm0107494", "entity_2_type_id": 125}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p0", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "[E1]Bcl3[/E1] specifically interacted with the general transcription factors [E2]TFIIB[/E2], TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Bcl3", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "TFIIB", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "pm0112772", "entity_2_type_id": 153}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p1", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "[E1]Bcl3[/E1] specifically interacted with the general transcription factors TFIIB, TBP, and [E2]TFIIA[/E2] but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Bcl3", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "TFIIA", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "pm0112153||pm0118250", "entity_2_type_id": 154}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s0_HPRD50.d23.s0.p0", "text": "A role for Plk1 phosphorylation of NudC in cytokinesis", "text_with_entity_marker": "A role for [E1]Plk1[/E1] phosphorylation of [E2]NudC[/E2] in cytokinesis", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p0", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and [E2]NudC[/E2], show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p9", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p14", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E1]NudC[/E1] is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NudC", "entity_1_idx": [[168, 172]], "entity_1_idx_in_text_with_entity_marker": [172, 176], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s3_HPRD50.d23.s3.p0", "text": "These results suggest that Plk1 phosphorylation of NudC may influence cytokinesis", "text_with_entity_marker": "These results suggest that [E1]Plk1[/E1] phosphorylation of [E2]NudC[/E2] may influence cytokinesis", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[51, 55]], "entity_2_idx_in_text_with_entity_marker": [64, 68], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s5_HPRD50.d36.s5.p0", "text": "By contrast, CD22 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type PTP-1C", "text_with_entity_marker": "By contrast, [E1]CD22[/E1] was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type [E2]PTP-1C[/E2]", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CD22", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[105, 111]], "entity_2_idx_in_text_with_entity_marker": [118, 124], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s0_HPRD50.d34.s0.p0", "text": "The human apoB mRNA editing protein is a cytidine deaminase showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases", "text_with_entity_marker": "The human [E1]apoB[/E1] mRNA editing protein is a [E2]cytidine deaminase[/E2] showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "apoB", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "cytidine deaminase", "entity_2_idx": [[41, 59]], "entity_2_idx_in_text_with_entity_marker": [54, 72], "entity_2_type": "pm0107865", "entity_2_type_id": 131}], "directed": false, "reverse": false}
{"id": "IEPA.d63.s160_IEPA.d63.s160.p0", "text": "However, in brown fat, we observed a 2-3-fold increase in the expression of UCP1 in response to dietary fat challenge, which may be related to diet-induced elevations in plasma leptin levels", "text_with_entity_marker": "However, in brown fat, we observed a 2-3-fold increase in the expression of [E1]UCP1[/E1] in response to dietary fat challenge, which may be related to diet-induced elevations in plasma [E2]leptin[/E2] levels", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UCP1", "entity_1_idx": [[76, 80]], "entity_1_idx_in_text_with_entity_marker": [80, 84], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[177, 183]], "entity_2_idx_in_text_with_entity_marker": [190, 196], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d41.s100_IEPA.d41.s100.p0", "text": "Regulation of insulin secretion via ATP-sensitive K+ channel independent mechanisms: role of phospholipase C", "text_with_entity_marker": "Regulation of [E1]insulin[/E1] secretion via ATP-sensitive K+ channel independent mechanisms: role of [E2]phospholipase C[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[14, 21]], "entity_1_idx_in_text_with_entity_marker": [18, 25], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[93, 108]], "entity_2_idx_in_text_with_entity_marker": [106, 121], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d41.s101_IEPA.d41.s101.p0", "text": "The further addition of carbachol, an agonist that activates an isozyme of phospholipase C distinct from that activated by glucose, together with K+, 20 mM glucose, plus diazoxide resulted in a sustained amplification of insulin secretion from mouse but not rat islets", "text_with_entity_marker": "The further addition of carbachol, an agonist that activates an isozyme of [E1]phospholipase C[/E1] distinct from that activated by glucose, together with K+, 20 mM glucose, plus diazoxide resulted in a sustained amplification of [E2]insulin[/E2] secretion from mouse but not rat islets", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "phospholipase C", "entity_1_idx": [[75, 90]], "entity_1_idx_in_text_with_entity_marker": [79, 94], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[221, 228]], "entity_2_idx_in_text_with_entity_marker": [234, 241], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d41.s102_IEPA.d41.s102.p0", "text": "The inability to activate a nutrient- and calcium-regulated phospholipase C isozyme in mouse islets to the same extent as in rat islets appears to account, at least in part, for these different insulin secretory responses under these unique conditions", "text_with_entity_marker": "The inability to activate a nutrient- and calcium-regulated [E1]phospholipase C[/E1] isozyme in mouse islets to the same extent as in rat islets appears to account, at least in part, for these different [E2]insulin[/E2] secretory responses under these unique conditions", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "phospholipase C", "entity_1_idx": [[60, 75]], "entity_1_idx_in_text_with_entity_marker": [64, 79], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[194, 201]], "entity_2_idx_in_text_with_entity_marker": [207, 214], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d32.s66_IEPA.d32.s66.p0", "text": "Gamma-aminobutyric acid mediation of the inhibitory effect of nitric oxide on the arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia", "text_with_entity_marker": "Gamma-aminobutyric acid mediation of the inhibitory effect of nitric oxide on the arginine vasopressin and [E1]oxytocin[/E1] responses to [E2]insulin[/E2]-induced hypoglycemia", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[107, 115]], "entity_1_idx_in_text_with_entity_marker": [111, 119], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[129, 136]], "entity_2_idx_in_text_with_entity_marker": [142, 149], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d32.s67_IEPA.d32.s67.p0", "text": "Previous studies have demonstrated that the nitric oxide (NO) synthase inhibitor L-NAME exerts positive effects on the arginine vasopressin (AVP) and oxytocin (OT) responses to insulin-induced hypoglycemia, suggesting inhibitory actions of NO", "text_with_entity_marker": "Previous studies have demonstrated that the nitric oxide (NO) synthase inhibitor L-NAME exerts positive effects on the arginine vasopressin (AVP) and [E1]oxytocin[/E1] (OT) responses to [E2]insulin[/E2]-induced hypoglycemia, suggesting inhibitory actions of NO", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[150, 158]], "entity_1_idx_in_text_with_entity_marker": [154, 162], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[177, 184]], "entity_2_idx_in_text_with_entity_marker": [190, 197], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d32.s69_IEPA.d32.s69.p0", "text": "Insulin-induced hypoglycemia increased by 2-fold (peak vs. baseline) plasma AVP and OT levels", "text_with_entity_marker": "[E1]Insulin[/E1]-induced hypoglycemia increased by 2-fold (peak vs. baseline) plasma AVP and [E2]OT[/E2] levels", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Insulin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "OT", "entity_2_idx": [[84, 86]], "entity_2_idx_in_text_with_entity_marker": [97, 99], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d32.s70_IEPA.d32.s70.p0", "text": "These data indicate a GABAergic mediation of the inhibitory modulation by NO of the AVP and OT responses to insulin-induced hypoglycemia", "text_with_entity_marker": "These data indicate a GABAergic mediation of the inhibitory modulation by NO of the AVP and [E1]OT[/E1] responses to [E2]insulin[/E2]-induced hypoglycemia", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "OT", "entity_1_idx": [[92, 94]], "entity_1_idx_in_text_with_entity_marker": [96, 98], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[108, 115]], "entity_2_idx_in_text_with_entity_marker": [121, 128], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d38.s92_IEPA.d38.s92.p2", "text": "2) IGF-1, IGF-2, and insulin also induced a Ca2+ mobilization from the endoplasmic reticulum: phospholipase C (PLC) inhibitors, neomycin, or U-73122 partially blocked the intracellular [Ca2+]i increase induced by IGF-1 and insulin and totally inhibited the effect of IGF-2", "text_with_entity_marker": "2) IGF-1, IGF-2, and insulin also induced a Ca2+ mobilization from the endoplasmic reticulum: [E1]phospholipase C[/E1] (PLC) inhibitors, neomycin, or U-73122 partially blocked the intracellular [Ca2+]i increase induced by IGF-1 and [E2]insulin[/E2] and totally inhibited the effect of IGF-2", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "phospholipase C", "entity_1_idx": [[94, 109]], "entity_1_idx_in_text_with_entity_marker": [98, 113], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d190.s454_IEPA.d190.s454.p0", "text": "Leptin effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and neuropeptide Y [In Process Citation]", "text_with_entity_marker": "[E1]Leptin[/E1] effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and [E2]neuropeptide Y[/E2] [In Process Citation]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Leptin", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "neuropeptide Y", "entity_2_idx": [[179, 193]], "entity_2_idx_in_text_with_entity_marker": [192, 206], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d190.s455_IEPA.d190.s455.p0", "text": "Leptin may act as a negative feedback signal to the hypothalamic control of appetite through suppression of neuropeptide Y (NPY) secretion and stimulation of cocaine and amphetamine regulated transcript (CART).", "text_with_entity_marker": "[E1]Leptin[/E1] may act as a negative feedback signal to the hypothalamic control of appetite through suppression of [E2]neuropeptide Y[/E2] (NPY) secretion and stimulation of cocaine and amphetamine regulated transcript (CART).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Leptin", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "neuropeptide Y", "entity_2_idx": [[108, 122]], "entity_2_idx_in_text_with_entity_marker": [121, 135], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d70.s171_IEPA.d70.s171.p2", "text": "Inhibition of 5-HT3 serotonergic receptors with ondansetron (4 or 8 mg) did not modify the basal secretion of AVP and OT and the OT response to insulin-induced hypoglycemia", "text_with_entity_marker": "Inhibition of 5-HT3 serotonergic receptors with ondansetron (4 or 8 mg) did not modify the basal secretion of AVP and OT and the [E1]OT[/E1] response to [E2]insulin[/E2]-induced hypoglycemia", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "OT", "entity_1_idx": [[129, 131]], "entity_1_idx_in_text_with_entity_marker": [133, 135], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[144, 151]], "entity_2_idx_in_text_with_entity_marker": [157, 164], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d165.s397_IEPA.d165.s397.p0", "text": "Interactions between leptin and NPY affecting lipid mobilization in adipose tissue", "text_with_entity_marker": "Interactions between [E1]leptin[/E1] and [E2]NPY[/E2] affecting lipid mobilization in adipose tissue", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[21, 27]], "entity_1_idx_in_text_with_entity_marker": [25, 31], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[32, 35]], "entity_2_idx_in_text_with_entity_marker": [45, 48], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d165.s401_IEPA.d165.s401.p0", "text": "Summing up, new evidence suggests that NPY and leptin may interact in a homeostatic loop to regulate body-fat mass and energy balance not only at the central nervous system level, but also directly at the adipocyte level", "text_with_entity_marker": "Summing up, new evidence suggests that [E1]NPY[/E1] and [E2]leptin[/E2] may interact in a homeostatic loop to regulate body-fat mass and energy balance not only at the central nervous system level, but also directly at the adipocyte level", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NPY", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[47, 53]], "entity_2_idx_in_text_with_entity_marker": [60, 66], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d119.s287_IEPA.d119.s287.p0", "text": "The gibberellin-responsive elements conserved in cereal alpha-amylase genes are not included in the 5'-upstream region of Rep1 or RepA", "text_with_entity_marker": "The [E1]gibberellin[/E1]-responsive elements conserved in cereal [E2]alpha-amylase[/E2] genes are not included in the 5'-upstream region of Rep1 or RepA", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "gibberellin", "entity_1_idx": [[4, 15]], "entity_1_idx_in_text_with_entity_marker": [8, 19], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[56, 69]], "entity_2_idx_in_text_with_entity_marker": [69, 82], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d186.s445_IEPA.d186.s445.p0", "text": "These findings are consistent with the concept that the underexpression of the nutrient-activated PLC isozyme may account for the minimal inositol phosphate (IP) and second-phase insulin secretory response from mouse islets", "text_with_entity_marker": "These findings are consistent with the concept that the underexpression of the nutrient-activated [E1]PLC[/E1] isozyme may account for the minimal inositol phosphate (IP) and second-phase [E2]insulin[/E2] secretory response from mouse islets", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PLC", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[179, 186]], "entity_2_idx_in_text_with_entity_marker": [192, 199], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d117.s285_IEPA.d117.s285.p5", "text": "The second class of mutant, gse (GA sensitivity), differed principally in GA sensitivity, requiring approximately 100-fold higher [GA3] for both leaf elongation and alpha-amylase production by aleurone", "text_with_entity_marker": "The second class of mutant, gse (GA sensitivity), differed principally in GA sensitivity, requiring approximately 100-fold higher [[E1]GA3[/E1]] for both leaf elongation and [E2]alpha-amylase[/E2] production by aleurone", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GA3", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[165, 178]], "entity_2_idx_in_text_with_entity_marker": [178, 191], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s209_IEPA.d89.s209.p2", "text": "UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin", "text_with_entity_marker": "[E1]UCP2[/E1], UCP3 and leptin gene expression: modulation by food restriction and [E2]leptin[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UCP2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s209_IEPA.d89.s209.p4", "text": "UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin", "text_with_entity_marker": "UCP2, [E1]UCP3[/E1] and leptin gene expression: modulation by food restriction and [E2]leptin[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UCP3", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s211_IEPA.d89.s211.p0", "text": "Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT", "text_with_entity_marker": "[E1]Leptin[/E1] increased LPL mRNA by 80%, [E2]UCP1[/E2] mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Leptin", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP1", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s211_IEPA.d89.s211.p1", "text": "Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT", "text_with_entity_marker": "[E1]Leptin[/E1] increased LPL mRNA by 80%, UCP1 mRNA twofold, and [E2]UCP3[/E2] mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Leptin", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP3", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s211_IEPA.d89.s211.p2", "text": "Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT", "text_with_entity_marker": "[E1]Leptin[/E1] increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased [E2]UCP2[/E2] mRNA levels twofold in EWAT", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Leptin", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP2", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s212_IEPA.d89.s212.p0", "text": "The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT", "text_with_entity_marker": "The present study indicates that [E1]leptin[/E1] increases the gene expression of [E2]UCP2[/E2] in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP2", "entity_2_idx": [[73, 77]], "entity_2_idx_in_text_with_entity_marker": [86, 90], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s212_IEPA.d89.s212.p1", "text": "The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT", "text_with_entity_marker": "The present study indicates that [E1]leptin[/E1] increases the gene expression of UCP2 in EWAT and that of [E2]UCP1[/E2], UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP1", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s212_IEPA.d89.s212.p2", "text": "The present study indicates that leptin increases the gene expression of UCP2 in EWAT and that of UCP1, UCP3 and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT", "text_with_entity_marker": "The present study indicates that [E1]leptin[/E1] increases the gene expression of UCP2 in EWAT and that of UCP1, [E2]UCP3[/E2] and LPL in BAT, whereas reduced food consumption but not leptin, decreases LPL expression in WAT", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP3", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d112.s271_IEPA.d112.s271.p0", "text": "Quantitative studies at early times demonstrated that cycloheximide treatment of aleurone layers increased mRNA levels 4-fold, whereas a combination of gibberellin plus cycloheximide treatment was required to increase alpha-amylase mRNA levels to the same extent", "text_with_entity_marker": "Quantitative studies at early times demonstrated that cycloheximide treatment of aleurone layers increased mRNA levels 4-fold, whereas a combination of [E1]gibberellin[/E1] plus cycloheximide treatment was required to increase [E2]alpha-amylase[/E2] mRNA levels to the same extent", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "gibberellin", "entity_1_idx": [[152, 163]], "entity_1_idx_in_text_with_entity_marker": [156, 167], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[218, 231]], "entity_2_idx_in_text_with_entity_marker": [231, 244], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d195.s471_IEPA.d195.s471.p0", "text": "We measured concentrations of NPY and CRH in specific hypothalamic regions [i.e., arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus and dorsomedial nucleus] of 7- to 8-wk-old lean and ob/ob mice at 1 or 3 h after intracerebroventricular leptin administration", "text_with_entity_marker": "We measured concentrations of [E1]NPY[/E1] and CRH in specific hypothalamic regions [i.e., arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial nucleus and dorsomedial nucleus] of 7- to 8-wk-old lean and ob/ob mice at 1 or 3 h after intracerebroventricular [E2]leptin[/E2] administration", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NPY", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[262, 268]], "entity_2_idx_in_text_with_entity_marker": [275, 281], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d195.s472_IEPA.d195.s472.p0", "text": "No rapid-onset effects of leptin on hypothalamic NPY or CRH concentrations were observed in intact mice", "text_with_entity_marker": "No rapid-onset effects of [E1]leptin[/E1] on hypothalamic [E2]NPY[/E2] or CRH concentrations were observed in intact mice", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[26, 32]], "entity_1_idx_in_text_with_entity_marker": [30, 36], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d195.s473_IEPA.d195.s473.p0", "text": "The addition of leptin to hypothalamic preparations from intact mice also did not alter NPY or CRH secretion", "text_with_entity_marker": "The addition of [E1]leptin[/E1] to hypothalamic preparations from intact mice also did not alter [E2]NPY[/E2] or CRH secretion", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[16, 22]], "entity_1_idx_in_text_with_entity_marker": [20, 26], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d64.s161_IEPA.d64.s161.p0", "text": "Similarly, carbachol, but not AVP or DDAVP, induced a significant increase in membrane-associated protein kinase C (PKC) enzyme activity", "text_with_entity_marker": "Similarly, carbachol, but not [E1]AVP[/E1] or DDAVP, induced a significant increase in membrane-associated [E2]protein kinase C[/E2] (PKC) enzyme activity", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AVP", "entity_1_idx": [[30, 33]], "entity_1_idx_in_text_with_entity_marker": [34, 37], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[98, 114]], "entity_2_idx_in_text_with_entity_marker": [111, 127], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d64.s162_IEPA.d64.s162.p0", "text": "In contrast, AVP had no effect on the distribution of any PKC isoform tested", "text_with_entity_marker": "In contrast, [E1]AVP[/E1] had no effect on the distribution of any [E2]PKC[/E2] isoform tested", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AVP", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[58, 61]], "entity_2_idx_in_text_with_entity_marker": [71, 74], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s265_IEPA.d110.s265.p0", "text": "The Ca2+ ionophore, A23187 or ionomycin, mimicked the effect of AVP, whereas the protein kinase C (PKC) activator, TPA, only induced a slight increase in AA release", "text_with_entity_marker": "The Ca2+ ionophore, A23187 or ionomycin, mimicked the effect of [E1]AVP[/E1], whereas the [E2]protein kinase C[/E2] (PKC) activator, TPA, only induced a slight increase in AA release", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AVP", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[81, 97]], "entity_2_idx_in_text_with_entity_marker": [94, 110], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s266_IEPA.d110.s266.p0", "text": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "text_with_entity_marker": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; [E1]PKC[/E1] inhibitors (staurosporine or Ro 31-8220) or down-regulation of [E2]PKCalpha[/E2], betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PKC", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKCalpha", "entity_2_idx": [[165, 173]], "entity_2_idx_in_text_with_entity_marker": [178, 186], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s266_IEPA.d110.s266.p1", "text": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "text_with_entity_marker": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; [E1]PKC[/E1] inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the [E2]AVP[/E2]-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PKC", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[268, 271]], "entity_2_idx_in_text_with_entity_marker": [281, 284], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s266_IEPA.d110.s266.p2", "text": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "text_with_entity_marker": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of [E1]PKCalpha[/E1], betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the [E2]AVP[/E2]-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PKCalpha", "entity_1_idx": [[165, 173]], "entity_1_idx_in_text_with_entity_marker": [169, 177], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[268, 271]], "entity_2_idx_in_text_with_entity_marker": [281, 284], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d95.s230_IEPA.d95.s230.p0", "text": "Species differences in the location of the Ca2+-dependent PKC isoforms suggest differences in function such as the relaying of photic or non-photic information to the clock mechanism, or the synchronization of AVP neurons and their subsequent output signals", "text_with_entity_marker": "Species differences in the location of the Ca2+-dependent [E1]PKC[/E1] isoforms suggest differences in function such as the relaying of photic or non-photic information to the clock mechanism, or the synchronization of [E2]AVP[/E2] neurons and their subsequent output signals", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PKC", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[210, 213]], "entity_2_idx_in_text_with_entity_marker": [223, 226], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d114.s275_IEPA.d114.s275.p0", "text": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "text_with_entity_marker": "To determine whether [E1]UCP-2[/E1] does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in [E2]leptin[/E2]-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UCP-2", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d114.s275_IEPA.d114.s275.p1", "text": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "text_with_entity_marker": "To determine whether [E1]UCP-2[/E1] does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive [E2]UCP-2[/E2]-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UCP-2", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d114.s275_IEPA.d114.s275.p2", "text": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "text_with_entity_marker": "To determine whether [E1]UCP-2[/E1] does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the [E2]UCP-2[/E2] gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UCP-2", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[238, 243]], "entity_2_idx_in_text_with_entity_marker": [251, 256], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d114.s275_IEPA.d114.s275.p3", "text": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "text_with_entity_marker": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in [E1]leptin[/E1]-unresponsive [E2]UCP-2[/E2]-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d114.s275_IEPA.d114.s275.p4", "text": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "text_with_entity_marker": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in [E1]leptin[/E1]-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the [E2]UCP-2[/E2] gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[148, 154]], "entity_1_idx_in_text_with_entity_marker": [152, 158], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[238, 243]], "entity_2_idx_in_text_with_entity_marker": [251, 256], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d114.s275_IEPA.d114.s275.p5", "text": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive UCP-2-underexpressing islets of diabetic ZDF rats, we transferred the UCP-2 gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "text_with_entity_marker": "To determine whether UCP-2 does, in fact, have uncoupling activity and, if so, whether such activity would favorably influence the abnormalities in leptin-unresponsive [E1]UCP-2[/E1]-underexpressing islets of diabetic ZDF rats, we transferred the [E2]UCP-2[/E2] gene to the islets of diabetic ZDF rats and lean (+/+) ZDF control rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UCP-2", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[238, 243]], "entity_2_idx_in_text_with_entity_marker": [251, 256], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d136.s324_IEPA.d136.s324.p0", "text": "The etiology for diabetes mellitus in PWS may be related to the morbid obesity and consequent insulin resistance, because a decrease of oxytocin neurons and leptin resistance in PWS may cause hyperphagia, inducing obesity", "text_with_entity_marker": "The etiology for diabetes mellitus in PWS may be related to the morbid obesity and consequent [E1]insulin[/E1] resistance, because a decrease of [E2]oxytocin[/E2] neurons and leptin resistance in PWS may cause hyperphagia, inducing obesity", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "insulin", "entity_1_idx": [[94, 101]], "entity_1_idx_in_text_with_entity_marker": [98, 105], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[136, 144]], "entity_2_idx_in_text_with_entity_marker": [149, 157], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d18.s40_IEPA.d18.s40.p0", "text": "The relative risks between highest and lowest quarters of flavonoid intake adjusted for age, smoking, serum cholesterol concentration, blood pressure, and body mass index were 0.69 (95% confidence interval 0.53 to 0.90) and 0.54 (0.33 to 0.87) for total and coronary mortality, respectively", "text_with_entity_marker": "The relative risks between highest and lowest quarters of [E1]flavonoid[/E1] intake adjusted for age, smoking, serum [E2]cholesterol[/E2] concentration, blood pressure, and body mass index were 0.69 (95% confidence interval 0.53 to 0.90) and 0.54 (0.33 to 0.87) for total and coronary mortality, respectively", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "flavonoid", "entity_1_idx": [[58, 67]], "entity_1_idx_in_text_with_entity_marker": [62, 71], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "cholesterol", "entity_2_idx": [[108, 119]], "entity_2_idx_in_text_with_entity_marker": [121, 132], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d16.s33_IEPA.d16.s33.p0", "text": "They are needed for the catabolism of cholesterol, bile acids, and steroid hormones; they hydrolyze a number of flavonoid glycosides to anticarcinogens; and they detoxify certain carcinogens", "text_with_entity_marker": "They are needed for the catabolism of [E1]cholesterol[/E1], bile acids, and steroid hormones; they hydrolyze a number of [E2]flavonoid[/E2] glycosides to anticarcinogens; and they detoxify certain carcinogens", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cholesterol", "entity_1_idx": [[38, 49]], "entity_1_idx_in_text_with_entity_marker": [42, 53], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "flavonoid", "entity_2_idx": [[112, 121]], "entity_2_idx_in_text_with_entity_marker": [125, 134], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d173.s419_IEPA.d173.s419.p0", "text": "We have established that the recovery of secreted N1 is increased by the protein kinase C agonists PDBu and PMA in a time- and dose-dependent manner in both cell lines", "text_with_entity_marker": "We have established that the recovery of secreted [E1]N1[/E1] is increased by the [E2]protein kinase C[/E2] agonists PDBu and PMA in a time- and dose-dependent manner in both cell lines", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N1", "entity_1_idx": [[50, 52]], "entity_1_idx_in_text_with_entity_marker": [54, 56], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[73, 89]], "entity_2_idx_in_text_with_entity_marker": [86, 102], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d173.s420_IEPA.d173.s420.p0", "text": "In contrast, secretion of N1 remains unaffected by the inactive PDBu analog alphaPDD and by the protein kinase A effectors dibutyryl cAMP and forskolin", "text_with_entity_marker": "In contrast, secretion of [E1]N1[/E1] remains unaffected by the inactive PDBu analog alphaPDD and by the [E2]protein kinase A[/E2] effectors dibutyryl cAMP and forskolin", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N1", "entity_1_idx": [[26, 28]], "entity_1_idx_in_text_with_entity_marker": [30, 32], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase A", "entity_2_idx": [[96, 112]], "entity_2_idx_in_text_with_entity_marker": [109, 125], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d37.s0_LLL.d37.s0.p1", "text": "Therefore, ftsY is solely expressed during sporulation from a sigma(K)- and GerE-controlled promoter that is located immediately upstream of ftsY inside the smc gene.", "text_with_entity_marker": "Therefore, [E1]ftsY[/E1] is solely expressed during sporulation from a [E2]sigma(K)[/E2]- and GerE-controlled promoter that is located immediately upstream of ftsY inside the smc gene.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ftsY", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "sigma(K)", "entity_2_idx": [[62, 70]], "entity_2_idx_in_text_with_entity_marker": [75, 83], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d37.s0_LLL.d37.s0.p2", "text": "Therefore, ftsY is solely expressed during sporulation from a sigma(K)- and GerE-controlled promoter that is located immediately upstream of ftsY inside the smc gene.", "text_with_entity_marker": "Therefore, [E1]ftsY[/E1] is solely expressed during sporulation from a sigma(K)- and [E2]GerE[/E2]-controlled promoter that is located immediately upstream of ftsY inside the smc gene.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ftsY", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "GerE", "entity_2_idx": [[76, 80]], "entity_2_idx_in_text_with_entity_marker": [89, 93], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d33.s0_LLL.d33.s0.p0", "text": "During endospore formation in Bacillus subtilis, the DNA binding protein GerE stimulates transcription from several promoters that are used by RNA polymerase containing sigmaK", "text_with_entity_marker": "During endospore formation in Bacillus subtilis, the DNA binding protein [E1]GerE[/E1] stimulates transcription from several promoters that are used by RNA polymerase containing [E2]sigmaK[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GerE", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "sigmaK", "entity_2_idx": [[169, 175]], "entity_2_idx_in_text_with_entity_marker": [182, 188], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d33.s1_LLL.d33.s1.p0", "text": "GerE binds to a site on one of these promoters, cotX, that overlaps its -35 region.", "text_with_entity_marker": "[E1]GerE[/E1] binds to a site on one of these promoters, [E2]cotX[/E2], that overlaps its -35 region.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GerE", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "cotX", "entity_2_idx": [[48, 52]], "entity_2_idx_in_text_with_entity_marker": [61, 65], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d12.s0_LLL.d12.s0.p0", "text": "Northern blot and primer extension analyses indicated that yfhS is transcribed by E sigma E during sporulation.", "text_with_entity_marker": "Northern blot and primer extension analyses indicated that [E1]yfhS[/E1] is transcribed by [E2]E sigma E[/E2] during sporulation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "yfhS", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "E sigma E", "entity_2_idx": [[82, 91]], "entity_2_idx_in_text_with_entity_marker": [95, 104], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d12.s1_LLL.d12.s1.p0", "text": "These results suggest that YfhP may act as a negative regulator for the transcription of yfhQ, yfhR, sspE and yfhP.", "text_with_entity_marker": "These results suggest that [E1]YfhP[/E1] may act as a negative regulator for the transcription of [E2]yfhQ[/E2], yfhR, sspE and yfhP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "YfhP", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "yfhQ", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d12.s1_LLL.d12.s1.p1", "text": "These results suggest that YfhP may act as a negative regulator for the transcription of yfhQ, yfhR, sspE and yfhP.", "text_with_entity_marker": "These results suggest that [E1]YfhP[/E1] may act as a negative regulator for the transcription of yfhQ, [E2]yfhR[/E2], sspE and yfhP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "YfhP", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "yfhR", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d12.s1_LLL.d12.s1.p2", "text": "These results suggest that YfhP may act as a negative regulator for the transcription of yfhQ, yfhR, sspE and yfhP.", "text_with_entity_marker": "These results suggest that [E1]YfhP[/E1] may act as a negative regulator for the transcription of yfhQ, yfhR, [E2]sspE[/E2] and yfhP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "YfhP", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "sspE", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d12.s1_LLL.d12.s1.p3", "text": "These results suggest that YfhP may act as a negative regulator for the transcription of yfhQ, yfhR, sspE and yfhP.", "text_with_entity_marker": "These results suggest that [E1]YfhP[/E1] may act as a negative regulator for the transcription of yfhQ, yfhR, sspE and [E2]yfhP[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "YfhP", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "yfhP", "entity_2_idx": [[110, 114]], "entity_2_idx_in_text_with_entity_marker": [123, 127], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d31.s0_LLL.d31.s0.p0", "text": "The results indicate that PhoP~P is sufficient to repress the transcription of the tagA and tagD promoters and also to activate the transcription of the tuaA promoter.", "text_with_entity_marker": "The results indicate that [E1]PhoP~P[/E1] is sufficient to repress the transcription of the [E2]tagA[/E2] and tagD promoters and also to activate the transcription of the tuaA promoter.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PhoP~P", "entity_1_idx": [[26, 32]], "entity_1_idx_in_text_with_entity_marker": [30, 36], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "tagA", "entity_2_idx": [[83, 87]], "entity_2_idx_in_text_with_entity_marker": [96, 100], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d31.s0_LLL.d31.s0.p1", "text": "The results indicate that PhoP~P is sufficient to repress the transcription of the tagA and tagD promoters and also to activate the transcription of the tuaA promoter.", "text_with_entity_marker": "The results indicate that [E1]PhoP~P[/E1] is sufficient to repress the transcription of the tagA and [E2]tagD[/E2] promoters and also to activate the transcription of the tuaA promoter.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PhoP~P", "entity_1_idx": [[26, 32]], "entity_1_idx_in_text_with_entity_marker": [30, 36], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "tagD", "entity_2_idx": [[92, 96]], "entity_2_idx_in_text_with_entity_marker": [105, 109], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d31.s0_LLL.d31.s0.p2", "text": "The results indicate that PhoP~P is sufficient to repress the transcription of the tagA and tagD promoters and also to activate the transcription of the tuaA promoter.", "text_with_entity_marker": "The results indicate that [E1]PhoP~P[/E1] is sufficient to repress the transcription of the tagA and tagD promoters and also to activate the transcription of the [E2]tuaA[/E2] promoter.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PhoP~P", "entity_1_idx": [[26, 32]], "entity_1_idx_in_text_with_entity_marker": [30, 36], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "tuaA", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
